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Abstract
DEVELOPMENT OF HIGH EFFICIENCY DRY POWDER INHALERS FOR USE WITH
SPRAY DRIED FORMULATIONS
By Dale Robert Farkas
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2017
Director: Dr. P. Worth Longest
Professor, Department of Mechanical and Nuclear Engineering and
Department of Pharmaceutics

Dry powder inhalers (DPIs) are advantageous for delivering medication to the
lungs for the treatment of respiratory diseases because of the stability of the powders,
relative low cost, synchronization of inhalation and dose delivery, and many design
options that can be used for optimization. However, currently marketed DPIs are very
inefficient in delivering medications to the lungs. This study has developed multiple new
high efficiency DPIs for use with spray dried excipient enhanced growth (EEG) powder
formulations based on the following platforms: capsule-based for oral inhalation, highdose for oral inhalation, inline with 3D rod array dispersion, and inline with capillary jet
dispersion. The capsule-based DPIs for oral inhalation implemented a 3D rod array for
aerosol dispersion with optimal designs producing mass median aerodynamic diameters
(MMADs) in the range of 1.3-1.5 µm and emitted doses in the range of 79-81%. Keys to

inhaler success were the orientation of the capsule and inclusion of the 3D rod array.
For the high-dose oral inhaler, performance was similar to the optimized capsule-based
devices, while aerosolizing a much larger mass of powder. Surprisingly, removal of the
fluidized bed of spheres improved performance producing a simple high dose device
containing only a single dose sphere. The inline device using the 3D rod array was
effective in producing particles of approximately 1.5 µm, at flow rates consistent with
high flow therapy using a 1 L ventilation bag as the delivery mechanism. Using a
capillary jet as the dispersion mechanism, further advances were made to allow for both
delivery using a low volume (LV) of air and delivery in low flow therapy. This easily
adaptable platform was able to produce a high quality aerosol out of a nasal cannula
with an ED greater than 60% and a size (~2 µm) that should produce minimal
extrathoracic losses. In conclusion, this study demonstrates (i) the design and
optimization of DPIs capable of delivering EEG aerosols to the lungs using oral
inhalation, (ii) the ability to deliver EEG aerosols using N2L aerosol administration, and
(iii) the design of a new flexible LV-DPI device that is easily adaptable to multiple
patients and delivery platforms, which are greatly needed in clinical environments.

Chapter 1

Specific Aims

The goal of this research is the development of multiple dry powder inhaler (DPI)
platforms for different applications that can effectively aerosolize excipient enhanced
growth (EEG) and other spray dried powders to provide lung targeted delivery of inhaled
therapeutics. Potential pharmacotherapies that could benefit from the technology
developed in this work include inhaled antibiotics, mucus clearance agents, antiinflammatories, and surfactants. Excipient enhanced growth is a new inhalation delivery
technique developed at VCU in which small hygroscopic aerosols are formed and
inhaled by the patient (Hindle et al. 2012). The initial small size of the aerosol largely
eliminates mouth-throat depositional losses for orally inhaled medications (Son et al.
2013a). Furthermore, the small initial size of the aerosol enables efficient nose-to-lung
(N2L) aerosol administration, which can be advantageous for delivering the aerosol over
an extended period of time or delivery during non-invasive ventilation (NIV) (Longest et
al. 2011b). The hygroscopic excipient employed in the multi-component particles
induces condensational growth of the particles into droplets within the lungs and
targeted deposition. While previous work at VCU has shown the EEG technique to
effectively target lung deposition of different therapeutics (Hindle et al. 2012, Longest et
al. 2012b), generating aerosols with small initial mass median aerodynamic diameters
(MMADs), for example < 1.5 µm, from a passive DPI is highly challenging.
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Approaches that can be used for producing small dry powder aerosols include (i)
optimization of the powder formulation with the inclusion of dispersion enhancers and
(ii) the development of new aerosolization devices. The VCU Team has previously
investigated the optimization of EEG formulations and aerosolization with existing and
modified devices (Longest et al. 2013b, Son et al. 2013a, Son et al. 2013b). This
project seeks to develop new and optimal devices for the deaggregation of EEG
formulations that produce the required small aerosols for high efficiency lung-target
delivery of different medications.
The developed devices are intended for traditional oral inhalation administration
in adults as well as inline devices for N2L aerosol administration in both adults and
children. For most applications considered, delivering high doses with a single loading
of the inhaler is an intended design goal. Device modifications and optimization are
performed through multiple iterations, using computational fluid dynamics (CFD) when it
is most useful. Aerosolization performance of the devices is tested using multiple in
vitro characterization techniques, together with evaluation of aerosol transmission
through human replica in vitro upper airway models. Ultimately, device performance is
characterized based on high emitted dose (ED) and small mass median aerodynamic
diameter (MMAD) (in the range ≥70% and ≤1.5 µm, respectively), and top performing
devices are proposed for each of the applications considered.
The inhaler systems investigated were as follows: an orally administered DPI for
adults and children, a high-dose oral DPI for adults and children, a high flow nasal
cannula delivery system to be used with a standard ventilation bag, a low flow nasal
delivery system for use in-line with a nasal cannula system, and a low volume device
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that can be attached to multiple patient interfaces to inject the aerosol into an already
present flow. Each system will be designed with 3D modeling software and optimized
as needed using a selective combination of Computational Fluid Dynamics (CFD) and
experimental testing. The devices will be built using rapid prototyping (3D printing) from
both in house machines as well as from outside companies, and these devices will be
tested in collaboration with the VCU Department of Pharmaceutics (Dr. Michael Hindle).
Each listed system will have its own optimized lead device to be presented, for a total of
5 final designs.

Objective 1: Develop a new DPI for oral inhalation using a capsule-based drug
loading approach and the proven 3D rod array technology.
All prescribed DPIs in the United States and the rest of the world are very
inefficient in delivering drug to the lungs of a patient. Large particles exiting the inhalers
cause high mouth-throat (MT) deposition as well as high variability in dose delivery. To
decrease the particle size exiting the DPI, a higher flow rate through the device is
sometimes used, but this can also cause increased MT deposition making this method
counterproductive (DeHaan et al. 2004). In order to minimize MT depositional loss, a
smaller particle size could be coupled with a relatively low flow rate. However, small
particle sizes entering the lung may lack sufficient momentum to deposit and may then
be exhaled by the patient. To remedy this situation, the small particles need to increase
in size once they enter the lung to foster deposition, decrease losses from exhalation,
and potentially target the site of deposition. The EEG method, proposed and developed
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at VCU, is designed to provide this highly desirable particle size increase once the
aerosol is within the lungs (Hindle et al. 2012, Longest et al. 2012b).
To deaggregate the powder for effective delivery, an inhaler geometry including a
3D rod array in the mouthpiece was designed previously (Son et al. 2013b). The rods
are perpendicular to the flow and cause increased turbulence to provide the energy
needed to break up the powder after exiting the capsule. The parameter used to
quantify the increase in turbulence in the system, non-dimensional specific dissipation
(NDSD), was proposed by Longest et al. (2013b). This parameter takes into account
the exposure time, turbulent energy, and turbulent length scale of the flow through the
device. The NDSD has been shown to have a direct correlation to the particle size
exiting a device and can assist with device optimization using CFD before performing
experimental device characterization.
The two proposed oral DPI designs in this study both include the 3D rod array
technology in the mouthpiece, but have different capsule chamber orientations, with one
being perpendicular and one being parallel with the incoming air flow. The use of these
inhalers is passive by design, in that user-generated inspiratory flow through the inhaler
creates the flow needed to empty the powder from the capsule. The tasks required for
Objective 1 are listed below.

Task 1.1: Develop prototype devices that align the capsule's primary axis perpendicular
(VCU1 DPI or CC1-3D) and parallel (VCU3 DPI or CC90-3D) with the incoming air flow
and provide a flow rate of 45 LPM at a 4 kPa pressure drop.
•

Status: Complete and published (Behara et al. 2014a, Behara et al. 2014b)
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Task 1.2: Investigate the effect of hole position on capsule vibration in the VCU1 device
using high-speed photography. Link the measured vibration outcome to aerosolization
performance.
•

Status: Complete and published (Behara et al. 2014a)

Task 1.3: Investigate the effects of different rod materials on aerosol deaggregation in
the VCU1 device.
•

Status: Complete and published (Behara et al. 2014a)

Objective 2: Develop an inline DPI platform that implements capsule loading and
the 3D rod array, and is actuated by a ventilation bag or gas source for operation
at high flow (~15 LPM) and low flow (~5 LPM).
A major application for both high and low flow nose-to-lung (N2L) delivery is
administering medication while a patient is on mechanical ventilation. Instead of using
invasive techniques (endotracheal or tracheostomy tube), noninvasive ventilation (NIV)
is often used to deliver both oxygen and medication to a patient. This is typically done
using a nasal cannula, face mask, or other type of interface that is designed to
continuously deliver oxygen in the same way as standard NIV techniques, but, when
medication needs to be delivered, a device inline with the flow could be activated to
produce an aerosol with the needed medication and use the flow produced by the
ventilation bag to carry the aerosol through the system and to the patient. The problem
with delivering medication using this technique is the amount of tubing and connectors
that the aerosol must pass through before reaching the patient, causing high losses.
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The design of the high flow delivery system proposed is based on that of the
original 3D rod array design. While the 3D rod array itself is very similar to the oral
inhaler design (Objective 1), the inlet and outlet were configured to connect with a
ventilation bag gas source and small diameter outlet, as would be needed to connect
with NIV gas delivery lines or a nasal cannula interface. To allow for decreased flow
rates through the devices and maintain good deaggregation of the powder, the 3D rod
array was modified based on CFD predictions and experimental results.
The low flow system is very similar to the high flow device, but additional
changes were made to the rod array to allow for a lower flow rate. This system was
also designed to be used with smaller tubing (4 mm vs. 10 mm), closer to that of a
standard oxygen cannula system. The device as well as y-connector and a nasal
cannula are also designed to replace the commercial cannula system used in most
hospitals in order to improve aerosol transmission. The tasks for this objective are
listed below.
Task 2.1: Prototype the device platform using a critical orifice to control flow rate with
required seals and connections for proper operation.
•

Status: Complete and published (Behara et al. 2014c)

Objective 3: Develop a high dose oral inhalation DPI for use with adults or
children that operates effectively with powder masses of 50 and 100 mg.
To deliver a large amount of formulation (50 mg or greater with a target
application of 100 mg) to a patient’s lungs, the previously developed DPIs using the 3D
rod array technology would not be appropriate as the capsules in these designs cannot
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hold the amount of powder required and is typically limited to ~25 mg for effective
operation. A new design based on a fluidized bed is proposed to accommodate a large
amount of powder and deaggregate it efficiently. The theory behind deaggregation
using the fluidized bed design involves using small spheres to grind together and impact
with a powder when a gas is forced through the bed (Prenni et al. 2000). The design of
this device includes a hollow dosing sphere and mixing balls inside of a chamber with a
90 degree bend. The tasks for completing this objective are shown below.
Task 3.1: Prototype and optimize a new high dose DPI using a fluidized bed design that
operates at pressure drops of 4 kPa (adult) and 2 kPa (diseased airways or child).
•

Status: Complete and published (Farkas et al. 2015)

Task 3.2: Screen and test aerosolization performance of the fluidized bed DPI at
pressure drops of 4 kPa and 2 kPa.
•

Status: Complete and published (Farkas et al. 2015)

Task 3.3: Test performance of the fluidized bed device containing only the dose sphere
in order to reduce device depositional losses.
•

Status: Complete and published (Farkas et al. 2015)
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Objective 4: Develop a new low-volume capsule-based inline DPI platform
actuated with an external (low volume) gas source such as a syringe or placebo
MDI. The device must be connectable to positive pressure systems such as a
mechanical ventilation line or NIV mask and prevent the ingress of humidified air
into the powder containment area.
Delivering inhaled medications to infants can be done in a number of ways:
endotracheal tubes, face masks, nasal cannulas, etc., but due to low tidal volumes it
can be difficult to generate a small particle aerosol and have sufficient inspiratory flow to
deliver it to the lungs. The design of a low volume device could be used to inject an
aerosol into the flow path of the chosen delivery method. The device is to be powered
by multiple small bursts of compressed air from either a syringe or a placebo (HFA-only)
metered dose inhaler (MDI), as well as the possibility of using a compressed air or
oxygen source.
The capsule device will be open along its longitudinal axis for capsule loading
and when assembled will pierce the capsule with the same capillaries used for the inlet
and outlet of the air and aerosol, respectively. The use of a syringe air-source would
require the user to refill the syringe with air after each actuation by pulling the plunger
back into position. Because this is a sealed system, the syringe will need to be
removed or a three way valve will need to be positioned between the syringe outlet and
the device to prevent powder from being pulled into the syringe and lost. The MDI
actuator will require an expansion chamber to evaporate the liquid HFA propellant
before reaching the capsule to prevent aggregation of the powder. Systems for low flow
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nasal cannula (LFNC) delivery will be developed to administer the aerosol leaving the
optimized device. The tasks for completing Objective 4 are listed below.
Task 4.1: Develop device prototypes for loaded doses in the range of 2-50 mg that
pierce the capsule during closure and are powered by low gas volumes from a syringe
or placebo MDI source.
•

Status: Complete and Accepted (Farkas et al. 2017)

Task 4.2: Test device performance and develop an optimized platform and gas source.
•

Status: Complete and Accepted (Farkas et al. 2017)

Task 4.3: Develop an optimized system and test delivery for administration during LFNC
gas administration in an adult using steady state conditions.
•

Status: Complete and In Review
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Chapter 2

Background

The following review is organized based on the four objectives defined in Chapter
1. A review of controlled condensational growth techniques is presented first to connect
the objectives, as all of the studies are aimed at producing devices to be used as
platforms for delivering medication in this fashion. Literature relevant to each specific
objective is then reviewed successively.

2.1 Controlled Condensational Growth Techniques
The excipient enhanced growth (EEG) method (Hindle et al. 2012, Longest et al.
2012a, Longest et al. 2012b) is a possible solution to the low lung delivery efficiency of
current commercial dry powder inhalers (DPIs). This method requires a small particle
size exiting the inhaler and, subsequently, entering the mouth-throat (MT) or nasal
airways in nose-to-lung (N2L) delivery to avoid deposition in these extrathoracic
regions. Once the aerosol passes the extrathoracic airways, the inclusion of a
hygroscopic excipient causes the particles to absorb the water vapor that naturally
occurs in the lungs and increase in size fostering lung retention and potentially targeting
the site of deposition.
Similar to the EEG approach is the Enhanced Condensational Growth (ECG)
approach (Hindle et al. 2010, Longest et al. 2011a). This approach requires the
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introduction of humidified air into the lungs that condenses when it meets inhaled
submicrometer particles in the airways, allowing them to increase in size and deposit
within the lungs in a targeted manner. Since the particles do not meet supersaturated
air until after the nose-mouth-throat (NMT), the particles effectively bypass these
regions, allowing for higher lung deposition and enabling targeted deposition in the
airways by controlling the growth of the particles. In a 2nd variation, the submicrometer
particle and saturated humidity stream are combined at the point of inhalation, and
inhalation velocity allows the particles to enter the lungs before appreciable size
increase can occur. With these ECG methods, a hygroscopic excipient is optional after
determining the desired particle size increase.
Both the EEG and ECG methods have been shown, in vitro and with
computational fluid dynamics (CFD), to effectively deliver medication to the lungs
(Longest et al. 2011b, Tian et al. 2013). The following studies will emphasize the EEG
approach based on the focus of this dissertation, which is creating EEG aerosols. The
reviewed studies will focus on the design of devices consisting of different techniques
for aerosol generation and lung delivery using spray dried EEG aerosols and starting
from the aggregated powder state. Active devices, requiring an external source of air
flow, as well as passive devices, requiring inhalation from the patient to generate the
aerosol, will be developed in this work. Techniques used for deaggregation in the
devices include the use of the previously developed 3D rod array (Son et al. 2013b,
Behara et al. 2014a, Behara et al. 2014b, Behara et al. 2014c), fluidized beds (Farkas
et al. 2015), and the use of an air source as the primary energy for deaggregation.
While there are many commercial DPIs available, these are not designed to deliver
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EEG powders and are highly inefficient with most powder formulations. For this reason,
new devices are needed that are designed specifically for creating EEG aerosols, with
smaller than conventional aerosol sizes, e.g., < 1.5 µm. Furthermore, beyond the Penn
Century Insufflator device for delivering test aerosols to animals, inline devices are not
currently commercially available, motivating the need for new devices.

2.2 Objective 1: Development of a High Efficiency Dry
Powder Inhaler

2.2.1 Handheld Dry Powder Inhalers
DPIs are becoming the most popular devices for delivering inhaled medication to
the lungs (Smith et al. 2010). A primary limitation associated with these devices is that
most commercial DPIs use formulations of carrier particles and struggle to generate fine
particle fractions less than 5 µm (FPF<5µm) above 40%. These devices are also highly
dependent on patient behavior, resulting in dramatic FPF reductions with decreasing
flow rates (Prime et al. 1999, Islam et al. 2012, Zhou et al. 2014). For example, the
Flovent Diskus inhaler (GlaxoSmithKline, Raleigh, NC) was shown in vitro to have MT
losses of 70% using a realistic airway model (Tian et al. 2011, Longest et al. 2012c).
The mass median aerodynamic diameter (MMAD) of the Diskus inhaler was found to be
2.99 µm at flow rate of 75 LPM, with this size increasing to 4.10 µm when lowering the
flow rate to 37 LPM (Longest et al. 2012c).
With an increasing aerosol size, the chance of MT deposition also increases.
The same holds true for an increasing device flow rate. While the aerosol exiting the
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DPI will most likely be smaller with a higher flow rate, the momentum will also increase,
causing impaction on the approximately 90 degree turn at the back of the throat. High
efficiency delivery to the lungs can reduce side effects of drugs by decreasing MT
deposition, thus decreasing systemic exposure. Many future possibilities for inhaled
medications, such as antibiotics, pain medications, and chemotherapy, have a very
specific dosing requirement for effectiveness and come with significant side effects
(Gagnadoux et al. 2008, Yi et al. 2010, Rubin 2011). Because of these side effects,
maximizing lung delivery efficiency and minimizing depositional loss in the extrathoracic
airways is very important in order to achieve the desired pharmaceutical effect in a safe
manner.
A study to show MT deposition variability between normal humans was
conducted by Delvadia et al. (2012) using the Budelin Novolizer (Meda
Pharmaceuticals, Bishops Stortford UK). Low, moderate, and high flow rates through
three different MT models (small, medium, and large) were used to show intersubject
variability in lung delivery efficiency. Each flow rate was paired with a specific geometry
for comparison purposes. Flow rate increases from the small to large MT models
showed an increase in MT deposition, as expected. For example, using the high flow
rate through the device and model, the losses increased (40 to 56%) as flow rate
increased (73 to 99 LPM) when changing from the small to medium model. However,
the device produced less MT deposition with the high flow rate when compared to the
low flow rate using the same model (48 vs 62%). This 14% increase in MT deposition
at a lower flow rate is most likely caused by the increase in aerosol size, due to reduced
deaggregation, resulting in an increase in momentum that counteracts the decrease in
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velocity. While the lower device retention in this study more than offset the increase in
MT deposition to produce a higher total lung dose (15-27% increase), the high
deposition of 48-62% in the MT region shows there is significant room for needed
improvement (Delvadia et al. 2012).
In a second study by Delvadia et al. (2013), using the medium MT model
characterized in the previous study (Delvadia et al. 2012), five commercial DPI systems
(HandiHaler, Aerolizer, Easyhaler, Turbuhaler, and Diskhaler) were tested in vitro for
comparison of lung dose and MT deposition between both each other as well as in vivo
data reported in previous studies (Borgstrom et al. 1994, Vidgren et al. 1994, Meyer et
al. 2004, Brand et al. 2007, Cass et al. 2012). The range of lung deposition in these
studies was between 13% with the Diskhaler (Cass et al. 2012) and greater than 30%
with the Easyhaler (Vidgren et al. 1994, Delvadia et al. 2013). While the HandiHaler
was shown to have the lowest MT deposition of approximately 25-30%, device retention
was much higher than the other devices (~60%), which resulted in a small lung dose of
less than 20% (Brand et al. 2007, Delvadia et al. 2013). Overall, this study showed a
high variability in lung doses and MT deposition between different commercially
available inhalers. Reducing this variability is important in order to determine correct
dosing actually received by the patient and to reduce the risk of side effects.
Spray dried pharmaceutical powder formulations, such as the Pulmosphere™
technology and the previously mentioned EEG method have improved inhaler
performance with the use of highly dispersible compounds that contain smaller primary
particle sizes, producing higher FPF values upon aerosolization (Sham et al. 2004,
Geller et al. 2011, Young et al. 2013, Weers et al. 2014). Pulmosphere™ technology is
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an emulsion-based spray-drying process that produces less dense, porous particles
(Geller et al. 2011). While spray dried powders, in general, experience a reduced
cohesive force and show an increase in dispersion, the porous surface of the
Pulmosphere™ particles are designed to allow for even less agglomeration (Geller et al.
2011). Using the T-326 Inhaler, Geller et al. (2011) reported a lung dose of only 34% of
the 80 mg loaded mass. This was because losses of 22 and 44% occurred due to
device retention and MT deposition, respectively.
Son et al. (2013a) optimized the spray drying of EEG powder formulations and
tested aerosolization behavior with the commercially available Aerolizer. The resulting
aerosol performance showed the MT deposition to be minimal (<5%) while the FPF
leaving the device was greater than 95%. However, the flow rate for the device (90
LPM) was considered to be too high for some patient populations (e.g., children and
COPD patients). Because of this, the HandiHaler was chosen to be optimized for the
EEG formulation in the study by Son et al. (2013) based on its similar aerosolization
characteristics while using a much lower flow rate (45 LPM) at an equivalent 4 kPa
pressure drop. Longest et al. (2013b) demonstrated that the addition of a 3D rod array
in the mouthpiece could increase device performance substantially by increasing the
new Non-Dimensional Specific Dissipation (NDSD) parameter of the fluid flow. This
parameter was shown to have a direct correlation with the mean particle size leaving
the inhaler (Longest et al. 2013b). As a result, the NDSD can be used as a
computational fluid dynamics (CFD)-based optimization and design parameter for
developing EEG inhalers.
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In summary, commercial devices have been shown to perform poorly, with low
lung doses due to high depositional losses in both the device and MT regions. Device
and formulation improvements have increased lung delivery efficiency, but much room
for improvement still exists. While the EEG formulation appears to be the best currently
available option, the challenge of creating an initially submicrometer particle size with a
DPI still remains.

2.3 Objective 2: Development of an Inline DPI System using
3D Rod Array Technology

2.3.1 Active DPIs
When compared to the number of passive devices, few active devices have been
used to form pharmaceutical aerosols (Tang et al. 2011, Laube et al. 2012, Pohlmann et
al. 2013). Potential applications of active devices include aerosol delivery to children
(Laube et al. 2012), aerosol delivery to patients undergoing mechanical ventilation
(Tang et al. 2011), nose to lung aerosol delivery (Longest et al. 2011b, Golshahi et al.
2013), and aerosol delivery to animals (Grainger et al. 2004). Since these devices do
not rely on a patient to produce the needed flow through the device, they can be used in
situations where the patient has decreased breathing capability or cannot follow the
multiple step instructions associated with passive devices. Everard et al. (1996) used a
modified version of the Turbuhaler DPI to aerosolize budesonide through a 9 mm
diameter endotracheal tube (ETT) with an active setup. Delivery through the device and
ETT was reported at 20%. Tang et al. (2011) used the Osmohaler, powered by an adult
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ventilation bag, to deliver an aerosol through both ETT and tracheostomy tubes for size
characterization. The setup of this experiment included a flow meter inline between the
bag and device, as well as a one-way valve positioned between the device and
impinger to prevent exhalation air from entering the device and corrupting the powder.
FPF<5µm values were between 20 and 30% with an emitted dose (ED) in the range of 5060%. Laube et al. (2012) used the Solovent® DPI to produce an aerosol to be
introduced to the Sofia anatomical infant nose-throat (SAINT) model using an active
setup that used a syringe as an airflow source. While the device was reported to emit
90% of the loaded dose, only 0.3-4% of that dose reached a filter used to represent the
lungs, with most of the losses being in the cardstock spacer between the device and the
model. In a study by Corcoran et al. (2013), the MicroDose DPI was proposed for
creating an aerosol using a piezoelectric system as the active means of powder
deaggregation. While device performance was not available in this study,
pharmacokinetic data showed that the dose was comparable to a standard auto-injector
pen with the same loaded dose. From the previously mentioned studies, current active
devices have a wide range of reported, approximate, lung delivery efficiencies (0.330%). FPFs are also very low, in the range of 20-30%, which makes them less
desirable in the administration of EEG aerosols that require a small aerosol to penetrate
the lungs.

2.3.2 Nose-to-Lung (N2L) Aerosol Administration
Aerosol administration through the nose to the lungs can be an efficient way to
deliver medication requiring continuous delivery over a long period of time, high doses
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of medication also over a longer period of time, medication needing to be administered
frequently, and delivery to patients under noninvasive ventilation (NIV). However, since
the nasal passages are very narrow, depositional losses are a concern when attempting
to pass an aerosol through the nose to the lungs (Longest et al. 2011b). Another
disadvantage of N2L delivery is the powder having to pass through small diameter
tubing and connectors that introduce flow direction (Longest et al. 2013a). The
connectors and tubing can provide the powder multiple deposition chances, thus
lowering the dose available to be delivered to the patient.
To overcome both the nose and system connections acting as a filter for the
aerosol, a smaller aerosol can be introduced. Submicrometer aerosols have been
shown using CFD as well as in vitro experiments to significantly decrease deposition
(Longest et al. 2011b). In this study, which used the ECG approach mentioned
previously, NMT deposition was reduced from 72% to 14%. Expiratory losses are also
a concern when dealing with a small aerosol as they may not deposit before exhalation
occurs. Longest et al. (2011b) showed that the ECG method can provide the necessary
particle size growth to decrease these losses as the size had more than doubled (0.9 to
2 µm) as the aerosol reached the lungs. Tian et al. (2014a) considered this approach in
more detail by studying both EEG and ECG delivery techniques, using CFD, through a
realistic NMT model using initial particles in the submicrometer range. When using an
aerosol with an MMAD of 0.9 µm entering the NMT, predicted lung doses for the three
cases studied were in the range of 71-87%, much larger than the 26% delivered with an
MMAD of 4.9 µm. In addition, the aerosol was predicted to grow, with the EEG method,
by 2.5-6% in diameter to prevent exhalation losses (Tian et al. 2014a).
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In summary, N2L delivery has many applications, including high dose delivery,
frequent repeated doses of medication, and delivery during NIV. Aerosol administration
using this type of method is known to be inefficient because of both losses in delivery
systems as well as losses in the nasal passage due to the long, narrow passages
connecting the nose to the throat. Streamlining of components, as well as creating
submicrometer particles are techniques developed by our group that have been used
with success to decrease these losses.

2.4 Objective 3: High-Dose Dry Powder Inhaler Development

2.4.1 Current DPI Dose Limitations
Currently available DPIs are, for the most part, designed around delivering a small
mass of formulation (0.5-20 mg). While these small doses are consistent with some
commercially available formulations, there are medications which require a much higher
dose to be effective. For example, antibiotics, anti-inflammatories, surfactants, and
mucus clearance drugs all utilize higher doses (Keller et al. 2010, Ruppert et al. 2010,
Young et al. 2013). Using a commercial device for these types of medication would
require multiple iterations of loading, inhalation, and reloading to obtain the correct
dosage while also ensuring the performance of the device is unchanging. Having to
load multiple capsules to obtain the correct dose of medication can be tedious and may
result in poor patient compliance, as well as decreased device performance if not done
properly. For some of these medications, such as antibiotics, incorrect dosing can lead
to unwanted side effects as well as reduced effectiveness.
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Aerosolizing a large mass of powder in a handheld device can prove difficult and
has previously required either some sort of external power or flow source to cause
vibrations or turbulence strong enough to disperse the powder (Corcoran et al. 2013) or
implemented an inhaler designed for smaller doses with multiple loading cycles (Geller
et al. 2011). Using multiple capsules can save time compared to extended treatments,
but loading multiple capsules is tedious, especially when it involves up to 10 loading
cycles, such as the Bronchitol (Pharmaxis Ltd, Sydney, Australia) system (Bilton et al.
2011).

2.4.2 Current High Dose DPIs
The Twincer inhaler is a passive device designed to deliver a loaded dose of up to
50 mg, but higher amounts have not currently been tested (de Boer et al. 2012). The
ED of the device was reported to be between 90 and 95% for the dose range of 10-50
mg. However, the FPF<5µm range of 59 to 67% shows that a larger aerosol than desired
for EEG delivery is leaving the device and will most likely lead to higher losses in the
MT region. This, coupled with the almost nonexistent FPF<1µm values that are required
for the EEG application, makes this ineffective for EEG delivery.
Another device, the Orbital multi-breath inhaler, was shown to deliver up to 400 mg
of multiple powder formulations (Young et al. 2013). This large mass was delivered
over 16 inhalations with ED of approximately 75%, but the particle size, while
satisfactory for formulations using a static particle size, was not ideal for EEG delivery,
even with a flow rate of 60 LPM. The device produced particle sizes with FPFs of 42-
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67% and MMADs of 3, 4.2, and 4 µm using Ciprofloxacin (Cipro), mannitol, and a 1:8
Cipro-mannitol co-spray-dried powder, respectively (Young et al. 2013).

2.4.3 Fluidized Beds
Fluidized beds have been used to generate aerosols for many applications, but
have mostly been used in large, commercial machines, not in a handheld device (Hinds
1999). This concept uses a collection of solids (often, spheres) that behave like a fluid
when a gas passes through them (Prenni et al. 2000). This fluid-like movement causes
the solids to move around and contact each other, producing high frequency vibrations
and a vibrating-like motion that can help deaggregate a powder.
Of the currently available high dose DPI designs, none have been designed
specifically to deliver an EEG aerosol. Because of this, the designs do not meet the
desired performance requirements and new devices must be explored to achieve the
needed performance. A fluidized bed design could prove useful in delivering this large
dose because of its good performance in commercial applications to create large
amounts of monodisperse aerosols of small sizes (Lind et al. 2010).
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2.5 Objective 4: Development of a Low-Volume CapsuleBased Dry Powder Inhaler and Nose-To-Lung Delivery
Platform

2.5.1 Low Volume Uses/Benefits
Some patients, especially infants, require a device that uses a small volume of
air to produce a useable aerosol. Infants have a small tidal volume and cannot safely
use traditional DPIs or even some of the devices that use lower flow rates to function
because the powder would either not be deaggregated properly or it would deposit in
the device before reaching the patient (Syedain et al. 2015). A new low volume inline
device is intended to effectively produce the aerosol for the patient with a small amount
of additional air that still allows for effective delivery. Across a range of applications
including infant mechanical ventilation, N2L delivery during low flow oxygen
administration, and aerosol delivery through a sealed mask in NPPV, an added gas
volume of approximately 2-5 mL is acceptable for forming the aerosol. This small
volume of added air is necessary to avoid complications with subjects that have small
tidal volumes such as infants (~50 mL). The device should be easy to load and should
be capable of aerosolizing typical high dose medications, all while being operated by a
caregiver. A potential high dose application involving the delivery of surfactants to
infants is given below, followed by a review of existing low volume devices.
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2.5.2 Surfactant Delivery
Respiratory distress syndrome in infants is usually caused by a lack of pulmonary
surfactant production associated with preterm birth (Rey-Santano et al. 2013). This is
currently corrected by delivery of a liquid bolus containing surfactant to the lungs via an
endotracheal tube (Syedain et al. 2015). This can cause complications including
transient hypoxia, hypercapnia, and changes in cerebral blood flow (Schipper et al.
1997, Murdoch et al. 1998). Delivery of surfactant in an aerosol form has been shown
to improve lung functions similar to the use of bolus instillation. However the aerosol
therapy produced less adverse effects when compared to the bolus technique (ReySantano et al. 2013).

2.5.3 Available Low Volume Devices
Laube et al. (2012) used the Solovent® DPI to deliver an aerosol using a 5 mL
syringe as the air source. High losses, greater than 96% of the ED, in the spacer
resulted in low lung delivery efficiency. The average diameter of particles in the powder
used in this study was 4.5 µm. This device was not designed to deaggregate powder
any further, as with a 3D rod array, but it can be assumed that since larger particles are
filtered out due to depositional losses, the average diameter was reduced before
reaching the patient.
The Microjet™ device is a characteristic inter-tracheal catheter spray unit
(requiring a liquid formulation) and was tested in one study by Syedain et al. (2015) to
deliver a surfactant aerosol to infants through an endotracheal tube. The device is
small (<1 mm in diameter) and can be inserted into ETTs as small as 2 mm. This
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device was designed to produce an aerosol using an airflow rate in the range of 0.05
and 0.24 LPM at high pressure (40-80 psi). The device creates a high velocity jet
exiting the device which is said to be reduced quickly after exiting the device to follow
the flow stream into the patient’s lungs. The majority of the particles leaving the device
were in the 2.5 to 5 µm range. While this device shows promise, the potential
consequences of a high velocity aerosol spray exiting the device and entering the
trachea may cause aerosol deposition in unwanted areas, as well as possible trauma,
such as pulmonary perforations caused by the liquid jet piercing the soft lung tissue, to
the patient.
The DP-4M Dry Powder Insufflator™ (PennCentury, Wyndmoor, PA, USA) device
is designed to produce an aerosol with less than 2 mL of air produced from a syringe or
air pump. The device has a chamber that can be hold a small amount of powder to be
delivered through the small stainless steel tube at the end of the device. The device
has been used to deliver multiple powder formulations of multiple sizes (Cryan et al.
2007, Hoppentocht et al. 2014b). While this device is designed for endotracheal
aerosol delivery to mice (Morello et al. 2009), it has been shown to produce a useable
aerosol for the delivery of insulin to monkeys (Grainger et al. 2004). The device
retention has also been shown to be low with some formulations, while using multiple
actuations of less than 1 mL (Hoppentocht et al. 2014b).
Hoppentocht et al. (2014b) performed a study to characterize the exiting aerosol
from the same DP-4M Insufflator used in the previously mentioned studies.
Formulations investigated include both spray-dried and micronized versions of
tobramycin, mannitol, inulin, and colistimethate sodium. 0.5 to 3 mg doses were
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investigated for 200, 500, and 1000 µL of air used for dispersion. Device retention and
particle sizes for each formulation had varying results. MMADs ranged from less than 3
µm to more than 30 µm, with larger particles coming from the higher loaded doses.
Device retention ranged from less than 5%, with some tobramycin cases, to close to
100% with some mannitol and inulin cases.
Existing devices each provide some characteristics of a high performance
design, but they do not provide all of the desired capabilities. Disadvantages of some of
these devices include complex loading, variability of delivery efficiency between
patients, as well as variability between performance with different powder formulations,
high losses in delivery systems, and possible complications due to high velocity air
streams entering the lungs. Based on this analysis, a new low-volume inline device is
required to effectively aerosolize and deliver EEG powder formulations that can meet
the following performance requirements: MMAD less than 1.5 µm, FPF<5µm greater than
90%, FPF<1µm greater than 30%, and an ED of at least 75%.
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Figure 2.1

Chart showing the origin of the devices in this research with an expanded

view of the overall device categories showing dispersion mechanisms for each.
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Table 2.1

Table defining characteristics used throughout the presented research.

Characteristic Terms
Low Dose

High Dose

Low Flow

High Flow

Low Volume

High Volume

Adult Negative Pressure
Drop

Child Negative Pressure
Drop

Definition
Powder masses typically
delivered using
commercial DPIs and
asthma medicines
Powder masses larger
than typically delivered in
commercial DPIs

Typical Values
0.5 – 20 mg (total
formulation mass)

>25 mg (total formulation
mass)

Ventilation flow rates used 1 – 8 LPM
for children/infants or for
adults without the
requirement of added
humidity
Ventilation flow rates
>10 LPM
higher than low flow
values which typically
require heating and
humidifying the air flow
patient comfort
DPI actuation air volumes ≤10 mL
on the order of test animal
and infant tidal volumes or
that are much smaller
than adult tidal volumes
Volumes associated with
1–4L
typical adult lung volumes
Pressure achievable when 4 kPa
a typical adult patient
inhales through an oral
DPI
Pressure achievable when 2 kPa
a typical child patient
inhales through an oral
DPI
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Chapter 3

Development of a High Efficiency Dry

Powder Inhaler for EEG Delivery
3.1 Objective
The objective of this study is to develop a capsule-based high efficiency oral DPI
intended for EEG aerosol delivery.

3.2 Introduction
Dry powder inhalers (DPIs) prescribed to patients all over the world are inefficient
in delivering drugs that are able to penetrate the lungs. The excipient enhanced growth
(EEG) method of drug delivery requires an inhaler producing a small particle size to
function properly (Hindle et al. 2012, Longest et al. 2012b). This small size can help to
prevent mouth-throat (MT) deposition from impaction on the back of the throat due to
the sudden change of direction. The inhaler to be used should also have a higher
resistance to keep the flow rate relatively low, thereby also helping to reduce the MT
deposition (DeHaan et al. 2004).
The objective of this study is to develop a high efficiency DPI intended for the
delivery of EEG aerosols. The optimized EEG powder formulation proposed by Son et
al. (2013a) is used in conjunction with the previously developed 3D rod array (Son et al.
2013b). Capsule chamber (CC) orientations explored include parallel and perpendicular
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to the inlet flow. All devices are tested with a pressure drop of 4 kPa for adult inhalation
conditions, unless otherwise stated, which produces a flow between 40-50 LPM at our
target inhaler resistance of 0.044

√𝑘𝑃𝑎
.
𝑙𝑝𝑚

Results are given in terms of device and capsule

retention, emitted dose (ED), fine particle fractions less than 5 µm (FPF<5µm), fine
particle fractions less than 1 µm (FPF<1µm), and the mass median aerodynamic diameter
(MMAD) of the aerosol produced. Aerosolization characteristics of a high performance
design will consist of an MMAD less than 1.5 µm, FPF<5µm greater than 90%, FPF<1µm
greater than 30%, and an ED at or above 75%.

3.3 Devices and Methods
Inhaler Design of the Capsule-Based High Efficiency DPIs
The capsule based oral inhalers to be tested consist of a capsule chamber (CC)
to house the size 3 capsule (Capsugel, Morristown, NJ) during use and a mouthpiece
with a 3D rod array inside to assist in aerosolization of 2 mg of EEG-AS formulation.
The VCU1 inhaler is designed around a CC that is perpendicular to the incoming flow,
while the VCU3 design uses flow parallel to the capsule, as different orientations to
empty the capsule. Figure 3.1 and Figure 3.2 show examples of VCU1 and VCU3,
respectively. The mouthpiece for both was optimized in the study by Son et al. (2013b),
using the 3D rod array as the deaggregation mechanism. Both prototyped and metal
versions of the rod array will be analyzed in this study.
CC designs for the VCU1 device included staggering the inlet holes from the
centerline, as well as a single inlet hole in the middle. The staggering of air holes,
shown in Figure 3.3 analyzed in this study include 0, 0.41, 0.83, 1.24, and 1.65 mm
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offset from the CC centerline. A single, central hole was also included to be analyzed.
Each of these CC designs use inlet hole diameters to match the desired pressure drop
of 4 kPa across the device when used with a flow rate of 45 LPM.
VCU3 CC designs, shown in Figure 3.4 include 45 and 90 degree angles
between the CC and the mouthpiece flow passage. Each design has a central hole
located at the top of the CC with a diameter chosen to produce a pressure drop of 4 kPa
at a flow rate of 45 LPM. Each design also incorporates the same 3D rod array used in
the VCU1 device.
The inhalers were created using Autodesk Inventor and exported as .STL files to
be prototyped. The files were then prepared using 3D Lightyear File Preparation
Software. The parts were built using a 3D Systems Viper SLA Prototyper (3D Systems
Inc., Rock Hill, SC) using Accura 60 stereolithography resin (3DSystems Inc.). Once
the parts were prototyped, they were cleaned using a Proclean SL Part Washer (3D
Systems Inc.) and dried in a 3D Systems dryer for approximately 90 min.

High-Speed Photography
The motion of the capsule inside of the chamber was analyzed using a Photron
PCI R2 high-speed camera at 2000 frames per second. This helped to show the overall
movement of the capsule as well as to determine the number of apparent chamber wall
impactions per second. Rapid changes in capsule direction near the wall surface were
assumed to be due to contact with the wall and counted as a capsule wall impaction.
The impactions were counted for a total of 1,500 frames to determine the total number
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per second. Three videos were analyzed for each device and the average impactions
per second were calculated from the data.

3.4 Results
The device retention and aerosolization performance for each capsule chamber
design of VCU1 are given in Table 3.1. CC1-4 all achieved between 64 and 68% ED
with FPF<5µm and FPF<1µm at or above 90% and 30%, respectively. MMADs produced
were also similar, in the range of 1.44-1.55 µm. While CC1-4 were not statistically
different in terms of ED and aerosolization characteristics, CC1 achieved the lowest
variability in device and capsule retention. For this reason, CC1 was chosen to be
optimized further. In an attempt to further increase deaggregation, the prototyped,
plastic, 3D rod array was replaced with stainless steel rods of the same dimensions.
Table 3.2 shows the increase in aerosolization performance as the FPF<1µm increased
5%, causing a decrease in MMAD from 1.44 to 1.30 µm. To increase the ED of the
device a coating of polytetrafluoroethylene (PTFE) was applied to the interior walls. ED
was increased from 64% to 81% while the particle size leaving the device was
unchanged (Table 3.2). CC1 was also compared with the Aerolizer, HandiHaler, and
the modified HandiHaler, from the study by Son et al. (2013b), in Figure 3.5. The
optimized device outperformed all of the commercial devices in both delivery and
aerosolization performance.
ED and aerosolization results comparing the CC90 and CC45 capsule chambers
to the CC1 device optimized previously can be found in Table 3.3. Both the CC90 and
CC45 devices showed increases in FPF<5µm and ED values. More importantly, the
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optimized CC1 device was compared to the CC90 device across a range of different
pressure drops which resulted in different flow rates through the devices (Table 3.4).
An increase from 2 to 6 kPa pressure drop across the CC1 device led to an increase to
70% from 61% ED while the CC90 only increased from 71 to 73%. FPF<5µm also
increased with CC1 (91 to 94%) from the pressure drop increase, with CC90 staying
constant at 95%. This FPF<5µm increase in CC1 corresponds to a decrease in MMAD
from 1.63 µm at 2 kPa to 1.50 µm at 6 kPa. CC90, again, produced a more consistent
value, across the range of pressures, of 1.54 µm at 2 kPa and 1.48 µm at 6 kPa. Figure
3.6 shows a comparison of both the CC1 and CC90 devices to reported values of
FPF<5µm and MMAD for various commercial inhalers. Even at extremely high flow rates
(150 LPM), the commercial devices fail to create an aerosol with an MMAD of less than
2 µm and an FPF<5µm of greater than ~40%.

32

3.5 Abbreviations
AS

Albuterol sulfate

CC

Capsule chamber

DPI

Dry powder inhaler

ED

Emitted dose

EEG

Excipient enhanced growth

FPF

Fine particle fraction

MMAD

Mass median aerodynamic diameter

MT

Mouth-throat

PTFE

Polytetrafluoroethylene
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Figure 3.1

Images of the best case VCU1 inhaler (CC1-3D) including (a) surface

model of the composite device with an internal 3D rod array, (b) an opened device for
capsule loading with a size 3 capsule, and (c) the prototyped device for experimental
testing. Panel (b) illustrates the device separated at the interface between the capsule
chamber (CC) analyzed in this study and the previously optimized downstream flow
passage (mouthpiece) and 3D rod array.
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Figure 3.2

The best case VCU3 inhaler (CC90-3D) with the capsule in the (a) loaded

(no flow), and (b) in-use (45 LPM) position. A minimum flow rate of 25-30 LPM is
required to elevate a capsule containing 2 mg of powder above the red line marked in
the capsule viewing window.
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Figure 3.3

Images of the VCU1 capsule chambers: (a) top view with dimensions and

a size 3 capsule in place, (b) side view illustrating height of all capsule chambers, and
(c) capsule aperture position on the capsule. Air inlet holes differentiate the capsule
chambers considered with (d) 2 inline inlets (CC1), (e) 2 inlets staggered by 1.65 mm
(CC5), and (f) one central inlet (CC6).
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Figure 3.4

Dry powder inhalers (DPI) considered consisting of different capsule

chambers (CC) coupled with the 3D rod array flow passage: (a) CC1-3D with two air
inlets and the capsule oriented perpendicular to the inlet airflow; (b) CC90-3D with the
capsule oriented parallel to the inlet airflow and a 90° angle between the CC and flow
passage; and (c) CC45-3D with a 45° angle between the CC and flow passage.
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Figure 3.5

Comparison of aerosolization performance [n=3; Mean (SD)] of CC1-3Dm-

PTFE with commercial and modified powder inhaler devices (batch 2 powders). (a)
Percent albuterol sulfate as a function of device and capsule retentions, (b) fine particle
fractions less than 5 and 1 µm, and (c) mass median aerodynamic diameters.
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Figure 3.6 Comparison of flow rate effects for the CC-3D inhalers and previously
reported commercial products in terms of (a) FPF<5µm and (b) MMAD. Salbutamol
Diskus, Diskhaler, and Turbuhaler were considered in the study of Prime et al.17 at flow
rates of 28-60 LPM. Salmeterol Diskus and Formoterol Turbuhaler were considered by
Tarsin et al. (2006), and the illustrated line represents the reported linear best fit of the
data.
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Table 3.1

The effect of air inlet hole staggering on the mean drug deposition and

aerosolization performance for VCU1 (CCs 1-5) coupled with the 3D rod array
mouthpiece tested at a 4 kPa pressure drop. Coefficient of variation (%) is shown in
parenthesis [n=3] (Behara et al. 2014a).
Description

CC1-3D

CC2-3D

CC3-3D

CC4-3D

CC5-3D

Offset distance (mm)
Air inlet hole diameter
(mm)
Air flow rate (L min-1)

0.00
3.16

0.41
2.78

0.83
3.17

1.24
2.78

1.65
3.08

50
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50
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Emitted (%)*
Capsule retention (%)*
Capsule
chamber
retention (%)
Mouthpiece retention (%)*

66.2 (1.8)
13.7 (10.5)
6.1 (17.3)

68.4 (3.6)
13.5 (17.4)
5.4 (30.3)

67.0 (10.0)
10.1 (6.7)
12.0 (40.4)

64.9 (17.3)
14.4 (50.3)
9.8 (81.9)

6.3 (63.9)**
90.4 (5.4)**
2.1 (55.1)

14.1 (4.4)

12.7 (8.0)

10.9 (21.7)

10.9 (21.2)

1.1 (37.7)**

FPF<5µm/ED (%)*
FPF<1µm/ED (%)*
MMAD (µm)*

93.8 (0.7)
30.9 (1.9)
1.47 (1.22)

93.6(1.1)
32.7 (4.1)
1.46 (2.54)

94.3 (3.0)
31.7 (3.4)
1.44 (0.68)

89.7 (1.0)
28.6 (7.3)
1.55 (3.76)

75.3 (16.4)**
20.8 (30.3)**
1.83 (15.39)**

*P<0.05 significant effect of air inlet staggering on % emitted, capsule & mouthpiece retentions,
FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way ANOVA).
**P<0.05 significant effect of % emitted, capsule & mouthpiece retentions, FPF <5µm/ED, FPF<1µm/ED and
MMAD compared to CC1-3D (post-hoc Tukey).
Batch-1 EEG formulation combination particles generated by Büchi Nano Spray Dryer (B-90).
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Table 3.2

Mean drug deposition and aerosolization performance of CC1 with resin or

metal 3D rod arrays and with the PTFE coated capsule and inhaler tested at a 4 kPa
pressure drop (equivalent to 50 L/min for each inhaler). Coefficient of variation (%) is
shown in parenthesis [n=3] (Behara et al. 2014a).
Description

CC1-3D

CC1-3Dm

CC1-3Dm-PTFE

Emitted (%)*
Capsule retention (%)*
Capsule chamber retention (%)*
Mouthpiece retention (%)*

63.8 (3.0)
14.1 (9.0)
8.8 (15.3)
13.2 (2.7)

64.7 (2.3)
16.2 (4.1)
8.8 (11.0)
10.2 (3.6)**

81.4 (2.7)**
7.3 (14.2)**
2.2 (25.4)**
9.1 (15.9)**

FPF<5µm/ED (%)
FPF<1µm/ED (%)*
MMAD (µm)*

93.9 (0.4)
32.2 (3.2)
1.44 (1.96)

94.5 (0.9)
37.3 (2.6)**
1.30 (1.74)**

92.7 (1.3)
36.8 (2.3)**
1.30 (0.97)**

*P<0.05 significant effect of uncoated devices built with resin and metal 3D arrays and
PTFE coated inhaler device with metal 3D array on % emitted, capsule, capsule
chamber & mouthpiece retentions, FPF<1µm/ED and MMAD (one-way ANOVA).
**P<0.05 significant effect of % emitted, capsule, capsule chamber & mouthpiece
retentions, FPF<1µm/ED and MMAD compared to CC1-3D with resin rod array (post-hoc
Tukey).
Batch-2 EEG formulation combination particles generated by Büchi Nano Spray Dryer
(B-90).
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Table 3.3

The effect of powder inhaler design on the mean AS deaggregation

performance when aerosolized at a 4 kPa pressure drop. Standard deviation is shown
in parenthesis [n=3] (Behara et al. 2014b).
Description

CC1-3D

CC90-3D

CC45-3D

Emitted dose (%)*

65.0 (4.1)

73.4 (4.1)

75.7 (0.4)**

FPF<5µm/ED (%)*
FPF<1µm/ED (%)*
MMAD (µm)*

91.4 (1.4)
29.2 (0.2)
1.52 (0.01)

95.1 (0.2)**
31.4 (0.1)**
1.49 (0.00)

94.3 (0.6)**
28.3 (0.8)
1.57 (0.02)**

*P<0.05 significant effect of inhaler design on % emitted, FPF<5µm/ED, FPF<1µm/ED and
MMAD (one-way ANOVA).
**P<0.05 significant difference compared to CC1-3D as shown in Fig. 3 (post hoc
Tukey).
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Table 3.4

The effect of airflow rate on aerosolization of AS using CC1-3D and CC90-3D designs. Data shown in grey

was duplicated from Table 3.3 for better presentation to the reader. Standard deviation is shown in parenthesis [n=3]
(Behara et al. 2014b).
Description

CC1-3D

CC90-3D

Air flow rate (LPM)
Pressure drop (kPa)

35
2

50
4

61
6

32
2

45
4

55
6

Emitted dose (%)*

61.0 (1.4)

65.0 (4.1)

69.9 (1.2)**

71.2 (1.6)

73.4 (4.1)

73.2 (1.9)

FPF<5µm/ED (%)*^
FPF<1µm/ED (%)*^
MMAD (µm)*^

91.3 (1.7)
27.1 (1.7)
1.63 (0.04)

91.4 (1.4)
29.2 (0.2)
1.52 (0.01)**

94.6 (0.3)**
28.6 (1.2)
1.50 (0.03)**

95.5 (0.1)
31.4 (0.4)
1.54 (0.01)

95.1 (0.2)**
31.4 (0.1)
1.49 (0.00)**

95.3 (0.2)
30.0 (0.7)**
1.48 (0.02)**

*P<0.05 significant effect for CC1-3D of air flow rate on % emitted, FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way
ANOVA).
^ P<0.05 significant effect for CC90-3D of air flow rate on FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way ANOVA).
**P<0.05 significant difference compared to 35 LPM with CC1-3D and 32 LPM with CC90-3D, respectively
(post hoc Tukey).
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Chapter 4

Develop an inline DPI system using the

3D rod array for high flow (15 LPM) and low flow (5
LPM)
4.1 Objective
The objective of this study is to develop an inline DPI system for delivering EEG
aerosols with low depositional losses in the device and high aerosolization efficiency.

4.2 Introduction
Administration of medication to patients on mechanical ventilation can be a
difficult problem to solve. Non-invasive ventilation (NIV) techniques can be used to
continuously deliver the oxygen needed by the patient without using a tracheostomy
tube or an endotracheal tube. This oxygen delivery system could be used to also carry
a drug in aerosol form through the nose-mouth-throat (NMT) and into the lungs. To
make this type of delivery feasible, losses in tubing and connectors should be minimal
to make sure the correct dose is being delivered to the patient (Longest et al. 2013a).
The objective of this study is to design an active DPI system capable of
delivering an EEG aerosol efficiently in terms of powder deaggregation and low system
retention. The system to be considered is an inline device with a flow control orifice, a
capsule chamber, and a 3D rod array connected to a high flow nasal cannula (HFNC),
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previously optimized by Longest et al. (2013a), with tubing. Flow control orifice size,
airflow rate, and 3D rod array designs will be varied to produce an optimized system.
The CC90 device developed by Behara et al. (2014b) will also be used in the system as
a comparison. Aerosolization characteristics of a high performance design will consist
of an MMAD less than 1.5 µm, FPF<5µm greater than 90%, FPF<1µm greater than 30%,
and an ED at or above 75%.

4.3 Devices and Methods
Experimental Setup
A schematic showing the experimental setup used in this study is shown in
Figure 4.1. A standard 1 L ventilation bag (Adult Manual Resuscitator, Legend Medical
Devices, South El Monte, California) was connected to the devices using 10 mm
connective tubing with a flow meter (Sensirion EM1, Sensirion AG, Stafa, Switzerland)
between the two for flow rate monitoring. The device was connected to the HFNC using
the same style 10 mm tubing.
The Low Flow Nasal Cannula (LFNC) system, shown in Figure 4.2, uses a
continuous flow through the device to deliver an aerosol through tubing, a streamlinedY, and a streamlined nasal cannula. The particle size exiting the nasal cannula will be
characterized first, then the optimized system will be connected to a realistic NMT
model to investigate the depositional losses and approximate lung dose.

45

Estimated Flow Values
To capture the flow profiles through each device, the flow meter was used during
experiments to record the flow from the ventilation bag in 0.02 second intervals. The
ventilation bag was squeezed by hand to produce the flow through the system. The
inlets of the devices to be studied are 2.0 mm, 2.3 mm, 3.1 mm, and 3.6 mm and the
max flow rates through each are 10, 22, 38, and 41 LPM, respectively, depending on
the rod array configuration used (232, 212, 343, or 565) as the dispersion mechanism.
To characterize the flow, multiple methods were used for each of the devices and these
values are given in Table 4.1 and Table 4.2. Total average flow rates were calculated
as the time average of all recorded data points. This method is useful in estimating the
total volume of air passed through each device, but the value given is most likely an
underestimation of the effective aerosolization flow rate. To account for this
underestimation, the root-mean-square (RMS) of the plateau values was taken. The
plateau was estimated, using an iterative process, to be approximately 70% of the
plateau average. The upper range of the flow rate was estimated by the Q 90 method,
which determined the flow rate that 90% of the total recorded flow values were under.
The max flow rate for each device was also recorded, but this value was only achieved
for a small amount of time during actuation.

Inhaler Design
The devices, shown in Figure 4.3, were created using Autodesk Inventor and
exported as .STL files to be prototyped. The files were then prepared using 3D
Lightyear File Preparation Software. The parts were built using a 3D Systems Viper SLA
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Prototyper (3D Systems Inc., Rock Hill, SC) using Accura 60 stereolithography resin
(3DSystems Inc.). Once the parts were prototyped, they were cleaned using a Proclean
SL Part Washer (3D Systems Inc.) and dried in a 3D Systems dryer for approximately
90 min. Both systems were designed to house a size 3 capsule filled with 2 mg of EEGAS formulation.
Figure 4.4a shows the device connected to the High Flow Nasal Cannula (HFNC)
using a length of tubing, while Figure 4.4b shows the device prototyped with the HFNC
directly attached. For comparison, the previously developed CC90 device was
prototyped with the HFNC directly attached (Figure 4.5). A front view of the HFNC is
given in Figure 4.6 to show the two separate inlets, one, streamlined, for the aerosol
and one for the humidified air. To optimize the inline devices, different capsule piercing
locations were also investigated (Figure 4.7).
The LFNC system, illustrated in Figure 4.2, uses a continuous flow through a
device similar to that used in the HFNC therapy. This device was designed to operate
at a lower flow rate (~5 LPM) while still creating a high quality aerosol to pass through
tubing and connectors and out of a custom nasal cannula. A commercial Y-connector
and cannula, illustrated in Figure 4.8a-b, are also explored in this study. Custom Yconnectors and cannulas, using 2 and 4 mm tubing, are shown in Figure 4.8c-f and are
compared to the commercial devices using device retention and particle sizing data.
The different cases to be investigated are given in Table 4.3.

47

4.4 Results
Based on Table 4.4, the best performing device, denoted 3.1-565-ECG (3.1 mm
inlet-565 rod array), achieved an ED of 71% with an MMAD of 1.39 µm (Case 3).
FPF<5µm values were lower than desired (83%), but were still high. A PTFE coating,
similar to the coating of the CC1 device from Objective 1, was applied to increase the
delivery efficiency and the comparison of the devices is given in Table 4.5. ED was
increased to 78% and the aerosolization performance remained similar to the device
without the coating. The device was also compared to the previously developed CC 90
device that was adapted to connect to the ECG cannula and the results are shown in
Table 4.6. While the aerosolization performance was similar between the devices, the
ED of the inline device was 5% higher (71% vs. 66%) than the adapted CC90 device.
Different rod array configurations were tested and compared to the 3.1-565 device.
Table 4.7 shows that the 2.3-343 device achieved a 4% higher ED, but the lower flow
rate caused a decrease in aerosolization performance shown by the higher MMAD
value. The 2.3-212 device was, all around, less effective than the 3.1-565 device,
producing a 2% less ED and an MMAD 0.2 µm larger.
The 2.0-232 inline DPI used in the LFNC delivery system was able to produce a
small particle size using only a flow rate of 5-10 LPM. The results of system retention
and particle size leaving the cannula are given in Table 4.8. The system using 4 mm
tubing from the Y-connector to the cannula showed a much lower retention than the
commercial system (<2% vs. 21%). The commercial system did produce a higher FPF
for both less than 5 and 1 µm. This data could, however, be skewed due to losses of
larger particles in the system. The optimized system was attached to a NMT model with
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a mannequin head used to create the realistic attachment of the system around the ears
and into the nostrils. The results using both 5 and 10 LPM through the device and 30
and 45 LPM through the NMT model are given in Table 4.9. Losses in the device,
including capsule retention, were above 20%, with the lower flow through the device
producing the highest losses. NMT losses were no higher than 3%, but the lower flow
rate of 30 LPM produced losses in the range of 1%.
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4.5 Abbreviations
AS

Albuterol sulfate

CM

Commercial

DPI

Dry powder inhaler

ED

Emitted dose

EEG

Excipient enhanced growth

FPF

Fine particle fraction

HFNC

High flow nasal cannula

HPMC

Hydroxypropyl methylcellulose

LFNC

Low flow nasal cannula

MMAD

Mass median aerodynamic diameter

MT

Mouth-throat

NIV

Noninvasive ventilation

NMT

Nose-mouth-throat

PTFE

Polytetrafluoroethylene

RMS

Root mean square

SL

Streamlined

50

Figure 4.1

The active dry powder inhaler (DPI) system including a ventilation bag,

flow meter (for experimental testing only), inline DPI (containing a flow control orifice
and 3D rod array), and streamlined nasal cannula.
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Figure 4.2

Schematic drawing of the inline LFNC system showing the device

connected to the Y-connector and cannula.
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Figure 4.3

Inline DPI devices consisting of a flow control orifice (2.3 – 3.6 mm

diameter), a capsule chamber, restraining mesh, 3D rod array and flow passage that
connects to 10 mm diameter ventilator tubing. Different flow control orifice size and rod
array pattern configurations were considered including (a) 3.6 mm orifice and 5-6-5 rod
array pattern, (b) 3.1 mm orifice and 5-6-5 rod array pattern, (c) 2.3 mm orifice and 3-43 rod array pattern, and (d) 2.3 mm orifice and 2-1-2 rod array pattern.
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Figure 4.4

Illustration of the DPI (a) with and (b) without connective tubing leading to

the ECG cannula. The length of the connective tubing in Panel (a) is not draw to scale.
In the experiments, only the 3.6-565 DPI contained a 13 cm length of 10 mm diameter
connective tubing between the device and ECG cannula. The other devices
implemented a much shorter (~1 cm) length or eliminated the connective tubing.
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Figure 4.5

Connection of the previously optimized passive CC90-3D inhaler used for

oral inhalation to the ECG cannula. In this setup, the CC90-3D inhaler was operated by
connecting the flow delivery line to the inlet orifice above the capsule chamber.
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Figure 4.6

Divided ECG cannula for dual stream aerosol delivery during HFNC

therapy. During aerosol administration, the aerosol stream from the DPI enters one
side of the cannula and flows through a streamlined passage into one nasal prong.
High flow therapy (heated and humidified) gas enters the other nasal prong.
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Figure 4.7

Capsule piercing apertures with different configurations denoted (a) Case

1, (b) Case 2, (c) Case 3, (d) Case 4, and (e) Case 5. Direction of flow during operation
and the restraining mesh are illustrated in Panel (a). Apertures with a diameter of 0.5
mm were located at the top (or bottom) of the capsule, midway the head (or base)
curvature, and at the start of the head (or base) curvature.
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Figure 4.8

Illustration showing (a) Commercial (CM) 2mm Y-connector, (b) CM

cannula, (c) Streamlined (SL) 2mm Y-connector, (d) SL 2 mm cannula, (e) SL 4mm Yconnector, and (f) SL 4mm cannula
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Table 4.1

Air flow characteristics for the 3.6-565-ECG and 3.1-565-ECG devices based on total average flow, RMS,

and Q90 metrics (n≥3; Mean±SD). The maximum instantaneous flow rate recorded is also reported (Behara et al. 2014c).

Method

3.6-565-ECG
3.1-565-ECG
Flow rate Duration Maximum flow Flow rate Duration Maximum flow
(LPM)
(s)
(LPM)
(LPM)
(s)
(LPM)

Total average 25.4 (1.6)
RMS
35.2 (1.9)
Q90
39.6 (2.2)

1.1 (0.2)
0.7 (0.1)
1.1 (0.2)

40.9 (2.6)

21.5 (1.8)
27.2 (1.9)
33.0 (2.3)

1.7 (0.3)
1.1 (0.0)
1.7 (0.3)

Total average: Average all flow values for entire bag squeeze.
RMS: root-mean-squared average of flow in the plateau of the flow rate profile.
Q90: Flow rate below which 90% of all measured values occur.
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37.7 (2.4)

Table 4.2

Air flow characteristics for the 2.3-343-ECG and 2.3-212-ECG devices based on total average flow, RMS,

and Q90 metrics (n≥3; Mean±SD). The maximum instantaneous flow rate recorded is also reported (Behara et al. 2014c).

Method

2.3-343-ECG
2.3-212-ECG
Flow rate Duration Maximum flow Flow rate Duration Maximum flow
(LPM)
(s)
(LPM)
(LPM)
(s)
(LPM)

Total average 10.8 (1.2)
RMS
14.7 (0.9)
Q90
18.1 (1.1)

3.4 (0.6)
2.0 (0.3)
3.4 (0.6)

21.6 (0.7)

8.0 (0.9)
11.6 (0.6)
13.1 (0.6)

3.5 (0.8)
1.5 (0.3)
3.5 (0.8)

Total average: Average all flow values for entire bag squeeze.
RMS: root-mean-squared average of flow in the plateau of the flow rate profile.
Q90: Flow rate below which 90% of all measured values occur.
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14.0 (0.6)

Table 4.3

Descriptions of experimental cases used with the 2.0-232 inline DPI

device using commercial (CM) or streamlined (SL) Y-connectors and cannulas with
continuous flow or ventilation bag modes of actuation.
Cases

a
b
c

Y-connector

Cannula

Device flow
rate
(LPM)
5
5
5
5
5
5
10
5
10
5

NMT-TB flow
rate (LPM)

0
CM-2mm
CM-2mm
45a
1
SL-2mm
CM-2mm
45a
2
SL-4mm
CM-2mm
45a
3
SL-4mm
SL-2mm
45a
4
SL-4mm
SL-4mm
45a
5
SL-4mm
SL-4mm
45b
6
SL-4mm
SL-4mm
45b
7
SL-4mm
SL-4mm
30b
8
SL-4mm
SL-4mm
30b
c
9
SL-4mm
SL-4mm
45b
Aerosol from cannula was directed into the NGI.
Aerosol from the cannula was directed into the nasal inlet of the NMT-TB model.
Ventilation bag actuated case with device flow rate calculated as a root-mean-square
(RMS) approximation over time with three actuations of the bag.
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Table 4.4

The effect of capsule piercing configuration on the mean AS device retention and aerosolization

performance at the exit of the ECG cannula for five different capsule piercing cases when the 1 liter bag was squeezed
four times through 3.1-565-ECG device. The device was connected to a streamlined ECG cannula positioned at the
entrance to the NGI. The standard deviation (SD) is shown in parenthesis [n=3] (Behara et al. 2014c).
Description

Case 1

Case 2

Case 3

Case 4

Case 5

ED (%)*

76.5 (0.9)

79.2 (0.7)

71.1 (1.0)**

73.9 (2.4)

70.9 (2.6)**

Capsule (%)*
CC (%)*
Flow passage (%)
Connecting tubing (~1 cm) (%)
ECG Cannula (%)

7.1 (0.5)
3.3 (0.8)
8.7 (0.4)
1.8 (0.2)
2.6 (0.3)

6.3 (0.7)
1.2 (0.1)**
8.8 (0.2)
1.8 (0.1)
2.7 (0.2)

8.5 (0.7)
6.8 (1.0)**
9.6 (0.6)
1.6 (0.3)
2.3 (0.2)

7.5 (0.4)
4.7 (0.7)
9.1 (0.4)
1.5 (0.1)
3.3 (2.0)

9.5 (1.6)**
7.6 (0.6)**
8.2 (0.7)
1.6 (0.3)
2.1 (0.0)

FPF<5µm/ED (%)*
78.1 (3.7)
71.6 (4.6)
83.1 (1.4)
81.8 (4.7)
80.4 (4.7)
FPF<1µm/ED (%)*
23.7 (2.7)
20.5 (2.3)
30.3 (1.6)
27.6 (3.3)
27.7 (3.9)
MMAD (µm)*
1.55 (0.06)
1.62 (0.04)
1.39 (0.05)**
1.48 (0.06)
1.45 (0.08)
*P<0.05 significant effect of capsule piercing on % ED, capsule and CC drug retention, FPF<5µm/ED, FPF<1µm/ED and MMAD
(one-way ANOVA).
**P<0.05 significant effect compared to Case 1 (post-hoc Tukey).
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Table 4.5

The effect of coating the device and capsule with PTFE on the mean AS

emitted dose and aerosolization performance for the 3.1-565-ECG device using Case 3
piercing with two bag actuations [n=3; Mean(SD)] (Behara et al. 2014c).
Description

No PTFE

PTFE

ED (%)

72.1 (2.5)

78.2 (0.9)*

FPF<5µm/ED (%)
FPF<1µm/ED (%)
MMAD (µm)

77.6 (8.3)
26.1 (5.4)
1.48 (0.11)

78.9 (5.8)
25.8 (3.8)
1.47 (0.07)

*p<0.05 significant difference between no PTFE and PTFE coating for ED (independent
samples t-test).
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Table 4.6

Comparison between the mean AS emitted dose and aerosolization

performance for the 3.1-565-ECG and CC90-3D devices (four bag actuations) (Behara et
al. 2014c).
Description

3.1-565-ECG

CC90-ECG

ED (%)

71.1 (1.0)

66.4 (2.2)*

FPF<5µm/ED (%)
FPF<1µm/ED (%)
MMAD (µm)

83.1 (1.4)
30.3 (1.6)
1.39 (0.05)

85.6 (0.7)*
30.9 (0.6)
1.42 (0.01)

*p<0.05 significant difference between the devices for ED and FPF<5µm/ED (independent
samples t-test).
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Table 4.7

The effect of orifice size (3.1 vs. 2.3 mm) and 3D rod configuration on the

mean AS emitted dose and aerosolization performance with four bag actuations
(Behara et al. 2014c).
Description

3.1-565-ECG

2.3-343-ECG

2.3-212-ECG

ED (%)

71.1 (1.0)

75.3 (2.5)

68.8 (4.4)

FPF<5µm/ED (%)*
FPF<1µm/ED (%)*
MMAD (µm)*

83.1 (1.4)
30.3 (1.6)
1.39 (0.05)

65.4 (6.4)**
20.7 (3.0)**
1.64 (0.07)**

60.2 (8.5)**
21.1 (4.7)**
1.59 (0.07)**

*P<0.05 significant effect of device on % FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way
ANOVA).
**P<0.05 significant differences compared to 3.1-565-ECG (post-hoc Tukey).
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Table 4.8

Emptying, deposition, and aerosolization characteristics exiting the

cannula for the AS formulation in the 2.0-232 inline DPI operated with continuous flow
through the device of 5 LPM and a NGI flow rate of 45 LPM [n=3; Mean (SD)]. Testing
was performed by Dr. S. R. Behara.
Description

Case 0
CM2CM2

Case 1
SL2CM2

Case 2
SL4CM2

Case 3
SL4SL2

Case 4
SL4SL4

Emitted dose (%)a

73.9 (1.2)

73.1 (3.0)

70.6 (1.9)

81.3 (5.6)

76.6 (3.9)

Capsule retention (%)
Capsule chamber (%)
Flow passage (%)b

5.0 (0.4)
8.1 (0.5)
12.9 (1.6)

5.1 (1.3)
9.8 (0.8)
12.1 (1.9)

4.8 (0.8)
11.0 (0.3)
13.6 (1.9)

4.1 (0.3)
9.6 (0.8)
5.0 (6.0)

4.3 (1.4)
9.5 (2.3)
9.6 (1.9)

Y-connector (%)
Tubing (%)
Cannula (%)

9.8 (1.4)
11.2 (1.3)
21.0 (3.3)

4.0 (1.0)
15.0 (1.6)
16.6 (2.2)

4.0 (1.4)
9.7 (2.1)
21.4 (3.3)

3.6 (0.6)
11.2 (0.8)
13.2 (0.4)

3.6 (0.8)
10.5 (3.5)
1.6 (0.3)

FPF<5µm/ED (%)*
95.7 (1.5)
94.1 (1.2)
92.6 (1.2)
87.1 (0.5)
85.3 (3.1)
FPF<1µm/ED (%)*
17.5 (1.5)
11.2 (2.9)
13.1 (2.8)
6.1 (1.3)
4.3 (0.6)
MMAD (µm)*
1.79 (0.03) 1.95 (0.07)
1.93 (0.08)
2.15 (0.03)
2.22 (0.02)
*P<0.05 significant effect of device on % FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way ANOVA).
a
Percentage of the loaded dose leaving the inline DPI device
b
Includes the 3D rod array and DPI flow passage
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Table 4.9

Emptying, deposition, and aerosolization characteristics exiting the NMT

for the AS formulation in the 2.0-232 inline DPI operated at continuous flow rates of 5 or
10 LPM with NMT flow rates of 30 or 45 LPM [n=3; Mean (SD)]. Testing was performed
by Dr. S. R. Behara.
Description

Case 5
5/45

Case 6
10/45

Case 7
5/30

Case 8
10/30

Emitted dose (%)a

71.0 (2.2)

79.6 (1.2)

71.3 (6.5)

73.5 (1.9)

Capsule retention (%)
Capsule chamber (%)
Flow passage (%)b

6.1 (1.7)
11.9 (2.3)
11.0 (1.3)

4.0 (0.5)
7.6 (0.7)
8.7 (1.0)

7.3 (0.6)
10.3 (3.4)
11.2 (2.8)

5.2 (0.8)
9.7 (0.9)
11.6 (1.9)

Y-connector (%)
Tubing (%)
Cannula (%)

3.7 (0.3)
9.1 (1.7)
1.1 (0.1)

5.0 (1.0)
10.8 (0.3)
1.7 (0.2)

4.3 (1.6)
9.7 (1.5)
1.5 (0.2)

4.8 (0.7)
7.9 (0.5)
1.6 (0.3)

NMT (%)
Upper TB (%)
Lung chamber (%)

2.8 (0.8)
0.0 (0.1)
2.0 (1.5)

3.0 (0.3)
0.1 (0.1)
4.2 (1.6)

1.5 (0.8)
0.0 (0.0)
4.4 (2.2)

1.1 (0.3)
0.0 (0.0)
2.2 (0.5)

FPF<5µm/ED (%)*
82.3 (4.1)
80.7 (3.9)
83.0 (6.3)
90.1 (2.6)
FPF<1µm/ED (%)*
2.0 (1.8)
5.9 (3.0)
3.3 (5.6)
10.0 (2.5)
MMAD (µm)*
2.24 (0.07) 2.12 (0.09) 2.23 (0.19) 2.11 (0.08)
*P<0.05 significant effect of device on % FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way
ANOVA).
a Percentage of the loaded dose leaving the inline DPI device
b Includes the 3D rod array and DPI flow passage
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Chapter 5

Develop a New High-Dose Dry Powder

Inhaler (DPI) Based on a Fluidized Bed Design
5.1 Objective
The objective of this study is to develop a high efficiency, high-dose DPI intended
for EEG aerosol delivery using a concept similar to a classic fluidized bed aerosol
generator.

5.2 Introduction
Dry powder inhalers (DPIs) continue to gain market share and are becoming the
most prescribed devices for delivering inhaled medications to the lungs (Smith et al.
2010). Recent studies have demonstrated high efficiency performance of three
dimensional (3D) rod array DPIs with aerosol fine particle fractions (FPF) < 5 µm
greater than 90%, mouth-throat depositional loss <5%, and little sensitivity to inhalation
flow rate (Son et al. 2013b, Behara et al. 2014a, Behara et al. 2014b). However, these
DPI development studies and high efficiency devices were tested with relatively low
doses of drug. For these devices to deliver a large dose medication, like an inhalable
antibiotic, multiple capsules may need to be used to administer a therapeutic dose. In
the recent study by Behara et al. (2014b), a DPI was developed that could produce an
aerosol with a mass median aerodynamic diameter (MMAD) of approximately 1.50 µm,
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an emitted dose (ED) greater than 75%, and FPF less than 5 µm and 1 µm (FPF<5µm/ED
and FPF<1µm/ED) of 95% and 31%, respectively, at an inhalation flow rate of 45 LPM and
a pressure drop of 4 kPa using an excipient enhanced growth (EEG) powder
formulation. In comparison, most commercial DPIs typically employ carrier-particle
based formulations (i.e. lactose blends) that struggle to generate FPF<5µm above 40%
and produce lower values at low flow making dispersion highly dependent on inhalation
flow rate (Prime et al. 1999, Islam et al. 2012, Zhou et al. 2014). However, spray dried
formulations (i.e. PulmosphereTM, EEG) have frequently improved inhaler performance
by decreasing particle sizes, thus increasing FPF<5µm values (Sham et al. 2004, Geller
et al. 2011, Young et al. 2013, Weers et al. 2014). The high efficiency performance
achieved by Behara et al. (2014b) was performed with a 2 mg formulation mass, which
is consistent with inhaled medications such as β2-agonists and corticosteroids.
However, delivery of higher dose medicines with these new high efficiency devices may
require loading and actuating multiple powder capsules. Repeated loading and
delivering the medications over multiple cycles is time consuming and may result in
poor patient compliance (Smith et al. 2010) and potential variability in delivery
efficiency.
Potential pharmaceutical applications that require high-doses of drug include most
inhaled antibiotics (e.g., tobramycin), non-steroidal anti-inflammatories (e.g., disodium
cromoglycate), mucus clearance agents (e.g., mannitol), and surfactants (e.g.,
survanta) (Keller et al. 2010, Ruppert et al. 2010, Young et al. 2013). To deliver these
high-dose inhaled medications, three approaches may be employed: (i) use active DPIs
often requiring multiple dose loadings, (ii) implement single capsule passive devices

69

and load multiple capsules, and (iii) develop new passive devices intended for highdose medications. Active DPIs provide a power source to assist with aerosolizing the
large powder mass. For example, the MicroDose DPI (MicroDose Therapeutx, Inc.,
Monmouth Junction, NJ) utilizes a vibrating piezoelectric system to form an aerosol from
a foil dosing blister that can contain up to approximately 400 mg of powder (Corcoran et
al. 2013). Aerosolization performance with active devices is typically good; however,
the implementation of a power source typically increases device cost and complexity
(Islam et al. 2012, Zhou et al. 2014). Currently, the most widely used strategy for
delivering high-doses of inhaled medications is a capsule-based device with multiple
cycles of loading and actuation. For example, the Podhaler (Novartis Pharmaceuticals,
San Carlos, CA) inhaler is used to effectively deliver a 112 mg dose of tobramycin to
cystic fibrosis patients (Geller et al. 2011). This approach provides a significant time
savings compared with nebulized delivery, which typically requires 15-20 minutes per
treatment; however, the patient is required to load and actuate 4 separate capsules
(Geller et al. 2011). Furthermore, mouth-throat depositional loss is reported to be >40%
with the PulmoSphere formulation and Podhaler combination. For the delivery of
mannitol as a mucus clearance enhancer, Bronchitol (Pharmaxis Ltd, Sydney, Australia)
is currently delivered as 10 separate capsules containing 40 mg each (Bilton et al.
2011).
High-dose devices can be classified as delivering 50 mg of powder and above.
Ideally, the same device should also be capable of delivering lower masses in the range
of 10 or 25 mg. The Twincer inhaler is a passive device that can be operated with a
loaded mass up to approximately 50 mg; however, higher masses have not been
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reported (de Boer et al. 2012). Recently, the Orbital multi-breath inhaler was introduced
as a true high powder mass platform capable of delivering doses up to 400 mg over a
series of 16 inhalations (Young et al. 2013). With high powder mass devices, multiple
inhalations with a single dose loading are considering advantageous to avoid
overloading the oropharynx and upper airways with deposited powder during a single
inhalation. The Orbital was found to produce aerosols with MMADs of 3, 4.2, and 4 µm
using ciprofloxacin (Cipro), mannitol, and a 1:8 Cipro-mannitol co-spray-dried powder,
respectively (Young et al. 2013). Fine particle fractions were in the range of 42-67%
and mouth-throat (MT) depositional loss was not reported at the tested inhalation flow
rate of 60 LPM.
A concept that has previously not been reported for the efficient aerosolization and
delivery of pharmaceutical powders in a handheld device is that of a fluidized bed. The
fluidized bed concept consists of a collection of small spheres, or other solids, that have
fluid-like movement when a gas is forced through them (Prenni et al. 2000). Chaotic
motion of the spheres induces turbulence and collisions that can effectively
deaggregate a powder as it passes through the bed. This approach was previously
reported in a large scale device used to produce test aerosols for evaluating filters and
aerosol characterization equipment (Hinds 1999). Fluidized beds have also been used
to meter and fill dose containment units used in inhalers, such as blisters and capsules
(Zhu et al. 2006). However, a miniature fluidized bed in an inhaler has not previously
been considered and may provide an effective approach for producing high efficiency
aerosolization of high-dose medications.
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The objective of this study is to develop a high efficiency, high-dose DPI intended
for EEG aerosol delivery using a concept similar to a classic fluidized bed aerosol
generator (Hinds 1999, Prenni et al. 2000, Lind et al. 2010). The inhaler contains the
fluidized bed, which consists of small light-weight mixing balls. Designs include
introduction of the powder directly to the fluidized bed and containment of the powder in
a separate dosing sphere that is placed in the fluidized bed. The effect of the mixing
balls is also considered by removing them from the design and only including the dose
sphere. A series of in vitro experiments was conducted to select leading design
conditions, optimize the design, and evaluate aerosolization characteristics compared
with existing high efficiency devices at different flow conditions that reflect the inhalation
capabilities of adults and children.

5.3 Materials and Methods
Overview
To develop and optimize the fluidized bed (FB) -DPI, a number of screening
experiments were first conducted. The proposed design, shown in Figure 5.1, consists
of a chamber with an off-center inlet for airflow to enter from the top, approximately sixty
PTFE mixing balls that are 4.76 mm in diameter (McMaster-Carr, Elmhurst, Illinois), a
powder dosing sphere with an outer diameter of 12 mm, an inner diameter of 10 mm,
and four 0.5 mm holes for the powder to exit, a mixing chamber, a mesh to retain the
mixing balls, and a mouthpiece. The effects of different mixing ball sizes, air inlets,
mixing chamber sizes, and number of holes in the powder dosing sphere were
evaluated in search of an optimized design. The inlet, chamber size, and ball size were
72

optimized to produce the maximum vibrational amplitude, as measured using a
piezoelectric force sensor. Next, the powder dosing sphere was optimized based on
emptying over time to produce a consistent amount of powder leaving the device during
each inhalation using a readily available spray dried mannitol powder. Performance of
the proposed device was then compared to a previously developed high efficiency DPI
for EEG aerosol delivery (i.e., the CC90-3D inhaler) (Behara et al. 2014b). The FB-DPI
was tested using 25 mg of an EEG ciprofloxacin (EEG-Cipro) formulation for
comparison with a single 25 mg capsule used in the previously developed CC 90-3D
device. The FB-DPI was also tested using 100 mg of the EEG-Cipro formulation, at a
characteristic adult pressure drop of 4 kPa, and 50 mg using a representative pediatric
pressure drop of 2 kPa. Results of aerosolization are given in terms of dosing sphere
(or capsule) and device retention, ED, FPF<5µm/ED and FPF<1µm/ED, and the MMAD of the
aerosol. Based on previous studies, high efficiency performance for the delivery of EEG
formulations will be defined by the production of an aerosol with the following
characteristics: an MMAD of approximately 1.50 µm, FPF<5µm/ED above 90%, FPF<1µm/ED
above 30%, and an ED of approximately 75% while using a relatively large mass (25100 mg) of powder (Behara et al. 2014a, Behara et al. 2014b).

Materials
Ciprofloxacin hydrochloride (Cipro) was purchased from Spectrum Chemicals
(Gardena, CA) and Pearlitol® PF-Mannitol was donated from Roquette Pharma
(Lestrem, France). Poloxamer 188 (Leutrol F68) was donated from BASF Corporation
(Florham Park, NJ). L-leucine and all other reagents were purchased from Sigma
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Chemical Co. (St. Louis, MO). Hydroxypropyl methylcellulose (HPMC) capsules (size
3) were donated from Qualicaps (Whitsett, NC).

Inhaler design
A fluidized bed can be created by inducing fluid motion through an array
consisting of many solids, usually of similar size and material. As the fluid, which is
typically air, moves through the bed of solids, the entire structure begins to behave
similar to a fluid rather than a solid structure (Green 1997). For creation of the highdose "fluidized bed" style DPI, small PTFE mixing balls are used to assist with the
emptying of the device as well as the deaggregation of the powder. Inhalation air is
drawn through the mixing balls from an inlet jet, causing them to move chaotically within
the mixing chamber, which empties the powder dosing sphere and breaks up
agglomerates of powder. The basic design of the proposed inhaler is shown in Figure
5.1. The design consists of the mixing chamber, an air inlet from the top, a mesh
preventing inhalation of the small mixing balls and dosing sphere, and a mouthpiece.
The edges on the inside of the device were rounded to prevent powder buildup in
corners that the mixing balls could not reach. The air inlet configurations to be
evaluated are shown in Figure 5.2 and labeled Inlets 1-6. Inlets directed from the
bottom of the chamber were also considered, but were found to be ineffective in
comparison to the top inlets.
Approaches to introduce the formulation into the inhaler were direct addition of
the powder mass on top of the fluidized bed or containment of the powder in a dosing
sphere. The initial prototyped design of the dosing sphere had inner and outer
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diameters of 10 and 12 mm, respectively. To release the powder, the dosing sphere
had either 2, 4, 6 or 8 circular openings (holes) with diameters of 0.5 mm each. The
sphere was built in two halves which were assembled after placing the powder inside.
The first hole was placed at a 20 degree offset from the center bisection of the sphere,
with a second hole opposite of this at 180 degrees. For the 4 hole design there are two
sets of two holes with center lines that intersect each other in the center of the sphere.
For the six and eight hole spheres, the holes were placed at equal intervals around the
outside of the sphere, so that for the six hole sphere, there would be three holes on both
the top and bottom halves and for the eight hole sphere there would be four holes on
each half. Furthermore, a fifth hole configuration, shown in Figure 5.3, was considered
that implemented 4 holes oriented in a way such that the center lines of the holes
intersected in the center of the sphere, but the center lines were offset 90 degrees when
looking from the top or bottom of the sphere. The dosing sphere was intended to
provide high emission from the device while uniformly releasing the powder over four
inhalations.
The inhalers and dosing spheres were created using Autodesk Inventor and
exported as .STL files to be prototyped. The files were then prepared using 3D
Lightyear Software. The parts were built using a 3D Systems Viper SLA System (3D
Systems Inc., Rock Hill, SC) using Accura 60 stereolithography resin (3D Systems Inc.).
Once the parts were prototyped, they were cleaned using a Proclean SL Part Washer
(3D Systems Inc.) and dried in a 3D Systems UV-light dryer for 90 minutes. The parts
were then sanded to provide a smooth finish.
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After prototyping and cleaning, the inhaler devices (but not dosing spheres) were
coated with a commercial polytetrafluoroethylene (PTFE) suspension (LU™708,
Sprayon Products, Cleveland, OH), which is a high contact angle (or low surface
energy) material. A suspension of PTFE was sprayed inside the entire device to form a
thin coating. Compressed air was blown through the coated portions until the surface
appeared dry. This coating was applied to reduce the powder buildup on the walls of
the device and to reduce static charge buildup due to a difference in the material of the
mixing balls and the prototyped chamber.

Evaluation of Vibrational Amplitude
To optimize the mixing chamber diameter (15, 20, or 25 mm), inlet configuration,
and mixing ball size (3.18, 3.97, or 4.76 mm), a screening method was used. A
polyvinylidene fluoride (PVDF) piezoelectric force sensor (LDT1-028K; Measurement
Specialties, Hampton, VA) was fixed to the outside of the chamber of the devices to
measure the intensity of vibration caused by the impaction of the spheres inside the DPI
at a steady state flow rate of 45 LPM (4 kPa pressure drop). The positive and negative
leads were then connected to an oscilloscope probe. The intensity of the vibration was
measured by reading the voltage output values on the oscilloscope. Peak-to-peak
voltage averages were used to measure the intensity of vibrations within the inhaler and
labeled the vibrational amplitude.
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Powder formulations
Formulations employed were a commercially available spray dried mannitol
powder for rapid screening of emitted dose (ED) at high-mass loadings and a spray
dried EEG formulation of the antibiotic ciprofloxacin. The spray dried mannitol powder
was PEARLITOL 25C (Roquette Pharma, Lestrem, France) with a reported primary
particle mean diameter of 25 µm. While larger in particle size than the EEG-Cipro
formulation, the PEARLITOL powder was selected for use in the screening studies as it
is highly dispersible, similar to EEG formulations, and readily available for high-mass
testing of the inhaler emptying characteristics without having the potential
pharmacological effects of the EEG-Cipro formulation.
An EEG formulation of co-spray dried mannitol and ciprofloxacin was prepared
using the approach described by Son et al. (2013a) Briefly, a 20% ethanol in water
mixture containing 0.5 % w/v of solutes consisting of Cipro, mannitol, L-leucine and
poloxamer 188 in a ratio of 30:48:20:2 (w/w %) was spray dried using a Büchi Nano
spray dryer B-90 (Büchi Laboratory-Techniques, Flawil, Switzerland). The powder
formulation was generated using an airflow rate of 120 LPM, 100% liquid flow rate using
the 4 µm nozzle diameter at an air inlet temperature of 70 oC. The resulting air outlet
temperature and spray dryer pressure were 40 oC and 35 mbar, respectively. Powder
was collected from the electrostatic precipitator of the spray dryer and was stored in a
desiccator until it was used. The powder yield was about 50-60%. Approximately 1 mg
of powder was dissolved in 100 mL of deionized water and analyzed for content
uniformity (n=3) of Cipro in the formulation using the USP HPLC method for Cipro. To
protect the powder formulations from the effects of ambient humidity, powders were
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stored in a desiccator to prevent moisture ingress and aerosolized following brief
exposure to environmental RH conditions.
As previously described, the EEG approach is intended to generate an aerosol
with a very small initial MMAD, typically 1.5 µm or below, and high FPF (Son et al.
2013a). Due to small size of the aerosolized particles, MT or extrathoracic deposition is
minimal (Son et al. 2013a). Once inside the airways, the EEG particles take up water
due to the inclusion of the hygroscopic excipient and become significantly larger
droplets (Hindle et al. 2012). This size increase of the droplets is used to ensure
aerosol deposition within the lungs, which would be largely exhaled without size
increase, and potentially control the region of drug delivery (Tian et al. 2013).

Evaluation of device emptying
The device with the highest vibrational amplitude was selected and implemented
for evaluation of ED from the five different dosing spheres. Initial screening was
conducted with 100 mg of the PEARLITOL 25C formulation loaded into the dosing
sphere and placed in the selected FB-DPI. A vacuum pump, flow controller and inline
filter were connected in series to the mouthpiece of the inhaler and the FB-DPI was
actuated using an inhalation flow rate of 60 LPM for 4 seconds producing an inhaled
volume of 4 L. The corresponding pressure drop over the device was 4 kPa. Four
inhalation cycles were used to evaluate the inhaler. The ED in these screening
experiments using PEARLITOL 25C was calculated by weighing the FB-DPI before and
after testing. Emptying of the inhaler over time was also tested using a 25 mg mass of
spray dried EEG-Cipro powder using four inhalations and analyzed by weight. This
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relatively low mass was employed to provide a conservatively low estimate of emptying,
as percent ED is expected to increase as loaded mass is increased.

Evaluation of previously developed capsule-based EEG DPIs at higher loaded mass
The previous study of Behara et al. (2014b) developed the CC90-3D rod array
DPI for use with EEG formulations and showed high efficiency performance with a 2 mg
loaded mass. In the current study, performance of the CC90-3D device is evaluated with
25 mg of the EEG-Cipro formulation, which is the approximate maximum that can be
placed in a single size 3 HPMC capsule (Qualicaps, Whitsett, NC). The loaded
capsules were then pierced using a 0.5 mm needle in the optimum configuration as
determined by Behara et al. (2014b) and placed in the CC90-3D inhaler. The powder
was then aerosolized into a Next Generation Impactor (NGI; MSP Corp., Shoreview,
MN) using a 2 or 4 kPa pressure drop across the device, which corresponded to flow
rates of 32 LPM or 45 LPM, respectively. For the adult 4 kPa pressure drop, powders
were aerosolized until a total air volume of 4 L was drawn through the inhaler at ambient
conditions (10-45% RH and 20-24 oC). For the pediatric 2 kPa pressure drop, the
powder was aerosolized until a total volume of 1.5 L was drawn through the device.
Four inhalation cycles were pulled through the device for the adult and pediatric
pressure drops.

Evaluation of fluidized bed high-dose device (FB-DPI)
To characterize the aerosolization performance of the FB-DPI, EEG-Cipro
formulation weights of 25, 50, and 100 mg were considered. Evaluation of 25 mg was
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used for direct comparison with the CC90-3D inhaler whereas 50 and 100 mg were
considered as high-doses for pediatric and adult applications, respectively. The
appropriate mass was weighted and placed in the prototyped dosing sphere, which was
then loaded into the FB-DPI. The powder was then aerosolized into the NGI at an
airflow rate corresponding to both a 2 and 4 kPa pressure drop across the device. For
the adult 4 kPa pressure drop, powders were aerosolized at 60 LPM until a total air
volume of 4 L was drawn through the inhaler. For the pediatric 2 kPa pressure drop, the
powder was aerosolized at 45 LPM until a total volume of 1.5 L was drawn through the
device, which is consistent with in vivo data for an approximately 7-year-old child(ICRP
1994, Tiddens et al. 2006). As in the other cases, 4 inhalation cycles were implemented
for each test. All measurements with the EEG-Cipro formulation were made with three
replicates.

Particle size characterization
The stages of the impactor were coated with silicone spray to minimize particle
bounce and re-entrainment. The powders were aerosolized with the DPI in a horizontal
position attached to the pre-separator on the NGI using a rubber mold made specifically
for the mouthpiece of this inhaler to ensure a perfect seal. To allow for horizontal
positioning of the inhaler, as it would be used by a patient, and avoid the use of an
induction port, the NGI was positioned on its side (oriented vertically). This positioning
of the NGI is not expected to affect sizing performance due to the reliance on impaction
and not sedimentation for aerosol capture. To assess the total aerosol size distribution
in the absence of a lactose carrier, the USP induction port was not used in this research
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and development study. After aerosolization, drug retained in the dosing sphere or
capsule, device, and the drug collected on the pre-separator, impaction plates and the
filter were extracted by washing with deionized water for quantitative HPLC analysis.
The cut-off diameters of each NGI stage at a specific airflow rate were calculated using
the formula specified in USP 35 (Chapter 601, Apparatus 5).

Device retention, emitted dose, and calculation of aerosol metrics
When using the EEG-Cipro formulation, the loaded Cipro dose was determined
from the initial weight of the powder taken for aerosolization and the percent of Cipro
content in the EEG formulation as measured by content uniformity. The mass of Cipro
retained in the dosing sphere, or capsule, and device was determined by HPLC and
expressed as a percentage of the loaded Cipro dose. Emitted dose was calculated by
subtracting the mass of Cipro retained in the dosing sphere and device from the loaded
Cipro dose. FPF of the EEG formulation (FPF<5µm/ED) and sub-micrometer FPF
(FPF<1µm/ED) were defined as the fraction less than 5 µm and 1 µm, respectively,
expressed as a percentage of the ED. MMAD, FPF<5µm/ED and FPF<1µm/ED were
calculated from linear regression equations resulting from cumulative percentage mass
vs. cut-off diameter of the respective stages on the NGI plots.

5.4 Results
Effects of chamber size and inlet configuration on vibrational amplitude
Results for the optimization of the chamber size, inlet configuration, and mixing
ball size are shown in Table 5.1. These values are the peak-to-peak voltage averages
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output from the piezoelectric averaged over five repetitions (vibrational amplitude). The
results were verified visually and indicated that the designs with the highest vibrational
amplitude values produced the highest amount of ball movement. The three different
mixing ball sizes, along with the 25 mm chamber and Inlet 5 (Figure 5.2e) produced the
most active ball movement. The different mixing ball sizes did not show any significant
difference in the ball movement of the optimum system (Table 5.1), so the largest ball
size, 4.76 mm, was selected. Based on this evaluation of maximum vibrational
amplitude at a constant inhalation flow rate, the leading design used in the subsequent
experiments implemented a 25 mm chamber diameter with airflow Inlet 5 and 4.76 mm
mixing balls.

Effect of powder dose sphere on emitted dose
The initial emptying results using PEARLITOL 25C are shown in Table 5.2 and
include the total ED from the inhaler and the percentage of the powder released from
the dosing sphere after a total of 4 inhalations at 60 LPM for 4 seconds. All of the
designs, excluding the 2 hole design, performed well in terms of ED, however this test
provided no information as to the emptying of the inhaler during each individual
inhalation. The design goal was to produce relatively uniform release of the powder over
each of the 4 inhalations.
Table 5.3 illustrates the cumulative dose emptying for each of the 4 inhalation
cycles achieved by each configuration of the dosing sphere. The 2 hole design
achieved a consistent release, but the overall ED was low at 58.8%. Without the dose
sphere, nearly the entire ED was released in the first inhalation (80.5%), and only
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increased to 81.4% with 4 inhalations. The 4 and 6 hole designs outperformed the 4
Hole-90° design in terms of overall emptying in this test, but the 4 Hole-90° design
produced the more consistent release of the powder that was desired. Specifically, for
the 4 and 6 hole designs 61.3% and 85.4% of the powder was released in the first
breath, respectively. The 4 Hole-90° only released 36.9% of the powder in the first
breath, then 63.3%, cumulatively, in the second breath. Based on both good emptying
and consistent release, the 4 Hole-90o design was selected for subsequent
experiments. The final design of the dosing sphere for the adult pressure drop, shown
in Figure 5.3, consisted of an outside diameter of 12 mm, inside diameter of 10 mm, and
four 0.5 mm holes with centerlines that intersect perpendicularly through the middle of
the ball (4 Hole-90o design). The dosing sphere for the pediatric pressure drop was of
the same design, but with an inside diameter of 8 mm and an outside diameter of 9.4
mm to keep the ball as light as possible. These designs were implemented in the final
testing of the aerosolization performance of the device using the EEG-Cipro formulation.

Results of CC90-3D inhaler with high-dose
For this high-dose study, the CC90-3D inhaler was very effective at deaggregating
the EEG-Cipro powder with the adult pressure drop of 4 kPa, even at its maximum fill
mass of 25 mg, as shown in Table 5.4. As expected with the larger mass, as well as
using multiple inhalations, the ED increased to 88.6% while the MMAD was found to be
1.55 µm, only a slight increase over the previous study of Behara et al. (2014b)
FPF<5µm/ED and FPF<1µm/ED values were similar to the previous study with only a slight
drop in the FPF<1µm/ED value from 31.4%, as reported previously, to 28.8% with the
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larger mass (Behara et al. 2014b). However, when the pediatric pressure drop was
used with the 25 mg formulation mass, there appeared to be insufficient airflow to
levitate the capsule and produce the aerosol. In contrast, the previous study of Behara
et al. (2014b) which implemented a 2 mg mass, showed consistent performance of the
device across pressure drops of 2-6 kPa. As a pressure drop of 2 kPa and formulation
weight of 25 mg is outside of the initial design criteria of the CC90-3D inhaler and ED
performance was poor, these results are not presented. However, it is expected that
the CC90-3D inhaler can be modified to perform well under these conditions by
optimization of the airflow inlet size and capsule chamber dimensions to allow for
levitation of the capsule at reduced flow rates.

Results of the high-dose fluidized bed device (FB-DPI)
The high-dose device was tested using 25 mg of the EEG-Cipro powder
formulation for comparison with the CC90-3D inhaler and the results are displayed in
Table 5.4. The aerosolization performance of the device at the adult pressure drop was
similar to that of the CC90-3D inhaler with a MMAD of 1.53 µm and a FPF<5µm/ED and
FPF<1µm/ED of 93.8% and 31.3%, respectively. However, the ED of 59.8% was
significantly lower than with the CC90-3D device with 25 mg of powder. The ED of the
FB-DPI increased to 71.4% when 100 mg was used while still achieving a 1.53 µm
MMAD, as well as a FPF<5µm/ED of 93.3% and FPF<1µm/ED of 36.4% as shown in Table
5.5. The pediatric pressure drop and 25 mg loaded mass produced an ED of 57.5%,
with only 12.4% retention in the dosing sphere, but 30.2% device retention. As
expected with a lower flow rate, the MMAD increased to 1.81 µm and the FPF<1µm/ED
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decreased to 20.0%, but the FPF<5µm/ED remained similar at 93.0%. The design of the
dosing sphere for the pediatric pressure drop limited the maximum mass to 50 mg
instead of 100 mg with the adult model. The results for the pediatric pressure drop
using 50 mg of powder are compared to the adult pressure drop at 100 mg in Table 5.5.
At 2 kPa and 50 mg loaded mass with the pediatric dose sphere, the device produced
an ED of 59.8%, a MMAD of 1.80 µm, a FPF<5µm/ED of 92.3%, and a FPF<1µm/ED of
21.8%, which is comparable to the 25 mg data.
In a final set of experiments, the mixing balls were removed from the system and
the motion of the dosing sphere alone was used to deaggregate and aerosolize the
powder. Results at a 4 kPa pressure drop with the adult dose delivery sphere and 25
mg loaded mass are displayed in Table 5.6 for the FB-DPI without the mixing balls.
Results indicated an ED of 73.8% without the mixing balls, which was significantly
(p<0.05; t-test) improved compared to the similar case with the balls (59.8%; Table 5.5,
FB-DPI 4 kPa). However, there were no significant changes in the aerosol quality when
the balls were removed with an MMAD of 1.53 µm, FPF<5µm/ED of 95.1%, and FPF<1µm/ED
of 31.4%.

5.5 Discussion
A primary outcome of this study is the first evaluation of an inhaler based on a
fluidized bed design. The design of the inhaler incorporating mixing balls caused a
significant decrease in the aerosol ED compared to the inhaler without the mixing balls
with more drug retention in both the dosing sphere and the device (absolute difference
of 16%), but the MMAD was unaffected by the presence of the mixing balls. This is
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likely because of the increased surface area, provided by the mixing balls, to which the
powder could adhere. The movement of the dose sphere was potentially hindered by
the mixing balls, thus increasing the retention in the dosing sphere.
The previously developed CC90-3D inhaler was able to produce a very high
quality aerosol with a 25 mg loaded mass at the adult pressure drop of 4 kPa.
However, 4 capsules and 4 inhalations per capsule would be required to achieve the
same nominal loaded formulation mass as the 100 mg FB-DPI device. The
performance of the CC90-3D device became extremely limited at the pediatric pressure
drop with a weight of 25 mg, which was beyond the initial design parameters of the
inhaler. It is expected that the capsule chamber of the CC90-3D inhaler can be
redesigned to allow for effective operation at this higher formulation weight compared
with the 2 mg weight considered by Behara et al. (2014b) however, this optimization is
beyond the scope of the current study.
Compared with the previously developed CC90-3D inhaler at a formulation weight
of 25 mg and adult pressure drop of 4 kPa, the optimal FB-DPI device produced nearly
identical aerosol characteristics but the ED was reduced from 88.6% to 59.8% (Table
5.4). The clear advantage of the FB-DPI is the ability to increase the loaded mass to
100 mg as considered in Table 5.5. Increasing the loaded mass to 100 mg at the adult
pressure drop did not change the aerosolization characteristics and increased the ED to
71.4%. This increase in ED associated with increased loaded mass is due to the
internal surface area of the dosing sphere, which is larger than the internal surface area
of the capsules used in the CC90-3D inhaler, in order to hold more powder.
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By using a combination of the fluidized bed device and the EEG powder
formulation, the FB-DPI was able to produce an aerosol much smaller than that of the
ORBITAL device using the co-spray-dried formulation, with an MMAD less than half the
size (1.53 µm vs 4.0 µm) and with much higher FPFs (93.8% vs. 42%)(Young et al.
2013). It should be noted that the primary particle size of the EEG-Cipro formulation
was submicrometer sized unlike the 2.9 µm ORBITAL formulation. The ED of the FBDPI after four inhalations was approximately 71.4% compared with the ORBITAL device
that appeared to emit approximately 75% of its dose at four inhalations. The ORBITAL
was also able to deliver a formulation mass of up to 400 mg, which could offset the
expected higher mouth-throat depositional loss associated with using a larger aerosol
MMAD.
The optimum fluidized bed device that resulted from this study had the following
characteristics: 25 mm chamber diameter, Inlet #5, 4.76 mm mixing ball diameter, and
the 4 Hole-90° dose sphere. This device was able to produce a 1.53 µm MMAD aerosol
with a FPF<5µm/ED of 93.3%, a FPF<1µm/ED of 36.4%, and an ED of 71.4% when used at
the adult pressure drop and maximum tested formulation weight of 100 mg. When used
at the pediatric pressure drop, the device was able to produce a 1.80 µm MMAD aerosol
with a FPF<5µm/ED of 92.3%, a FPF<1µm/ED of 21.8%, and an ED of 59.8% using the
maximum tested pediatric formulation weight of 50 mg. In both the adult and pediatric
cases, the small aerosol (i.e. MMAD < 2 µm) is expected to produce low MT
depositional loss. For example, Son et al. (2013a) previously demonstrated that an
EEG aerosol with a MMAD of approximately 1 µm produced a MT depositional loss of
<5%, compared with 80% for a commercial formulation and inhaler. Using a 3D rod
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array DPI and EEG formulation, MT depositional loss was reduced to <3% (Son et al.
2013b). For the adult inhalation conditions, the shortcoming of the optimized FB-DPI is
the ED of 71.4%, whereas previous high efficiency DPIs have achieved ED values
>75% (Behara et al. 2014a, Behara et al. 2014b). Testing the device without the mixing
balls indicated that ED could be increased without altering the performance. This was
an interesting finding considering that fluidized beds are known to contribute to powder
deaggregation and are often used in industry to produce high quality fine aerosols
(Hinds 1999). An additional test of the vibrational amplitude without the mixing balls but
including the dose sphere indicated a value of 566.4, which is higher than the values
reported in Table 5.1 for the FB-DPI designs with mixing balls and supports an
association between the measured vibrational amplitude and DPI performance. In
contrast, increased vibrational frequency created by the mixing balls may reduce
vibrational amplitude and limit ED. Furthermore, the use of smaller mixing balls, as with
the studies of Lind et al. (2010) and Prenni et al. (2000) for packed beds, may further
decrease ED due to increased surface area of the spheres as a whole and likely
increased vibrational frequency. As a result, the high dose device can be simplified and
improved by removing the mixing balls and only retaining the dosing sphere and inhaler
body. These findings motivate further study of the high dose DPI in order to maximize
ED and deaggregation with the simplest possible device. However, this optimization is
beyond the scope of the current study, which was intended to characterize the
performance of an inhaler that was based on using the well recognized approach of a
fluidized bed for aerosol deaggregation. As previously described, the use of CFD
simulations together with concurrent in vitro experiments can be applied to further
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optimize the device design in a quantitative manner (Longest et al. 2009, Hindle et al.
2013, Longest et al. 2013b).
Considering the pediatric delivery conditions and 50 mg formulation weight,
performance of the FB-DPI appears acceptable. Shortcomings of the device at 2 kPa
appear to be an ED of ~60% and a small increase in particle size with a MMAD of 1.8
µm. A recent study of commercial inhalers tested under pediatric delivery conditions
produced MT deposition values of 60-80% (Below et al. 2013). In contrast, our
preliminary MT deposition results with EEG formulations and pediatric airway conditions
indicate losses <10%. Based on results for the FB-DPI device at 100 mg and 4 kPa, it
is expected that removing the mixing balls from the pediatric inhaler will again improve
ED. Further decreases in MMAD, if needed, can likely be achieved through
optimization of the dosing sphere (e.g., hole position and size) and modifying the
number of required inhalations.
Limitations of the current study include use of vibrational amplitude and Pearlitol
powder to screen the initial designs. Vibrational amplitude was found to be highest in
the case without the mixing spheres, which implies that use of this parameter as a
screening tool for DPI performance may be valuable. However, vibrational frequency
was not considered and could potentially reduce ED as in the study of Behara et al.
(2014a) The highly dispersive EEG formulations were expected to deaggregate like
much larger Pearlitol particles; however, this association has not been proven. In the
sizing experiments, neither an induction port nor a mouth-throat geometry was used in
order to best quantify the size distribution of the aerosol leaving the inhaler and entering
the respiratory tract. It was not our intent to perform compendial quality control
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experiments; however, it is expected that the preseparator captures the drug that would
have deposited in the induction port (or mouth-throat) considering that it has a smaller
cutoff size. As a result, it is expected that FPF calculations were not biased based on
exclusion of the MT geometry. In addition, while the stages of the NGI were coated with
a silicone spray, as suggested by USP, it is acknowledged that with the higher masses
of powder used in this study, particle bounce may not have been completely prevented.
Some small powder deposits were seen on the nozzles of the NGI after experiments
which suggest some particle bounce may be present, which may lead to small changes
in the particle size distribution (Rissler et al. 2009, Grasmeijer et al. 2012).
Additional limitations of this study include the investigation of a single chamber
design and orientation, the evaluation of the device only with an inlet at the top of the
chamber, and the evaluation of a single EEG drug formulation. Other chamber designs
could prove to be more effective at lowering the device retention, but could also have a
negative effect on the particle size. Positioning the inlet on the side or the back of the
inhaler could also have an effect on the performance of the device and needs to be
studied further for confirmation. The EEG-Cipro powder was the only formulation
studied, but the data from the CC90-3D device was similar to the EEG-Albuterol Sulfate
(AS) formulation used in the study by Behara et al. (2014b).
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5.6 Abbreviations
AS

Albuterol sulfate

Cipro

Ciprofloxacin hydrochloride

DPI

Dry powder inhaler

ED

Emitted dose

EEG

Excipient enhanced growth

FB

Fluidized bed

FPF

Fine particle fraction

HPLC

High-performance liquid chromatography

HPMC

Hydroxypropyl methylcellulose

MMAD

Mass median aerodynamic diameter

MT

Mouth-throat

PTFE

Polytetrafluoroethylene

PVDF

Polyvinylidene fluoride

SD

Standard deviation
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Figure 5.1

Image of fluidized bed dry powder inhaler (FB-DPI) showing the air inlet,

mixing chamber, mixing balls, restraining mesh and mouthpiece.
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Figure 5.2

Images of the inlet configurations: (a) Inlet 1 attached to inhaler showing

flow direction, (b) Inlet 2, (c) Inlet 3, (d) Inlet 4, (e) Inlet 5, and (f) Inlet 6.
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Figure 5.3

Images showing the dosing sphere developed for this device: (a) side view

of the two halves separated, (b) isometric view of the two halves separated, and (c)
assembled dose sphere with the 4 Hole-90° design.
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Table 5.1

Peak-to-Peak Voltage averages (vibrational amplitude) for chamber sizes,

mixing ball sizes, and inlet configurations. The standard deviation (SD) is shown in
parenthesis [n=5].
Inlet configuration
3
4

Chamber size

Mixing ball
size

15mm

3.18 mm
3.97 mm
4.76 mm

144 (43.8)
N/A
N/A

224.8 (33.4)
253.6 (75.0)
N/A

375.1 (57.4)
360.0 (52.4)
208.8 (75.8)

379.2 (75.8)
299.2 (97.0)
291.2 (96.7)

20mm

3.18 mm
3.97 mm
4.76 mm

168.4 (25.1)
114.8 (23.9)
115.2 (36.2)

190.8 (25.9)
176.8 (70.3)
284.8 (59.2)

362.4 (72.5)
380.0 (59.5)
377.6 (83.3)

273.6 (43.2)
311.2 (48.8)
371.2 (33.8)

3.18 mm
120.8 (36.1)
3.97 mm
178.8 (25.8)
4.76 mm
144.8 (33.4)
All values given in millivolts (mV).

206.0 (22.5)
240.8 (64.1)
266.4 (54.4)

280.8 (48.9)
207.2 (33.0)
166.0 (52.7)

409.6 (40.1)
483.2 (40.2)
442.4 (69.1)

2

25mm
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Table 5.2

Screening of dosing sphere emptying by weight using 100 mg of

PEARLITOL 25 C [n=1].
Description

ED (%)
Dosing sphere released (%)

No dosing
sphere

2
Hole

4
Hole

4 Hole90°

6
Hole

8
Hole

92.2
N/A

44.9
50.3

84.0
97.7

92.9
96.9

88.0
97.9

90.2
98.8
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Table 5.3

Screening of dosing sphere emptying by weight as a function of inhalation

number using 100 mg of EEG-Cipro formulation (Batch 1 and Batch 2) [n=1].
Cumulative % Released from
Dosing Sphere
1st inhalation (%)
2nd inhalation (%)
3rd inhalation (%)
4th inhalation (%)

No dose
sphere

2
Hole

4
Hole

4 Hole90°

6
Hole

80.5
81.3
81.3
81.4

18.4
37.4
48.6
58.8

61.3
91.2
94.2
96.0

36.9
63.3
76.3
82.0

85.4
94.7
95.9
96.5
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Table 5.4

Comparison of aerosolization using the previously developed inhaler CC90-3D to the new fluidized bed (FB) -

DPI with 25 mg of EEG-Cipro (Batches 11 and 12). The standard deviation (SD) is shown in parenthesis [n=3].
Description

CC90-3D 4 kPa

FB-DPI 4 kPa

FB-DPI 2 kPa

ED (%)*

88.6 (1.4)

59.8 (2.9)**

57.5 (4.4) **

Capsule/Sphere (%)*
Device (%)*

3.4 (2.1)
8.0 (1.2)

21.1 (4.4) **
19.1 (1.6) **

12.4 (3.7) **
30.2 (1.6) **

FPF<5µm/ED (%)
94.8 (0.4)
93.8 (1.4)
93.0 (1.6)
FPF<1µm/ED (%)*
28.8 (1.7)
31.3 (1.6)
20.0 (1.6) **
MMAD (µm)*
1.55 (0.04)
1.53 (0.01)
1.81 (0.03) **
* p <0.05 significant effect of inhaler on % ED, capsule/sphere retention, device retention, FPF<1µm/ED and MMAD
(one-way ANOVA)
** p<0.05 significant difference compared to CC90-3D (post hoc Tukey)
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Table 5.5

Comparison of the FB-DPI at adult and pediatric flow rates using

maximum designed mass in the dosing sphere using the EEG-Cipro formulation
(Batches 11 and 12). The standard deviation (SD) is shown in parenthesis [n=3].
Description

4 kPa - 100mg

2 kPa - 50mg

ED (%)

71.4 (2.1)

59.8 (1.73)*

Capsule/Sphere (%)
Device (%)

13.3 (3.0)
15.3 (1.5)

16.8 (1.8)
23.4 (0.7)*

FPF<5µm/ED (%)
93.3 (0.3)
92.3 (0.4)
FPF<1µm/ED (%)
36.4 (2.9)
21.8 (1.5)*
MMAD (µm)
1.53 (0.10)
1.80 (0.07)*
* p <0.05 significant different from 4kPa - 100mg (student t-test)
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Table 5.6

Performance of the FB-DPI without mixing balls using 25 mg of EEG-Cipro

(Batches 11 and 12). The standard deviation (SD) is shown in parenthesis [n=3].
Description

Without mixing balls

ED (%)

73.8 (1.9)

Capsule/Sphere (%)
Device (%)

11.4 (2.1)
14.7 (0.2)

FPF<5µm/ED (%)
FPF<1µm/ED (%)
MMAD (µm)

95.1 (2.1)
31.4 (1.3)
1.53 (0.04)
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Chapter 6

Develop a low-volume capsule-based

inline DPI actuated by an external gas source to be
used with multiple delivery platforms
6.1 Objective
The objective of this study is to design a low-air-volume device to deliver EEG
aerosols. The device should have the capability to be mounted to multiple delivery
platforms such as an NIV face mask and inline with an external respiratory gas source.

6.2 Introduction
Inline dry powder inhalers (DPIs) are actuated by a stream of gas that is passed
through the device from an external positive pressure source (Everard et al. 1996, Tang
et al. 2011, Behara et al. 2014c, Walenga et al. 2017). These devices are useful for
generating and delivering an aerosol to patients that may not be able to use a DPI such
as children younger than approximately 5 or 6 years old (Rubin 2011, Laube et al. 2012,
Goralski et al. 2014). The positive pressure gas source can be used to assist with deep
inspiration and help maintain a breath hold in individuals with compromised lung
function. This deep positive pressure inspiration may enable the aerosol to penetrate
further into the lungs compared with negative pressure inhalation through a high
resistance device. Inline DPIs can be connected directly into both noninvasive and
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invasive mechanical ventilation systems allowing for the simultaneous delivery of
respiratory gas support and therapeutic aerosols (Dhand 2005, Tang et al. 2011, Hess
2015, Longest et al. 2015, Walenga et al. 2017). Furthermore, inline DPIs are
frequently used to deliver test aerosols to animals when evaluating the safety and
efficacy of inhaled medications (Grainger et al. 2004, Duret et al. 2012).
Based on the ability to deliver a positive pressure breath, inline DPIs have
previously been proposed as stand-alone devices to deliver respiratory therapies to
children. For example, Manion et al. (2012) proposed the PuffhalerTM, which consists of
a squeeze bulb, burst valve, blister powder storage and reservoir mask. With spray
dried formulations, fine particle fractions (FPF) less than 5.8 µm were 40-60% and
emitted dose (ED; as a percentage of loaded mass) was near 50%, with a majority of
the aerosol lost in the optimized reservoir bag. Laube et al. (2012) reported use of the
SoloventTM inline DPI that consists of an air syringe positive pressure gas source,
capsule, spacer and mask. With the SoloventTM connected directly to an infant nosethroat model and delivering air volumes of 50-200 mL, the percent of loaded drug found
on the throat filter (which approximates lung delivery) was 0.28 - 3.87%, with the
majority of drug lost in the spacer reservoir. These findings indicate that a reservoir or
spacer should be avoided if possible when delivering aerosols to children using inline
DPIs. Hence, the aerosol should be generated very quickly during inhalation and
require a much smaller volume of air for effective aerosolization.
The PennCenturyTM DP-4 Dry Powder Insufflator is an inline DPI that has been
used for over a decade to deliver aerosols to test animals and cell cultures. For the
widely used mouse and rat PennCenturyTM devices, the loaded dose is in the range of

102

1-5 mg of powder and recommended air volumes are 0.2 and 2 mL, respectively.
Aerosolization performance depends on a wide range of factors, including the
formulation, loaded mass, and air volume (Duret et al. 2012, Hoppentocht et al. 2014a).
For spray dried formulations under optimal conditions, device retention is approximately
20% and emitted mass median aerodynamic diameters (MMAD) of mannitol powder
approach values achieved by specialized lab testing equipment such as the Sympatec
RODOS dispersion unit (Hoppentocht et al. 2014a). Inclusion of a drug molecule such
as tobramycin in the spray dried formulation increases the PennCenturyTM MMAD by a
factor of approximately 2 compared with RODOS dispersion. Loading of the
PennCenturyTM device requires a small spatula and can be time consuming, highlighting
the laboratory testing intent of this design. Furthermore, variability in performance
increases as loaded dose increases beyond 1 mg (Hoppentocht et al. 2014a).
Studies of inline DPIs intended for human use have reported the delivery of
albuterol sulfate,(Behara et al. 2014c, Longest et al. 2014b) mannitol,(Tang et al. 2011)
budesonide,(Everard et al. 1996, Pornputtapitak et al. 2014) surfactants,(Pohlmann et
al. 2013) and various antibiotics (Manion et al. 2012, Longest et al. 2015). Tang et al.
(2011) placed the Osmohaler DPI in an airtight container that enabled actuation with a
manual ventilation bag and was connected to a straight endotracheal tube (ETT). The
manual ventilation bag was used to generate peak flow rates in the range of 87 - 133
L/min (LPM) to aerosolize high dose capsules containing 40 to 80 mg of mannitol
powder (AridolTM). Delivery efficiency to the distal end of the ETT was 50 to 60% of the
loaded dose and the associated MMAD was approximately 7 µm. Based on this study,
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it appears that very high flow rates (~100 LPM) and large air volumes (multiple
squeezes of an adult ventilation bag) are required to aerosolize high doses of powder.
For high dose surfactant aerosol delivery, Pohlmann et al. (2013) recently
presented a design that passed pulses of air directly through a powder bed. Using
pressure pulses consisting of 10-30 mL of air and a spray dried surfactant formulation,
high masses of powder could be aerosolized producing aerosols in the range of 3 to 3.5
µm. These findings indicate that passing controlled volumes of air directly through a
powder reservoir can effectively aerosolize a highly dispersible spray dried formulation.
However, the air delivery system of Pohlmann et al. (2013) appears complex and, as
stated by the authors, the very high masses of aerosol require humidity to coat the
particles with water prior to inhalation. Delivery efficiency to the end of a conducting
tube and prior to nasal prongs was 55% of the aerosolized dose (Pohlmann et al. 2013).
Our group has recently developed a new inline DPI consisting of a flow control
orifice, capsule chamber and three dimensional (3D) rod array (Behara et al. 2014c).
As described in Longest et al.,(Longest et al. 2013b) the 3D rod array maximizes
aerosol deaggregation compared with other approaches for a set amount of input power
by maximizing turbulent energy in the small turbulent eddies. The inline DPI is powered
by a manual ventilation bag and the flow rate through the device is controlled by the
orifice size. For a spray dried excipient enhanced growth (EEG) formulation (Hindle et
al. 2012, Son et al. 2013a) of albuterol sulfate, a device with a 2.3 mm flow control
orifice and 3-4-3 rod array pattern (2.3-343 inline DPI) produced a flow rate of only 10
LPM with ED (as a percentage of loaded dose) and MMAD values of approximately
75% and 1.6 µm (Behara et al. 2014c). Longest et al. (2015) considered a spray dried
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formulation of ciprofloxacin in the same device and reported an ED from a streamlined
nasal cannula(Longest et al. 2013a) of approximately 70% with an MMAD of 1.4 µm.
Based on the EEG approach, the nasal deposition was <2% leading to high efficiency
nose-to-lung (N2L) aerosol delivery. In the conference publication of Longest et al.
(2014b), we reported a device with a 2.0 mm flow control orifice and 2-3-2 rod array
pattern (2.0-232 inline DPI) that aerosolized albuterol sulfate at a flow rate of only 5
LPM for use with low flow nasal cannula oxygen.
Advantages of the previously developed 3D rod array inline DPI include high ED
and excellent deaggregation (Behara et al. 2014c, Longest et al. 2014b, Longest et al.
2015). The capsule-based platform makes the device easy to load. Due to the use of
the flow control orifice, the device is not sensitive to bag pressure above a nominal
amount. However, as flow rate is reduced to 5 LPM and below, it becomes increasingly
difficult to achieve an MMAD near 1.5 µm,(Longest et al. 2014b) which is desirable for
high efficiency nose-to-lung aerosol delivery and use of the EEG approach. The typical
air volume for each of these devices was 1 L per actuation. Furthermore, performance
is dependent upon capsule piercing pattern, (Behara et al. 2014c) and capsule piercing
can be difficult inside a positive pressure device. Finally, higher masses of powder
become more difficult to aerosolize at lower flow rates.
There appears to be a need for an inline DPI device that can aerosolize relatively
large (10 mg and above) masses of spray dried powder formulations using very low
dispersion air volumes (~10 mL per actuation). High powder masses are required for
the aerosol delivery of most antibiotics, surfactants, non-steroidal anti-inflammatories,
and many biopharmaceuticals. These high doses are required in adults and children,
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where, for example, Morley et al. (1981) delivered 25 mg capsules of dry powder
surfactant to preterm infants with respiratory distress syndrome. Low dispersion air
volume through the device enables application in both high flow and low flow settings.
A 10 mL air volume is viewed as the upper end of ventilation that can be delivered to a
late preterm infant (Jauernig et al. 2008, Walsh et al. 2010, Sunbul et al. 2014).
Furthermore, injection of 10 mL of air should not interfere with most noninvasive or
invasive mechanical ventilation systems. The inline DPI device should be airtight and
operate on positive pressure to allow connection to mechanical ventilation systems or
sealed patient interfaces like streamlined nasal cannula (Longest et al. 2013a, Longest
et al. 2013c) or a face mask (Walenga et al. 2017). Importantly, the device should be
easy to load and minimize usage steps (Smith et al. 2010).
The objective of this study is to develop and characterize a new inline DPI for
aerosolizing spray dried formulations with powder masses of 10 mg and higher using an
air volume of 10 mL per actuation. The device will be developed based on knowledge
gained from our previous work with high efficiency DPIs (Behara et al. 2014a, Behara et
al. 2014c, Behara et al. 2014b, Longest et al. 2015) and rapid screening using 3D
printing technology. In vitro aerosol experiments will be used to determine regional
device retention, ED and to characterize the aerosol. Initial device performance will be
based on 10 mg powder loading, and, for a lead design, a significantly higher powder
mass will be tested. Aerosol plume size will also be assessed to aid in future
incorporation of the device into positive pressure systems with low depositional losses.
High efficiency performance is expected based on our previous DPI experience (Behara
et al. 2014a, Behara et al. 2014c, Behara et al. 2014b, Longest et al. 2015).
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Specifically, high efficiency performance for the delivery of EEG formulations will be
defined by the production of an aerosol with the following characteristics: an MMAD of
less than 1.5 µm, fine particle fraction (FPF) less than 5 µm as a percentage of ED
(FPF<5µm/ED) above 90%, FPF<1µm/ED above 30% and an ED greater than 75%. The
challenge is, clearly, to now achieve this level of DPI performance with a device that
requires only 10 mL of dispersion air per actuation and is easy to load and operate.

6.3 Materials and Methods
Overview
In contrast with our previous inline DPIs that are intended to operate with relatively
high dispersion air volumes (Behara et al. 2014c, Longest et al. 2015), the low air
volume (or LV) devices developed in this study pass all of the available airflow through
a capsule dose containment unit. The air source is a simple syringe connected via a
luer-lock fitting and filled with 10 mL of room air that is operated manually. Based on
experiments with a number of preliminary concepts, the two leading LV designs are
presented as Figure 6.1 and Figure 6.2, respectively. A common feature in both devices
is that metal capillary tubes pierce the capsule when the device is closed, forming an
airtight flow path through the device. In one design, the airflow pathway is in a single
direction, or straight through (ST) the capsule and device (Figure 6.1). In the second
design, the capillary-based inlet and outlet are on a single side (SS) of the capsule,
resulting in a near 180-degree turn in the airflow path. In both designs, the outlet
capillary directs aerosol through a flow channel with a final diameter of 7 mm. These
two leading designs are optimized and compared in this study based on modifications to
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the inlet and outlet capillary properties. To improve dispersion of the 10 mg powder
mass, we also introduce the concept of a dispersion ball placed inside the capsule. Use
of a lightweight polytetrafluoroethylene (PTFE) dispersion ball is expected to create
vibrational motion as observed in Farkas et al. (2015) to enhance capsule emptying. As
a representative EEG formulation, the new inline DPIs are tested with a previously
described (Son et al. 2013a, Son et al. 2013b) EEG formulation of albuterol sulfate.
Using this formulation, previous inline DPIs have produced MMAD values as low as
1.47 µm with an ED value of 78.2% using high dispersion air volumes with
approximately 1 L of air per actuation. The primary particle size of the EEG formulation
is tested using a Sympatec (Sympatec GmbH, Clausthal-Zellerfeld, Germany) laser
diffraction system with a RODOS aerosol dispersion accessory, which uses a pressure
drop of 4 bar (400 kPa) to disperse a small amount of the powder. Aerosol
characterization from the devices is based on drug quantification using high
performance liquid chromatography (HPLC) analysis of the various DPI components to
determine the emitted dose and by cascade impaction using the Next Generation
Impactor (NGI), to determine the fine particle fraction and MMAD. Further details of the
devices, formulation and characterization studies are provided in the following sections.

Materials
Albuterol Sulfate (AS) USP was purchased from Spectrum Chemicals (Gardena,
CA) and Pearlitol® PF-Mannitol was donated from Roquette Pharma (Lestrem, France).
Poloxamer 188 (Leutrol F68) was donated from BASF Corporation (Florham Park, NJ).
L-leucine and all other reagents were purchased from Sigma Chemical Co. (St. Louis,
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MO). Quali-V, Hydroxypropyl methylcellulose (HPMC) capsules (size 0) were donated
from Qualicaps (Whitsett, NC).
Spray dried albuterol sulfate EEG formulations were produced using the
optimized method described by Son et al. (2013a) Three batches of spray dried
formulations were employed for these studies. The primary particle size for each of the
spray drying batches was determined using a laser diffraction method with a Sympatec
ASPIROS/RODOS dry dispersing unit and HELOS laser diffraction sensor.

Inhaler Design
Both inhaler designs (ST and SS) are opened at approximately midway the
capsule chamber, the capsule is loaded into one of the halves, and the capillaries pierce
the capsule when the device is re-assembled. A bayonet fitting and o-rings have been
employed to ensure an airtight seal in the capsule chamber. Both inhaler designs
investigated in this study use a standard luer-lock to a connect the syringe to deliver
dispersion air through a single 0.6 mm inlet capillary and into a size 0 capsule which
has a volume of 0.68 mL. The capillary remains in place during dispersion as the air
inside of the syringe is forced through the capillary into the powder bed within the
capsule. The powder is entrained and is carried through the outlet capillary
configuration. Designs of the outlet capillaries are shown in cross section (to scale with
respect to each other) in Figure 6.3. The Straight-Through (ST) design, shown in Figure
6.1, is designed with the inlet and outlet capillaries on opposite ends of the capsule,
both centered on the capsules longitudinal axis. The Single-Sided (SS) design, shown
in Figure 6.2, is oriented with both the inlet and outlet capillaries piercing through the
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head of the capsule. The capillaries of the SS design are angled at ~8 degrees towards
the centerline of the longitudinal axis of the capsule, so that the capillary central axes
intersect halfway between the middle and the bottom of the capsule. This angle was
selected to increase turbulent dispersion within the capsule.
The inhaler designs were created using Autodesk Inventor and exported as .STL
files to be prototyped. The files were then prepared using Objet Studio preparation
software and were built using a Stratasys Objet24 3D Printer (Stratasys Ltd., Eden
Prairie, MN) using VeroWhitePlus material. Support material was cleaned away from
the model material using a Stratasys waterjet cleaning station and the devices were
allowed to fully dry before use. The capillaries used in the devices were custom cut
from lengths of stainless steel (SAE 304) capillary tubing and were angled on one side
to allow for easy piercing of the capsule upon insertion. The capillaries were then
secured into place using water resistant epoxy and allowed to cure fully before use. It is
noted that the sharpened capillaries are sufficiently recessed inside the capsule
chamber of the device to facilitate safe assembly.

Evaluation of LV devices
Aerosolization performance of the LV-DPIs was characterized using 10 mg of
EEG-AS powder formulation, which was accurately weighed and manually filled into
size 0 capsules. This mass of powder filled approximately 3% of the capsule volume.
Capsules were then placed in one half of the LV-DPI device and the capsule was
pierced when the two halves were sealed together. After the devices were assembled, a
10 mL syringe was filled with room air and then connected via the luer-lock onto the LV-
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DPI inlet. To maintain a consistent distance from the outlet of the devices to the inlet of
the NGI for aerosol sizing, a custom adaptor was fabricated which held the LV-DPIs
approximately 3 cm away from the NGI preseparator inlet. The powders were
aerosolized with the LV-DPI in a horizontal position as shown in Figure 6.1 and Figure
6.2 with the gravity vector pointing down the page. As minimal size change is expected
in the aerosol under ambient temperature and relative humidity (RH) conditions,
experiments were conducted with ambient air (T = 22 ± 3 oC and RH = 50 ± 5 %) with
the NGI at room temperature. To allow for horizontal positioning of the inhaler, the NGI
was positioned on its side (oriented vertically) to test both the ST and SS devices. The
NGI was operated at 45 L/min and the preseparator and individual stages were coated
with MOLYKOTE® 316 silicone spray (Dow Corning, Midland, MI) to minimize particle
bounce and re-entrainment. The flowrate of 45 LPM was chosen to ensure collection of
the aerosol, which exited the device 3 cm away from the preseparator inlet, and
maintain reasonable stage cutoff diameters for evaluating a small size aerosol. To
actuate the DPI, the plunger of the syringe was depressed quickly (~0.2 seconds to
empty) to aerosolize the powder into the inlet of the NGI. The syringe was then
disconnected from the inhaler, refilled with room air, and reconnected to the device for a
total of 5 actuations. Using the optimized device, an additional study was performed
using 50 mg of powder to evaluate the effect of higher powder mass loadings. A slower
syringe emptying test (~0.5 seconds to empty) was also made with a 10 mg loaded
mass using the optimized device to simulate extreme variability between users. Syringe
emptying times were determined using a single operator and high speed photography
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(1000 frames/sec). All measurements were made with three replicates for each design
configuration.

Aerosol performance characterization methods
After aerosolization, drug masses retained in the capsule, device, and the drug
collected on the preseparator, impaction plates and the filter of the NGI were recovered
by washing with appropriate volumes of deionized water and quantified by HPLC
analysis. The mass of AS retained in the capsule and device, determined by HPLC,
was expressed as a percentage of the nominal AS dose. The emitted dose was
calculated by subtracting the mass of AS retained in the capsule and device from the
nominal AS dose.
In order to determine the nominal dose of AS in the EEG-AS formulation, known
masses of the formulation were dissolved in 100 mL of water and the mean amount of
AS per mg of formulation was determined using HPLC analysis. For each aerosolization
experiment, the measured formulation AS content and the mass of formulation loaded
into the capsule was used to determine the nominal dose of AS.
The cut-off diameters of each NGI stage at the operating flow rate of 45 LPM
were calculated using the formula specified in USP 35 (Chapter 601, Apparatus 5) and
were used to calculate MMAD and fine particle fractions of the delivered aerosol. Fine
particle fraction of the EEG formulation (FPF<5µm/ED) and sub-micrometer FPF
(FPF<1µm/ED) were defined as the fraction less than 5 µm and 1 µm, respectively,
expressed as a percentage of the ED. MMAD, FPF<5µm/ED and FPF<1µm/ED were
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calculated by linear interpolation using a plot of cumulative percentage drug mass vs.
cut-off diameter.

Aerosol Plume Characterization
The plume characteristics of aerosols generated by the different studied outlet
orientations was also investigated. To measure the plume characteristics, the device
was loaded and actuated as described above (evaluation of LV devices). The outlet of
the device was positioned such that the aerosol was emitted against a black
background labelled with marks in both the vertical and horizontal directions to provide
a scale. A camera (Pextax K-30) was positioned to capture images at 30 fps. For
comparison, a still image recorded when the plunger was fully depressed was used to
determine the horizontal and vertical spreads of the plume, which were calculated using
the scale marks. This information will help with future implementation of the device into
a continuous flow path for use in an inhaler or for aerosol administration during
mechanical ventilation.

6.4 Results
EEG Formulation Dispersion Characterization
The dispersion characteristics and primary particle size for each of the batches of
EEG-AS formulation employed in this study was determined using a Sympatec laser
diffraction setup. When comparing the novel LV-DPIs over a period of time, it was
important to determine the batch to batch consistency of the EEG-AS powder
formulation using a consistent method of dispersion (ASPIROS/RODOS unit). For
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comparison to the aerosolization performance determined by the NGI, the geometric
sizes determined by the laser diffraction method were converted to aerodynamic
diameters using a theoretical EEG-AS particle density of 1.393 g/cm3 (Longest et al.
2011a). Figure 6.4 shows the mean particle size distribution for the three batches of
EEG-AS formulation used in this study. The mean (SD) MMAD and FPF values were
calculated from this data and are also shown in Figure 6.4. The overall mean MMAD
was 1.29 µm calculated from the laser diffraction sizing with the ASPIROS/RODOS
dispersion unit. The coefficient of variation for the MMAD for the three batches was 7%
indicating the relative reproducibility of the spray drying process to produce a small
sized powder formulation. The mean FPF<5µm/ED and FPF<1µm/ED across batches were
found to be 99.3% and 33.8%, respectively with coefficients of variability of 0.8 % and
7.6 %, respectively. These results represent very high efficiency aerosol dispersion that
was achieved using a benchtop dispersion unit operating at relatively high pressure.
Low coefficients of variability provided further confidence that batch-to-batch variability
is low for the powder formulations employed in this study.

Effect of Outlet on Straight-Through Design
The Straight-Through (ST) design is the simplest of the two investigated, with a
single inlet and outlet centered on the longitudinal axis of the capsule. A single 0.6 mm
inlet capillary was used for each design in order to create a high velocity jet to aid in
powder dispersion. The performance results of the ST design are provided in Table 1.
The first outlet tested, shown in Figure 6.3a, used a 0.6 mm capillary identical to the
inlet capillary. This outlet produced a small aerosol, with a mean MMAD (n=3) of 1.57
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µm, but almost half (49.6%) of the powder stayed inside the capsule, with only 44.8% of
the total loaded powder mass emitted from the device. Increasing the outlet capillary
size was expected to increase the ED while reducing the amount of deaggregation that
was achieved. However, when the diameter was increased to 1.17 mm (shown in
Figure 6.3b), the MMAD was not significantly different (1.64 µm) while the ED
significantly increased to 57.3% (Table 6.1) compared to the 0.6 mm outlet. Four 0.6
mm outlet capillaries (Figure 6.3c) were then placed in a circular pattern around the
longitudinal axis of the capsule, as close together as possible. The four-fold increase in
cross-sectional area versus the single 0.6 mm outlet was expected to increase the ED
while the small diameter of each individual capillary would improve deaggregation. The
mean FPF<5µm/ED and FPF<1µm/ED values of 96.4% and 24.2%, respectively, as well as a
MMAD of 1.57 µm mirrored that of the single 0.6 mm outlet (Table 6.1) and were not
significantly different. The ED was significantly increased to 55.9% with four outlets from
44.8% with one 0.6 mm outlet, but the capsule retention was still very high. The
addition of a small PTFE ball, 2.4 mm in diameter, inside the capsule was incorporated
to help decrease the capsule powder retention by increasing vibration to prevent
powder sticking to the walls. The ball addition resulted in a 6% absolute increase in ED
without changing the emitted aerosol particle size (Table 6.1) compared to four outlets
and no ball. A statistical comparison (post-hoc Tukey) of the 4x0.6 mm outlet case with
and without the ball indicated no change (p≥0.05). The ST design with 4×0.6 mm outlet
and ball performed the best in terms of emitted dose while maintaining good powder
dispersion. However, the capsule drug retention (28.9%) was still high and the ED was
lower (61.9%) than the performance requirement of 75% that was initially set.
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Effect of Outlet on Single-Sided Design
To help with increasing the ED, a more complex design was tested with the inlet
and outlet on the same end of the capsule. This Single-Sided (SS) device, with
performance results shown in Table 2, was designed to use the same 0.6 mm inlet as
the ST design, as well as the same outlet configurations. Only the orientation of the
capillaries piercing the capsule was changed to assist in ED, and to potentially prevent
a negative effect on the emitted aerosol particle size. Using the single 0.6 mm outlet in
the SS design, the ED increased by more than 30% (absolute difference; compared to
ST), resulting in 77.7% of the dose being emitted after five actuations. However, the
mean MMAD increased to 2.19 µm with the SS design from 1.57 µm with the ST
design. Capsule retention was 17.8% with the SS 0.6 mm outlet, which still appeared
relatively high. Increasing the outlet capillary diameter to 1.17 mm for the SS device
successfully decreased the capsule retention to 5.8% (Table 6.2). However, the FPF
values decreased significantly compared to the 0.6 mm outlet, corresponding with an
increased MMAD value of 3.12 µm. The 4x0.6 mm outlet with and with the PTFE ball
were also tested with this configuration in an attempt to lower the particle size without
compromising ED. Using these outlet configurations did not significantly alter the ED or
MMAD compared to the 0.6 mm outlet. Also, with the SS configuration, addition of the
ball did not have a significant effect on the ED or the MMAD when comparing the results
of the 4x0.6 mm outlet with and without the ball. To find a compromise between the ED
produced by the 1.17 mm outlet and the dispersion produced by the 0.6 mm outlet, an
outlet diameter of 0.89 mm was selected. The 0.89 mm diameter outlet capillary was
able to emit 84.8% of the loaded powder, which was not significantly different than the
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ED from the 1.17 mm outlet. Powder dispersion was also comparable to the 0.6 mm
outlet with an MMAD of 2.13 µm. An FPF<5µm/ED of 89.3% and an FPF<1µm/ED value of
14.7% was observed with the 0.89 mm outlet.
Comparison of ST and SS Devices
The best performing ST and SS devices were then analyzed in a side-by-side
comparison, shown in Table 6.3. The ST device was able to produce an aerosol with a
significantly smaller MMAD (1.56 µm vs. 2.13 µm) and with a significantly higher
FPF<1µm/ED value (25.1% vs. 14.7%), compared to the SS device. However, capsule
retention was 20% lower (absolute difference) with the SS device, resulting in a
significantly larger ED (84.8% vs. 61.9%). Although not all of the desired performance
metrics were achieved with the SS-0.89 mm device, it was chosen as a best case in this
study for further investigation.

Comparison of SS-0.89mm Device Using Varying Actuation Conditions
Using the SS-0.89mm device as the leading design for this study, further testing
was conducted in terms of increased powder mass and increased actuation time. A
high dose test of 50 mg of the same EEG-AS powder formulation was conducted, as
well as a test using the original 10 mg loaded dose, but with a slower depression of the
syringe lasting approximately 0.5 seconds (versus ~0.2 sec originally). The results of
these tests are presented in Table 6.4 and Table 6.5 alongside the original data from
the optimized device. With the larger loaded mass, ED increased approximately 8%,
but this also resulted in a 0.9 µm increase in MMAD (Table 6.4). This increase in
MMAD also corresponded in a decrease in FPF values. Slower actuation of the device
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resulted in a 10% absolute increase in ED and a 0.6 µm increase in MMAD (Table 6.5).
Fine particle fraction (FPF<5µm/ED) decreased as expected with a larger aerosol, but
FPF<1µm/ED did not change from the original value.

Effect of Outlet on Plume Size
Using the SS device, each outlet configuration was tested delivering the aerosol
into an open environment. Powder was aerosolized with the outlet facing vertically
upward and captured on video, with the frames at the point in time that the syringe
plunger was fully depressed used to measure the plume characteristics (Figure 6.5). A
vertical orientation was implemented such that maximum entrainment of the plume
acting against gravity could be determined in future analysis. Particle size experiments
with the device oriented vertically and with the impactor suspended upside down
indicated a negligible change in aerosol size compared with a horizontal device
orientation. From the images in Figure 6.5, the measurements of the plume dimensions
were taken and simplified to show height, width and angle, and these simplified
diagrams are shown in Figure 6.6. The 0.6 mm outlet produced the largest plume, in
terms of both height and width, while the 4x0.6 mm outlet produced the smallest. Since
the cross sectional area of the 4x0.6 mm outlet is four times larger, the velocity of the
particles leaving the device should be four times less, carrying them away from the
outlet slower as was observed. However, the velocity of the 1.17 mm outlet should be
slower than the 0.89 mm outlet, but the results of the test show that the plume is closer
to the device for the smaller of the two outlets at the moment the syringe is empty. This
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may be due to inaccuracy of this visual measurement method, or complexity of a
transient multiphase turbulent jet entering a quiescent environment.

6.5 Discussion
The outcome of this study is the development of an easy to use DPI powered by
only a small volume of air. This device has the potential to be implemented into several
types of delivery systems because of its use of a positive pressure air source to create
an aerosol of very high quality. The optimum device that emerged from this study was a
capsule-based LV-DPI with a single inlet, designed to be connected to a standard luerlock syringe, and an aerosol single outlet that was 7 mm in diameter at the distal end
(Figure 6.2), to decrease loss of the exiting particles. An inlet capillary 0.6 mm in
diameter and an outlet capillary 0.89 mm, located on the same end of the capsule, were
used to pierce the capsule while remaining in place to administer the five actuations of
10 mL air volume through the capsule containing the powder to be aerosolized.
Even with the combination of the best performing inhaler design and the EEG-AS
powder formulation, the optimized device was not able to meet all of the desired
performance metrics with the five actuations of 10 mL air volume in this study.
However, the SS device was able to emit almost all of the loaded dose with close to
90% being smaller than a 5 µm aerodynamic diameter. Best case performance with a
10 mg loaded dose of powder, included an ED of 84.8%, MMAD of 2.13 µm, FPF <5µm/ED
of 89.3%, and FPF<1µm/ED of 14.7%. In comparison, the targeted ideal design
characteristics were an ED of greater than 75%, MMAD of 1.5 µm, FPF<5µm/ED of greater
than 90%, and FPF<1µm/ED greater than 30%.
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An inline device developed by Pohlmann et al. (2013) was able to emit 55% of
the loaded powder mass to produce an aerosol with an MMAD of 3.16 µm using 14 mL
compressed air volume. However, FPFs were much lower than those that are required
for the EEG aerosol applications (less than 10% FPF<1µm/ED). The ability of the
Pohlmann et al. (2013) device to store and deliver a larger powder mass (up to 3
grams) could partially offset the larger depositional losses generated by the larger
particle size, but this would mean more wasted medication. By comparison, the
Puffhaler was able to emit 60% of the loaded dose using a manually operated squeeze
bulb, but was only able to achieve a maximum of 21% of the particles under 3.3 µm
(Manion et al. 2012). The FPF<3.3µm/ED for the SS-0.89 mm device in this study was
calculated to be 79%. The PennCentury insufflator (DP-4M) was designed to deliver
small amounts of drug using less than 2 mL of air for dispersion. While device drug
retention and particle size varied greatly depending on powder formulation, the device
was shown to have the ability to emit ~90% of loaded powder masses in the range of 13 mg (Hoppentocht et al. 2014a). The DP-4M was able to disperse some powder
formulations to a size resembling that of the RODOS dispersed aerosol. However, with
the addition of drug to the formulation, effectiveness of the device to disperse the
aerosol was decreased. The best reported performance of the DP-4 device from
Hoppentocht et al.,(2014b) with a powder formulation containing drug was obtained
using a spray-dried formulation of colistimethate sodium. With an air volume of 1 mL
from the pressurized air pump and a powder mass of 3 mg, this device/formulation
combination produced an ED close to 90% and a median particle size of approximately
4 µm.
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The recently developed 3-4-3 3D rod array device proposed by our group was
able to produce a high quality aerosol with a loaded dose of 2 mg and an air volume of
1 L per actuation (Behara et al. 2014c). An ED of 75%, coupled with an MMAD of 1.6
µm, produced by the 3D rod array device indicate very good performance, but
FPF<5µm/ED and FPF<1µm/ED values of 65% and 21%, respectively, were lower than
targeted (Behara et al. 2014c). In comparison, the SS-0.89 mm device was able to emit
10% more of the loaded dose with a higher percentage of the dose smaller than 5 µm.
It is noted that the SS-0.89 mm device aerosolized 5 times the amount of powder using
1% of the air volume of the 3-4-3 3D rod array device per actuation (5% of the total
dispersion air volume).
A potential concern with the device is exposure of the EEG hygroscopic powder
to humidity and connection of the device to humidified ventilation systems. As
implemented in this study, the device and EEG powder performed well when operated
with room condition air (T = 22 ± 3 oC; RH = 50 ± 5 %) as intended. Performance of the
device with excess humidity air in the syringe (e.g. RH > 70%) was not considered. It is
noted that the device is intended to be used in pressurized and humidified systems,
when needed. The 10 mL syringe containing room air provides the device air source
and prevents backflow of humidified air through the device. Future designs of the
device will prevent the need to remove the syringe with each air refilling. As a result,
the device can be connected to a positive pressure humidified system without water
vapor entering the capsule and degrading the powder quality. A similar positive
pressure device operated with a manual ventilation bag (containing room air) was used
in the study of Walenga et al. (2017) by our group in which a 3D rod array inline DPI
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was connected to a noninvasive positive pressure ventilation mask that was supplied
with humidified airflow. The device performed well even in the presence of the
humidified ventilation flow. Furthermore, the aerosol was delivered into the airways at
an adequate velocity that prevented significant size growth prior to entry into the lungs
(Walenga et al. 2017).
A potential shortcoming of the newly developed LV-DPIs is the ability to control
the plume size exiting the device for use in future delivery systems. If the momentum of
the particles generated by the device is too high, depositional losses will increase
significantly before the aerosol can be carried to the patient. Slowing of the air flow
through the syringe was shown to have a negative effect on the overall size of the
aerosol (MMAD increase of 0.6 µm; Table 6.5), but also showed an increase in ED with
a similar fraction of submicrometer particles. Another potential limitation of this active
style DPI is the requirement to coordinate actuation with inhalation. However, this
coordination can be signaled or automated and will depend on the application in which
the device is used. Future improvements in filling of the air syringe to increase ease of
use are planned.
Syringe emptying times may be partially dependent on the operator of the device.
To maintain a simple low-cost device, the air syringes were emptied by hand in all
cases. The fast emptying time of 0.2 s was easy to achieve by the operator depressing
the air syringe as quickly as possible. In contrast, the operator had to practice with the
device to reliably produce the slower 0.5 s emptying time. However, difficulty with
producing an emptying time of 0.5 s is not a concern given that the fast emptying time of
0.2 s performed better. A flow control orifice as in the study of Behara et al. (2014c) can
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be used on future designs if it becomes necessary to limit variability in syringe emptying
time among operators.
Additional limitations present in this study will be further explored in the future.
Delivery to a realistic lung model was not investigated, but will be considered after
developing a delivery system and interface to administer the aerosol to a patient.
Further optimization of the device will also be considered when implementing the
delivery system, but it is expected that only small changes are needed, if any, to
improve aerosol penetration through the delivery system. Only a single drug
formulation was tested in this study, EEG-AS, but other EEG formulations, such as
Ciprofloxacin have been used in previous DPI development studies with similar
performance to AS (Farkas et al. 2015).
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6.6 Abbreviations
3D

Two dimensional

AS

Albuterol sulfate

DPI

Dry powder inhaler

ED

Emitted dose

EEG

Excipient enhanced growth

ETT

Endotracheal tube

FPF

Fine particle fraction

HPLC

High performance liquid chromatography

HPMC

Hydroxypropyl methylcellulose

LPM

Liters per minute

LV

Low volume

MMAD

Mass median aerodynamic diameters

N2L

Nose-to-lung

NGI

Next Generation Impactor

PTFE

Polytetrafluoroethylene

SS

Single-sided

ST

Straight-through
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Figure 6.1

Axial cross section of the assembled Straight-Through (ST) device

showing the inlet and outlet capillaries inside of the capsule.
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Figure 6.2

Axial cross section of the assembled Single-Sided (SS) device showing

the inlet and outlet capillaries inside of the capsule.
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Figure 6.3

Cross-sectional view of the outlet capillaries with the following internal

diameters: a) 0.6 mm, b) 1.17 mm, c) 4x0.6 mm, and d) 0.89 mm.
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Figure 6.4

Average cumulative particle size distribution of the three powder batches

as a function of aerodynamic diameter (converted based on a formulation density of
1.393 g/cm3). Average MMAD and fine particle fractions (bottom right) are shown with
standard deviations (SD) given in parentheses.
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Figure 6.5

Still images taken at the moment of complete syringe actuation showing

plume of aerosol particles leaving the SS device for each outlet case: a) 0.6 mm, b)
0.89 mm, c) 1.17 mm, and d) 4x0.6 mm.
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Figure 6.6

Simplified images showing height, width, and approximate angle of

particle plume after device actuation based on visual inspection of pictures: a) 0.6 mm,
b) 0.89 mm, c) 1.17 mm, and d) 4x0.6 mm.
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Table 6.1

Optimization of Straight-Through (ST) LV DPI device outlet internal

diameter. Mean aerosol characteristics with standard deviations (SD) shown in
parenthesis [n=3].

Description

0.6mm

1.17mm

4x0.6mm

4x0.6mm
w/ ball

ED (%)*

44.8 (4.8)

57.3 (4.9)**

55.9 (4.2)**

61.9 (2.0)**

Capsule (%)*
Device (%)

49.6 (4.9)
5.6 (0.3)

35.0 (6.0)**
7.7 (1.6)

35.6 (2.6)**
8.5 (1.6)

28.9 (2.2)**
9.2 (1.5)

FPF<5µm/ED (%) 95.7 (1.2)
93.7 (1.3)
96.4 (0.3)
FPF<1µm/ED (%) 22.4 (0.9)
23.8 (6.0)
24.2 (0.7)
MMAD (µm)
1.57 (0.04)
1.64 (0.09)
1.57 (0.01)
*p<0.05 significant effect of device outlet diameter on % ED and
retention (one-way ANOVA).

95.2 (1.4)
25.1 (2.8)
1.56 (0.03)
% capsule drug

**p<0.05 significant difference compared to 0.6mm outlet (post-hoc Tukey).
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Table 6.2

Optimization of Single-Sided (SS) LV DPI device outlet internal diameter.

Mean aerosol characteristics with standard deviations (SD) shown in parenthesis [n=3].

Description

0.6mm

0.89mm

1.17mm

4x0.6mm

4x0.6mm
w/ ball

ED (%)

77.7 (6.3)

84.8 (3.0)

87.9 (2.4)

82.0 (7.3)

80.3 (4.4)

Capsule (%)*
Device (%)*

17.8 (5.7)
4.5 (1.4)

8.8 (2.0)**
6.4 (1.7)

5.8 (1.1)**
6.3 (1.3)

9.5 (5.5)
8.5 (2.0)

10.6 (3.1)
9.1 (1.5)**

FPF<5µm/ED (%)* 83.2 (3.8) 89.3 (0.5)
61.6 (8.9)**
FPF<1µm/ED (%)* 14.1 (1.1) 14.7 (1.1)
9.6 (1.4)**
MMAD (µm)*
2.19 (0.18) 2.13 (0.07) 3.12 (0.40)**
*p<0.05 significant effect of device outlet on % capsule
FPF<5µm/ED, FPF<1µm/ED and MMAD (one-way ANOVA).

67.2 (4.5)** 68.5 (2.3)**
11.8 (1.1)
12.4 (0.9)
2.80 (0.23)
2.72 (0.11)
and device drug retention,

**p<0.05 significant difference compared to 0.6mm outlet (post-hoc Tukey).
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Table 6.3

Comparison of ST and SS optimized devices. Mean aerosol

characteristics with standard deviations (SD) shown in parenthesis [n=3].
Description

ST-4x0.6mm w/ ball

SS-0.89mm

ED (%)

61.9 (2.0)

84.8 (3.0)*

Capsule (%)
Device (%)

28.9 (2.2)
9.2 (1.5)

8.8 (2.0)*
6.4 (1.7)

FPF<5µm/ED (%)
95.2 (1.4)
89.3 (0.5)*
FPF<1µm/ED (%)
25.1 (2.8)
14.7 (1.1)*
MMAD (µm)
1.56 (0.03)
2.13 (0.07)*
*p <0.05 significant difference between ST-4x0.6mm w/ ball and SS-0.89mm (student
t-test)
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Table 6.4

Comparison of optimized SS device using the original 10 mg dose and a

higher dose of 50 mg. Mean aerosol characteristics with standard deviations (SD)
shown in parenthesis [n=3].
Description

10 mg

50 mg

ED (%)

84.8 (3.0)

92.5 (2.7)*

Capsule (%)
Device (%)

8.8 (2.0)
6.4 (1.7)

4.6 (2.0)*
2.9 (0.7)*

FPF<5µm/ED (%)
89.3 (0.5)
74.2 (6.2)*
FPF<1µm/ED (%)
14.7 (1.1)
9.2 (0.8)*
MMAD (µm)
2.13 (0.07)
3.01 (0.21)*
*p <0.05 significant difference between 10 mg and 50 mg (student t-test)
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Table 6.5

Comparison of optimized SS device using the original 0.2 s actuation and

with a slower device actuation (0.5 sec). Mean aerosol characteristics with standard
deviations (SD) shown in parenthesis [n=3].
Description

10 mg-0.2 sec

10 mg-0.5 sec

ED (%)

84.8 (3.0)

95.6 (2.0)*

Capsule (%)
Device (%)

8.8 (2.0)
6.4 (1.7)

3.0 (1.4)*
1.3 (0.6)*

FPF<5µm/ED (%)
89.3 (0.5)
73.0 (1.7)*
FPF<1µm/ED (%)
14.7 (1.1)
13.4 (1.0)
MMAD (µm)
2.13 (0.07)
2.71 (0.04)*
*p <0.05 significant difference between 10 mg-0.2 sec and 10 mg-0.5 sec (student ttest)
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Chapter 7

Application of an Inline Dry Powder

Inhaler to Deliver High Dose Pharmaceutical Aerosols
during Low Flow Nasal Cannula Therapy
7.1 Objective
The objective of this study is to further develop an inline DPI, based on previous
work, that requires low air volume (LV-DPI) to efficiently deliver pharmaceutical aerosols
to adults during LFNC therapy.

7.2 Introduction
Inline dry powder inhalers (DPIs) create a pharmaceutical aerosol using a gas
stream supplied from a positive pressure source, such as an air syringe or manual
ventilation bag (Everard et al. 1996, Laube et al. 2012, Behara et al. 2014c,
Pornputtapitak et al. 2014, Longest et al. 2015). Advantages of these devices
compared with conventional inhalation driven DPIs include high quality aerosol
generation (Behara et al. 2014c), use in subjects that cannot generate sufficient
inspiratory flow (Laube et al. 2012), reproducible aerosol delivery (Longest et al. 2015),
and assistance with deep inspiration and breath hold (Tang et al. 2011). As aerosol
generation is not dependent on patient inspiratory effort and following inspiration
instructions, inline devices may be useful for administering aerosols to infants and
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young children (Laube et al. 2012, Pohlmann et al. 2013). Based on operation with a
positive pressure gas source, these devices can also be used to administer aerosols
during invasive and noninvasive ventilation (Everard et al. 1996, Tang et al. 2011,
Longest et al. 2015).
A vast majority of studies considering aerosol delivery during mechanical
ventilation have implemented nebulizers and metered dose inhalers (Miller et al. 2003,
Dhand 2008, Ari et al. 2012, Dhand 2012, Hess 2015). In contrast, few studies have
considered DPI delivery during mechanical ventilation (Everard et al. 1996, Tang et al.
2011, Walenga et al. 2017). This limited use may be because of the perception that
humidity in the ventilation system will degrade the powder quality and aerosolization
performance (Dhand 2005). However, successful inline DPI devices for use with
humidified systems have separated the humidified ventilation and DPI actuation gas
streams (Walenga et al. 2017). This approach enables the implementation of DPIs in
mechanical ventilation systems, with the associated advantages of rapid dose delivery,
capability to administer high dose inhaled medications, reduced expense compared with
many nebulizer systems, and stable well established drug formulations.
Everard et al. (Everard et al. 1996) published one of the first successful studies of
a DPI used in a mechanical ventilation system. In this study the budesonide Turbohaler
was placed in an airtight container with an air inlet from a mechanical ventilation bag
and an aerosol outlet leading to a 9 mm endotracheal tube (ETT). Under adult
ventilation conditions, 20% of the initial drug mass was delivered to the end of the ETT.
Pornputtapitak et al. (2014) aerosolized nanoclusters of budesonide nanoparticles using
a positive pressure inline device positioned between a mechanical ventilator Y-
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connector and ETT. The emitted dose fraction for one way flow was 65%, but was
decreased as relative humidity (RH) increased to a clinically used value. Tang et al.
(Tang et al. 2011) used a containment chamber and the Osmohaler actuated with a
mechanical ventilation bag to aerosolize mannitol powder. Delivery efficiencies to the
end of adult tracheal tubes were approximately 50-60% of the loaded dose. Feng et al.
(Feng et al. 2017) adapted this system for operation with airflow from a mechanical
ventilator by bypassing the humidifier with a three-way valve resulting in a delivery
efficiency of approximately 25% of the loaded powder mass to the end of an ETT. Our
group has proposed an inline DPI actuated with a manual ventilation bag that employs
excipient enhanced growth (EEG) spray dried aerosol formulations (Son et al. 2013a,
Son et al. 2013b) and a 3D rod array structure (Longest et al. 2013b) to maximize
aerosol dispersion (Behara et al. 2014c, Longest et al. 2014b, Longest et al. 2015).
Behara et al. (Behara et al. 2014c) demonstrated that this device produced a high
quality aerosol with best case mass median aerodynamic diameter (MMAD) less than
1.5 µm and device emitted doses (ED) greater than 70%. In vitro estimated lung
delivery efficiency as a fraction of capsule loaded dose was >60% for a nasal cannula
interface (Longest et al. 2015) and 80-90% for use with a noninvasive positive pressure
ventilation mask (Walenga et al. 2017).
Low flow oxygen nasal cannula therapy, or LFNC therapy, delivers blended oxygen
to the nasal cavity at gas flow rates up to ~8 LPM in adults and ~1 LPM in children to
treat hypoxemia (Ward 2013). With LFNC therapy, the ventilation gas is typically not
heated or humidified to maintain system simplicity and the flow rate remains low to
avoid nasal discomfort associated with cold temperature and drying. To remain
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unobtrusive, small diameter tubing and small nasal cannula bore sizes are used,
typically with internal diameters (IDs) in the range of 2-4 mm. Patients receiving LFNC
therapy and other forms of noninvasive ventilation often require pharmaceutical
aerosols for the treatment of underlying lung conditions. Simultaneous administration of
a pharmaceutical aerosol through noninvasive ventilation systems and into the lungs
(nose-to-lung or N2L delivery) is viewed as convenient and prevents the removal of
ventilator support during aerosol delivery (Hess 2007, Bhashyam et al. 2008, Dhand
2012). However, aerosol delivery efficiency through small diameter tubing and cannula
systems is known to be very low, with typical values in the range of 0.6 – 2.5% even at
flow rates of 2 – 5 L/min (LPM) (Perry et al. 2013, Sunbul et al. 2014).
Based on previous studies, a number of factors are expected to significantly
improve aerosol delivery efficiency during LFNC therapy and noninvasive ventilation in
general. Small particle pharmaceutical aerosols have been shown to effectively
penetrate nasal cannula systems and enable efficient N2L delivery (Golshahi et al.
2013, Longest et al. 2013c, Golshahi et al. 2014a, Golshahi et al. 2014b, Zeman et al.
2017). It was previously demonstrated that “streamlined” ventilation components can
significantly improve the penetration of pharmaceutical aerosols, especially in nasal
cannula systems for N2L delivery (Longest et al. 2013a, Longest et al. 2013c, Longest
et al. 2014b). For an inline DPI, a small amount of air volume should be used to
generate the aerosol as higher air flows will create impaction in the small diameter
tubing and potentially exceed the subject’s inhalation flow rate. Finally, the aerosol
should be created in short bursts to enable synchronization with inhalation and
maximize the probability of the aerosol entering the lungs. Previously proposed inline
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DPI and nasal cannula systems can satisfy some of these requirements (Behara et al.
2014c). However, the relatively large gas volumes (~1 L) that are used with these
devices may prevent their effective use in the LFNC system without significant efforts to
limit and synchronize aerosol formation time with inspiration.
As an alternative to inline DPIs operated with large gas volumes, our group has
recently proposed a low volume (LV) DPI design that operates on approximately 10 ml
of room air per actuation. In this design, hollow capillary tubes are used to pierce the
capsule containing the powder and form a continuous flow passage through the device.
As a result, the entire 10 ml of actuation air passes through the device and capsule to
form the aerosol. Air jets formed by the capillaries inside the capsule create significant
turbulence and deaggregate the powder. A simple syringe with a luer-lock connector
filled with room air was used to provide the 10 ml actuations and was compressed in
approximately 0.2 s resulting in a short burst of 3 LPM flow. A straight-through design,
with inlet and outlet capillaries on opposite ends of the capsule together with an EEG
powder formulation produced a device emitted dose of 62%, mass median aerodynamic
diameter (MMAD) of 1.6 µm and a fine particle fraction (FPF) less than 5 µm of 95.2%.
Based on device attributes, the LV-DPI is expected to perform well in delivering aerosol
during LFNC. Specifically, the small aerosol size should effectively penetrate the small
diameter nasal cannula. The device flow rate of 3 LPM is not expected to interfere with
gas delivery or cause excessive deposition in the LFNC system. Finally, the very rapid
aerosol generation should enable effective synchronization with inspiratory flow.
The objective of this study is to develop an inline DPI that requires low air volume
(LV-DPI) to efficiently deliver pharmaceutical aerosols to adults during LFNC therapy.
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Devices will be produced with 3D printing and evaluated in terms of regional deposition,
emitted drug fraction and aerosolization using a loaded powder mass of 10 mg. As in
previous studies, high efficiency performance for the delivery of EEG formulations will
be defined by the production of an aerosol with the following characteristics: an MMAD
of less than 1.5 µm, fine particle fraction (FPF) less than 5 µm as a percentage of ED
(FPF<5µm/ED) above 90%, FPF<1µm/ED above 30% and a device ED greater than 75%. To
achieve this performance, the previous LV-DPI straight-through design will first be
improved to increase device emitted dose while maintaining small aerosol size. A
spacer design is then developed to integrate the aerosol plume into the LFNC system
with minimal aerosol loss. Finally, aerosol transmission through a complete LFNC
system is considered with realistic tubing curvatures. Considering the extremely small
tubing and cannula diameters of the LFNC system, effective delivery through the
cannula interface is extremely challenging. However, it is expected that small particle
EEG aerosols and streamlined ventilation components will significantly improve aerosol
transmission. Considering that transmission efficiency through similar small diameter
nasal cannula systems under LFNC conditions is on the order of 1% and below,
achieving a 60% cannula ED of the initially loaded drug powder will be a significant
advancement.

7.3 Materials and Methods
Overview
The low air volume devices developed in this study are based on our previous
work developing a LV-DPI, which was evaluated based on the aerosol characteristics at
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the device exit. The next logical step is to integrate the LV-DPI into a system to deliver
the aerosol to a human subject. LFNC therapy was selected as a challenging system
for the simultaneous delivery of high dose inhaled medications. From our previous
study (Farkas et al. 2017),the straight-through (ST) devices are able to produce a high
quality aerosol, so this design is chosen as the starting point for continued development.
Considering that the previous emitted dose from the device was 62%, further
improvements are sought in this study to increase the total system emitted dose. The
air source for the LV-DPI is a manually operated 10 mL syringe that is threaded onto the
device using an airtight luer-lock connection. A 3-way stopcock is attached between the
syringe and device to prevent airflow through the device in the wrong direction while
connected to the positive pressure system when the air syringe is refilled. Based on the
previous study (Farkas et al. 2017), the optimal outlet capillary diameter is chosen to be
0.89 mm for all cases as both the aerosol characteristics and the plume characteristics
are expected to be favorable for introduction into the LFNC system. As a representative
EEG formulation, the new inline DPIs are tested with a previously described EEG
formulation of albuterol sulfate (Son et al. 2013a, Son et al. 2013b). The primary
particle size of the EEG formulation was tested using a Sympatec (Sympatec GmbH,
Clausthal-Zellerfeld, Germany) laser diffraction system with a RODOS aerosol
dispersion accessory, which uses a pressure drop of 4 bar (400 kPa) to disperse a
small amount of powder. Aerosol characterization from the LV-DPI systems are based
on drug quantification using high performance liquid chromatography (HPLC) analysis
of the various components (LV-DPI, spacer and cannula interface) to determine the
emitted dose and by cascade impaction using the Next Generation Impactor (NGI), to
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determine the fine particle fraction and MMAD. Further details of the devices,
formulation and characterization studies are provided in the following sections.
Materials
Albuterol Sulfate (AS) USP was purchased from Spectrum Chemicals (Gardena,
CA) and Pearlitol® PF-Mannitol was donated from Roquette Pharma (Lestrem, France).
Poloxamer 188 (Leutrol F68) was donated from BASF Corporation (Florham Park, NJ).
L-leucine and all other reagents were purchased from Sigma Chemical Co. (St. Louis,
MO). Quali-V, Hydroxypropyl methylcellulose (HPMC) capsules (size 0) were donated
from Qualicaps (Whitsett, NC).
A single batch of spray dried albuterol sulfate EEG formulation was produced
using the optimized method described by Son et al. (2013a). The primary particle size
for the spray dried batch was determined using a laser diffraction method with a
Sympatec ASPIROS/RODOS dry dispersing unit and HELOS laser diffraction sensor.

Inhaler Design
The straight-through device containing a 0.6 mm capillary inlet (0.6mm_v1) is
shown in Figure 7.1a while the device containing three 0.6 mm capillaries
(3x0.6mm_v1) is shown in Figure 7.1b. The 3x0.6mm inlet was designed to have three
jets of air come in contact with the powder, effectively pushing a wall of air to reduce the
chance of powder getting stuck behind the inlet capillaries where the air flow is reduced
significantly. Images comparing the 0.6 mm and 3x0.6 mm inlet cross sections are
shown in Figure 7.1e and Figure 7.1f, respectively. The capillaries were originally
inserted approximately 6 mm into the capsule. After observations of where the losses
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were occurring in the devices, it was determined that a significant amount of the powder
was depositing behind the inlet capillary openings, keeping the airflow from carrying it to
the outlet. It was thought that decreasing the insertion distance of the capillaries as far
as possible would be beneficial, so the distance was decreased step by step until it no
longer created a reliable piercing of the capsule. The retraction distance was
determined to be 4 mm, leaving 2 mm inserted into the capsule. These devices,
denoted 0.6mm_v2 and 3x0.6mm_v2, are shown in Figure 7.1c and Figure 7.1d,
respectively.
The inhaler designs were created using Autodesk Inventor and exported as .STL
files to be prototyped. The files were then prepared using Objet Studio preparation
software and were built using a Stratasys Objet24 3D Printer (Stratasys Ltd., Eden
Prairie, MN) using VeroWhitePlus material at a 32 µm resolution. Support material was
cleaned away from the model material using a Stratasys waterjet cleaning station and
the devices were allowed to fully dry before use. The capillaries used in the devices
were custom cut from lengths of stainless steel (SAE 304) capillary tubing and were
angled on one side to allow for easy piercing of the capsule upon insertion. When the
capillary pierces the capsule using the single side sharpening, a small flap of the
capsule material is left hanging inside of the capsule. With the retracted outlet capillary,
it was thought that this flap would cover the outlet, blocking the flow and increasing
capsule retention. To prevent this blockage, the capillary was sharpened on both sides
to create two smaller flaps, one on each side of the capillary. The capillaries were then
secured into place using water resistant epoxy and allowed to cure fully before use. It is
noted that the sharpened capillaries are sufficiently recessed inside of the device to
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allow for safe assembly. A rendering of the assembled best case device for this study is
shown in Figure 7.2.

Spacer Designs
The Spacer 1 design (Figure 7.3a) was constructed with the intent to keep the
incoming ventilation gas flow separated from the aerosol plume until the plume had
expanded for several centimeters. The ventilation gas flow passed through a narrow slit
(~ 1 mm wide) for 10 mm in order to unify the flow. The ventilation gas then entered a
mixing chamber region, which was 25 mm in diameter and 45 mm long, next to the
outer wall with the intent of inward flow motion and reducing wall deposition. The total
volume of spacer 1 was 40.4 cm3, which at a flow rate of 5 LPM is expected to add
approximately 0.5 s of travel time to the particles. The interior walls were made as
smooth as possible and all connections were streamlined to avoid unwanted powder
losses.
Spacer 2, shown in Figure 7.3b, was designed to reduce the aerosol plume size
by introducing uniform flow as soon as it exits the device. Recirculation was believed to
be responsible for a portion of the losses in the Spacer 1 design. To promote uniform
flow through the spacer, a series of cylindrical rods, 1.75 mm in diameter and spaced
with a 1 mm gap between, was introduced to the incoming air flow. Six of these arrays
are stacked together along the central axis of the spacer, in a 3D grid formation, so that
each vertical array was followed by a horizontal array. Also, the vertical and horizontal
arrays that make up the third and fourth set of arrays are offset so that the centers of
the rods are positioned in the center of the gap of the array in front and behind that are
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oriented in the same direction, so that a front view of the grid appears to be completely
blocked. The total volume of the spacer that the aerosol goes though is 33.7 cm3,
which is similar to the volume after the aerosol meets the airflow in Spacer 1 (33.5 cm 3).
In the Spacer 2 design, the straight mixing section has a diameter and length of 30 mm
and 80 mm, respectively. This mixing section then smoothly connects to a 4 mm tubing
outlet over a length of 55 mm.
Both spacers consist of inlet, straight mixing, and outlet sections. These sections
were connected using threaded overlaps designed and prototyped onto the pieces and
sealed using two o-rings for each connection. The devices were also connected to the
spacers using a threaded connection to match the luer-lock style threads on the device
outlets.

Streamlined Components
Previous studies have demonstrated that with noninvasive ventilation systems,
sites of flow expansion and contraction as well as sudden direction changes are
responsible for high depositional losses of aerosol (Longest et al. 2013a, Longest et al.
2013c). Our group has proposed a “streamlined” design concept in which all conduit
sudden expansions and contractions are eliminated and direction changes are restricted
to a minimum radius of curvature (Longest et al. 2011b, Longest et al. 2013a, Longest
et al. 2014a, Longest et al. 2014b). This streamlined component approach has
previously shown significant increases in aerosol transmission efficiency in both high
flow (Behara et al. 2014c) and low flow (Longest et al. 2014b) N2L delivery systems.
Based on the study of Longest et al. (2014b), an optimized streamlined nasal cannula
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and Y-connector were implemented in this study as shown in Figure 7.4. Both devices
utilize 4 mm internal diameter tubing, which is consistent with the 2 – 4 mm range of
commercial LFNC systems. Luer-lock style connectors were included in the connection
components to facilitate assembly and disassembly of an airtight system for determining
sectional aerosol deposition. These relatively bulky connectors will not be needed in a
final design for clinical use.

LFNC System Setup
The 4 mm diameter tubing, shown in Figure 7.5, connecting the Y-connector to
the cannula was ~60 cm long to simulate the length needed to curve the tubing around
the ears and allow the spacer to reside sufficiently far from the patient. A simulated
patient with the nasal cannula in place is shown in Figure 7.6a. Figure 7.6b shows the
device/spacer setup, while connected to ventilation gas using a standard barb fitting,
and connected to the Y-connector. All tubing connections were sealed using a similar
sealing system to the device, where the male connector is inserted (with two o-rings for
sealing) into the corresponding female connector (either on the cannula or Y-connector)
and twisted 30° to lock into place.

Evaluation of Devices, Spacers, and Full Delivery System
Aerosolization performance of the LV-DPIs was characterized using 10 mg of
EEG-AS powder formulation, which was accurately weighed and manually filled into
size 0 capsules. This 10 mg mass of powder filled approximately 3% of the capsule
volume. It is estimated that the capsules can hold approximately 100 mg without
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powder contacting the capillaries when the device is operated in the intended horizontal
position. Loaded capsules were placed in one half of the LV-DPI device and pierced
when the two device halves were sealed together with a 30° turn. After the devices were
assembled, a 10 mL syringe was filled with room air and then connected via the luerlock onto a 3-way stopcock that was connected to the LV-DPI inlet. To maintain a
consistent distance from the outlet of the devices to the inlet of the NGI for aerosol
sizing, a custom adaptor was fabricated which held the LV-DPIs approximately 3 cm
away from the NGI preseparator inlet. The powders were then aerosolized with the LVDPI in a horizontal position. As minimal size change is expected in the aerosol under
ambient temperature and relative humidity (RH) conditions, experiments were
conducted with ambient air (T = 22 ± 3 oC and RH = 50 ± 5 %) with the NGI at room
temperature. To allow for horizontal positioning of the inhaler, the NGI was positioned
on its side (oriented vertically). The NGI was operated at 45 L/min and the preseparator
and individual stages were coated with MOLYKOTE® 316 silicone spray (Dow Corning,
Midland, MI) to minimize particle bounce and re-entrainment. The flowrate of 45 LPM
was chosen to ensure collection of the aerosol and maintain reasonable stage cutoff
diameters for evaluating a small size aerosol. To actuate the DPI, the plunger of the
syringe was depressed quickly (~0.2 seconds to empty) to aerosolize the powder into
the inlet of the NGI. The stopcock valve was then turned to the off position for the
device and the syringe was refilled with room air through the open port for a total of 5
actuations. Syringe emptying times were determined in our previous work using a
single operator and high speed photography at 1000 frames/sec (Farkas et al. 2017).
All measurements were made with three replicates for each design configuration.
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After the best case device was chosen, the spacer was optimized using the same
device for comparison. The spacers were tested in the horizontal position using the
same adapter designed to hold the devices 3 cm away from the inlet of the NGI, as
described above. After each replicate, the spacer was disassembled, and the sections
were assayed separately. The spacer ED is defined as the percentage of the loaded
dose that was not retained in both the device and spacer after 5 actuations.
For steady state testing, the powder exiting the cannula was directed in the NGI
while being held in place by a clamp. The cannula was not sealed to the NGI and it was
expected that the NGI flow rate of 45 LPM was sufficient to capture all aerosol exiting
from the cannula. A similar curvature to the tubing shown in Figure 7.6a was used to
allow the spacer and device to be used horizontally on the benchtop. Images showing
the powder exiting the cannula are shown in Figure 7.7 while flowing into an open
environment. After testing, all of the components were disassembled and assayed
separately with the cannula ED being defined as the percentage of the loaded dose that
made it through all of the components and into the NGI.

Aerosol performance characterization methods
After aerosolization, drug masses retained in the capsule, device, spacer, and
system components (tubing, Y-connector and cannula), and the drug collected on the
preseparator, impaction plates and the filter of the NGI were recovered by washing with
appropriate volumes of deionized water and quantified by HPLC analysis. The mass of
AS retained in the capsule, device, spacer, and system components, determined by
HPLC, was expressed as a percentage of the nominal AS dose. The device emitted
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dose (device ED) was calculated by subtracting the mass of AS retained in the capsule
and device from the loaded AS dose. The spacer ED was calculated by subtracting the
mass of AS retained in the capsule, device, and spacer from the loaded dose.
Likewise, the cannula ED was calculated by subtracting the AS retained in all of the
components from the loaded dose.
In order to determine the nominal dose of AS in the EEG-AS formulation, known
masses of the formulation were dissolved in 50 ml of water and the mean amount of AS
per mg of formulation was determined using HPLC analysis. For each aerosolization
experiment, the measured formulation AS content and the mass of formulation loaded
into the capsule was used to determine the nominal dose of AS.
The cut-off diameters of each NGI stage at the operating flow rate of 45 LPM
were calculated using the formula specified in USP 35 (Chapter 601, Apparatus 5) and
were used to calculate MMAD and fine particle fractions of the delivered aerosol. Fine
particle fraction of the EEG formulation (FPF<5µm/ED) and sub-micrometer FPF
(FPF<1µm/ED) were defined as the fraction less than 5 µm and 1 µm, respectively,
expressed as a percentage of the ED. MMAD, FPF<5µm/ED and FPF<1µm/ED were
calculated by linear interpolation using a plot of cumulative percentage drug mass vs.
cut-off diameter.

7.4 Results
EEG Formulation Dispersion Characterization
The dispersion characteristics for the batch of EEG-AS formulation used in this
study was determined using a Sympatec laser diffraction system using an
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ASPIROS/RODOS unit for comparison to previous studies as well as comparison to the
aerosolization performance of the devices in this study. The geometric diameters given
by the laser diffraction system were converted to aerodynamic diameters using the
theoretical particle density of 1.393 g/cm3 (Longest et al. 2011a). The MMAD was
calculated to be 1.18 µm while the FPF<5µm/ED and FPF<1µm/ED values were found to be
100% and 38.2%, respectively. The results of this test show that the powder is highly
dispersible when using a benchtop dispersion unit that operates at high pressures.

Device Optimization
Two capillary inlet configurations were tested in this study to optimize the
straight-through (ST) design: an inlet containing a single 0.6 mm diameter capillary and
an inlet containing three 0.6 mm capillaries spaced evenly around the long axis of the
device. Performance results of the ST designs are given in Table 7.1. The first inlet
configuration tested was the original inlet from our previous work (Farkas et al. 2017),
the single 0.6 mm inlet. The performance, which was comparable to the previous study,
included an ED of 63.1% and an MMAD of 1.56 µm. To attempt to decrease the
amount of powder left in the capsule, the number of inlet capillaries was increased to
three in a circular pattern around the long axis of the device. With an ED of 62.1% and
MMAD of 1.66 µm, there was no significant difference found between the single and
three inlet devices.
It was observed through device testing that powder was being lost on the inlet side
of the devices, in places the jet from the inlet capillaries would not impact. To prevent
this, the capillaries were retracted by no more than 4 mm to give a consistent piercing of
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2 mm inside the capsule. These devices with retracted capillaries are denoted as
0.6mm_v2 and 3x0.6mm_v2. Both devices showed a significant increase in ED, with
the 0.6mm_v2 LV-DPI producing a mean device ED of 84.6% and the 3x0.6mm_v2 LVDPI producing a mean device ED of 78.1%. Both devices showed an increase in
MMAD (1.77 µm) and a slight decrease in FPF<1µm/ED values (20%), but the ~20%
higher ED was considered to offset the small size increase. Because no significant
differences were found between the 0.6mm_v2 and 3x0.6mm_v2 LV-DPIs, the simpler
of the two designs, 0.6mm_v2, was chosen as the best case for further study. Further
details of device performance and statistical comparisons are provided in Table 7.1.

Comparison of Spacer Designs
Two spacer designs were chosen for investigation for this study with the function
of controlling the aerosol plume exiting the device to allow for transport of the powder
through the delivery system. Spacer 1, which is shown in Figure 7.3a, was designed to
keep the incoming airflow separate from the aerosol plume while allowing the plume to
expand. Once the plume had expanded, the airflow would then meet with the plume
through a 1 mm wide slit around the circumference of the flow path of the spacer. This
design had a mean spacer retention of 12.2% with the MMAD increasing to 2.28 µm,
which is 0.51 µm larger than the size exiting the LV-DPI device (Table 7.2).
Corresponding FPF<5µm/ED and FPF<1µm/ED values decreased from the values leaving the
device to 89.4% and 12.2%, respectively. The second spacer design (Spacer 2), shown
in Figure 7.3b, included six rod array inserts, each rotated 90 degrees from the next,
composed of equally spaced cylindrical rods. These inserts were designed to help
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produce a uniform inlet airflow to help reduce losses in the spacer. In addition, this
design also introduced the aerosol to the airflow as it exited from the device. This
spacer saw a slight reduction in losses to produce a mean spacer retention value of 9%
with a similar size to Spacer 1 (MMAD = 2.31 µm) and with similar FPF values: 86.5%
<5 µm and 13% <1 µm. Spacer 2 was then chosen to investigate further by connecting
it to the full LFNC delivery system (Figure 7.5).

Effect of Flow Rate on Aerosol Characteristics
The original flow rate, 5 LPM, which was used to choose the best spacer option,
served as the starting point to observe the aerosol characteristics exiting the cannula
with the results given Table 7.3. With the best-case device and spacer (0.6mm_v2 and
spacer 2), the mean cannula ED was 64.6% with a mean MMAD of 2.41 µm, mean
FPF<5µm/ED of 84.4%, and FPF<1µm/ED of 11.3%. In an attempt to decrease either
hygroscopic growth or electrostatic attraction losses of smaller particles in the very
narrow tubing, which were thought to be potential sources of the size increase from the
outlet of the device to the outlet of the cannula, the flow rate was increased to 8 LPM.
The increase in flow rate decreases the retention time of the powder in the system to
allow either less time for hygroscopic growth or less time for the static charge to attract
the small particles to the walls. The cannula ED at 8 LPM of 63.4% was not affected by
the flow rate change. However, the cannula emitted size decreased significantly to 1.93
µm at 8 LPM, which provides an absolute difference of 0.48 µm (20% smaller). Fine
particle fractions also increased at 8 LPM as FPF<5µm/ED was 92.4% and FPF<1µm/ED was
16.2%, indicating a smaller aerosol.
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7.5 Discussion
Through careful optimization of the LV-DPI, device ED was increased from 62.1%
to 84.6%. While the device emitted MMAD was increased to 1.77 µm, dispersion of the
powder remained high with FPF values of 95.2% < 5 µm and 20.2% < 1 µm.
Introduction of a new inline spacer enabled the aerosol to be combined with the LFNC
delivery line with minimal loss and maintained separate ventilation and DPI actuation
gas streams. Optimization of the spacer design reduced spacer loss from 12.2%
(concentric design) to 9% (uniform flow design). A low total spacer volume was
maintained (< 33.7 cm3) to provide an acceptable time delay between device actuation
and transmission through the nasal cannula. The aerosol exiting the nasal cannula was
larger than exiting the LV-DPI device and was greater than 2 µm, which is larger than
the ~1.5 µm MMAD that was desired. However, aerosol transmission efficiency out of
the cannula (i.e., cannula ED) achieved the targeted >60% goal and was as high as
65% under optimized conditions.
One surprising outcome of this study was that aerosol size increased through the
LFNC system resulting in a greater than 2 µm outlet MMAD at a LFNC flow rate of 5
LPM. Increasing the LFNC flow rate to 8 LPM produced approximately the same overall
system depositional loss, but reduced the ex-cannula MMAD to 1.93 µm. One possible
explanation of this size increase is hygroscopic growth of the EEG aerosol, which is a
time dependent process (Longest et al. 2012a). Longer residence time with 5 LPM flow
allows for more growth and a larger outlet aerosol. However, the LFNC gas is assumed
to be almost completely dry. The humidity for aerosol growth would then come entirely
from the 10 ml of room air injected into the system with each actuation, which seems
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unlikely. An alternative explanation may be aerosol charge. Dry powder aerosols are
known to have an electrostatic charge, especially in dry environments (Byron et al.
1997, Kwok et al. 2009). Smaller particles are also likely more influenced by charge
than larger particle (Vinchurkar et al. 2009). Hence, the electrostatic charge on the
small particles may cause a disproportionate loss of the small particle size fraction at 5
LPM thereby increasing the overall size of the aerosol. Importantly, with either
scenario, the net aerosol transmission efficiency through the cannula is high and in the
range of 63-65%. If a smaller aerosol with MMAD < 2 µm is desired at the cannula
outlet to minimize nasal depositional loss, then increasing the gas flow to 8 LPM for the
short time of aerosol administration provides a reasonable option.
The aerosol size exiting the cannula will primarily affect nasal depositional loss
(Garcia et al. 2009, Schroeter et al. 2015) as well as the final droplet size achieved by
the EEG aerosol (Longest et al. 2011a). The degree of nasal deposition will depend on
the nasal inhalation flow rate and may be different from ambient inhaled aerosols due to
the presence of the nasal cannula (Walenga et al. 2014). From previous experiments
with nasal aerosols with a nasal cannula interface, depositional loss with a 2 µm particle
at a nasal inhalation flow rate of 30 LPM is expected to be approximately 10% or less.
As a result, the estimated lung delivery efficiency including nasal losses will be ~50-60%
of the initial loaded dose. Furthermore, depending in the lung region to be targeted, it
may be beneficial to start the EEG particle size at ~ 2 µm in order to achieve a larger
final droplet size (Longest et al. 2011a, Tian et al. 2014b). Based on the study of
Longest et al. (2011a), a 2 µm initial EEG particle can achieve a final size > 6 µm within
the lungs.
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Perhaps more important to total lung deposition than the inhaled 2 µm MMAD
aerosol is the fact that the aerosol is delivered very rapidly. The transit time (the time
required for the aerosol to reach the cannula after syringe actuation) of the delivery
system was similar for 5and 8 LPM and is approximately 0.2 s for both flow rates.
However, delivery duration (the duration of time that aerosol is exiting the cannula) from
the cannula was affected by the flow rate and at 5 and 8 LPM is approximately 0.75 and
0.5 s, respectively. This compact time window should enable actuation with the start of
nasal inspiration. A simple pressure monitor or flow direction element on the cannula
can be used to sense inspiratory or expiratory flow. Ideally, conscious subjects can be
instructed to inhale deeply through the nose for a period up to 3 s, enabling all of the excannula dose to enter the nose. Synchronization with inspiration and nasal depositional
losses will be considered in future studies.
Optimization of the device in this study provided a significant improvement in ED
compared with the previous LV-DPI development study (Farkas et al. 2017). The
primary device change that enabled this improvement was retracting the capillaries
approximately 4 mm each. Physically, this retraction maintained higher velocity near
the capillary walls and prevented powder deposition near the capillary bases. A slight
increase in aerosol size was observed to a device outlet MMAD of 1.77 µm for the best
case design. This size increase of 0.21 µm is likely due to both more of the powder
being aerosolized and reduced shear forces associated with the capillary outlet
positioned closer to the capsule wall. Other design improvements to increase ED were
less effective. Due to no significant difference in the 0.6 mm and 3x0.6 mm inlet
designs, the simpler, single 0.6 mm capillary inlet was chosen for further study. Both
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the optimization of the spacer and flow rate selection for cannula delivery used the
same device for comparison.
Previous studies evaluating N2L aerosol delivery using small diameter cannula
consistent with LFNC systems are rare. Perry et al. (Perry et al. 2013) previously
considered transmission efficiency of an Aeroneb Solo mesh nebulizer at multiple flow
rates through a nasal cannula system. At an airflow rate of 5 LPM the percentage of
nominal dose exiting adult, pediatric and infant small bore cannula were 2.5, 0.6 and
0.6%, respectively. The aerosol MMAD exiting the adult cannula at 5 LPM was 0.48 µm
(Perry et al. 2013). Particles in the size range of 0.5 µm are expected to have limited
lung deposition and be largely exhaled (Kim et al. 2000). In contrast, the newly
developed LV-DPI system delivered 65% of the initial dose through the cannula,
resulting in a 26-fold increase compared with the conventional mesh nebulizer system
and adult cannula size of Perry et al. (Perry et al. 2013). Furthermore, the exiting
aerosol size of 2 µm and use of EEG particles are expected to enable lung targeted
deposition and minimal exhaled aerosol loss (Tian et al. 2013).
Limitations of the current study include the need for additional device
improvements, addition of a nasal cavity model and breathing waveform, evaluation of
flow synchronization and consideration of lung deposition and exhaled dose.
Considering device improvements, currently the syringe must be removed with each
actuation and refilled with room air. This limitation will be overcome with the
introduction of a one-way valve that enables device refilling while assembled. Inclusion
of a nasal model is needed to verify high transmission of the aerosol to the lungs. It is
expected that the back pressure introduced with the spacer and nasal cannula interface

157

marginally reduced performance. Therefore, including a breathing subject may improve
cannula ED and aerosol size. Aerosol transmission measurements were made to
evaluate the potential for flow synchronization. However, experiments with a breathing
waveform are still needed. Finally, many studies equate tracheal filter deposition with
lung deposition, which ignores the exhaled aerosol fraction. Improved lung deposition
and reduced exhaled dose expected with EEG aerosols (Tian et al. 2014b) need to be
confirmed.
In conclusion, this study has successfully improved the LV-DPI and applied the
device to achieve high efficiency delivery of a dry powder aerosol in a LFNC system.
Device modifications were implemented to improve ED and reduce spacer depositional
loss. Transmission efficiency of loaded drug mass through the optimized system was
65%, which represents a 26-fold increase compared with similar commercial systems
(Perry et al. 2013). Application of this technology to other less challenging systems with
larger tubing diameters will further increase transmission efficiency. A primary
advantage of using a dry powder device is the large powder mass that can be
administered in a short amount of time. The developed system delivered a 10 mg
powder mass in approximately 38 s (assuming a 7.5 s breathing cycle for deep
inspiration) compared to a minimum 7 min with a mesh nebulizer at a 0.5%
concentration, not accounting for system losses. Potential applications of this device
include high dose inhaled medications such as inhaled surfactants, antibiotics,
mucolytics, and anti-inflammatories. Further studies are needed to verify the potential
for synchronization with inhalation, high lung transmission efficiency, and low exhaled
dose.
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7.6 Abbreviations
AS

Albuterol sulfate

DPI

Dry powder inhaler

ED

Emitted dose

EEG

Excipient enhanced growth

ETT

Endotracheal tube

FPF

Fine particle fraction

HPLC

High performance liquid chromatography

HPMC

Hydroxypropyl methylcellulose

ID

Internal diameter

LFNC

Low flow nasal cannula

LPM

Liters per minute

LV

Low volume

MMAD

Mass median aerodynamic diameters

N2L

Nose-to-lung

NGI

Next Generation Impactor

RH

Relative humidity

ST

Straight-through
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Figure 7.1

Mid-plane cross-sectional view of the LV-DPI devices with inlet-outlet

capillary diameters and needle insertions: a) 0.6mm-0.89mm_v1, b) 3x0.6mm0.89mm_v1, c) 0.6mm-0.89mm_v2, d) 3x0.6mm-0.89mm_v2, e) 3x0.6mm-0.89mm;
and, inlet capillary patterns drawn to scale for the (e) single inlet and (f) three capillary
inlet.
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Figure 7.2

Semi-transparent 3D rendering of the ST-0.6mm_v2 device.
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Figure 7.3

Section views of the two spacer designs: a) Spacer 1, b) Spacer 2.
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Figure 7.4

3D renderings of the streamlined components from the delivery system: a)

Cannula, b) Y-Connector
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Figure 7.5

Schematic drawing showing the overall layout of the delivery system with

each component labelled.
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Figure 7.6

Complete LFNC plus LV-DPI delivery system: a) tubing and cannula

mocked up on a mannequin head, b) assembly of the syringe, device, spacer, and yconnector.

165

Figure 7.7

Still images of powder leaving the cannula at different times during

administration: a) just before powder exits, b) powder beginning to exit, c) midway
through dose, d) just as powder stops exiting.
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Table 7.1

Optimization of Straight-Through (ST) LV DPI device. Mean aerosol

characteristics with standard deviations (SD) shown in parenthesis [n=3].

Description

0.6mm_v1

Inlet Capillary Dimensions
3x0.6mm_v1
0.6mm_v2

3x0.6mm_v2

Device ED (%)* 63.1 (4.8)

62.1 (1.5)

84.6 (6.3)**,***

78.1 (3.0)**,***

Capsule (%)*
Device (%)*

28.6 (3.9)
9.3 (2.5)

14.4 (5.8)**,***
1.0 (0.6)***

18.7 (1.8)**,***
3.2 (1.2)***

30.4 (6.1)
6.4 (3.1)

FPF<5µm/ED (%)* 97.8 (0.1)
95.7 (1.5)
95.2 (0.4)
93.5 (1.5)**
FPF<1µm/ED (%)* 23.9 (0.5)
21.3 (1.0)
20.2 (1.7)**
20.1 (1.0)**
MMAD (µm)*
1.56 (0.01)
1.66 (0.04)
1.77 (0.08)**
1.77 (0.03)**
*p<0.05 significant effect of device configuration on % ED and % capsule drug retention
(one-way ANOVA).
**p<0.05 significant difference compared to 0.6mm_v1 (post-hoc Tukey).
***p<0.05 significant difference compared to 3x0.6mm_v1 (post-hoc Tukey).
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Table 7.2

Optimization of LV-DPI Spacer. Mean aerosol characteristics with

standard deviations (SD) shown in parenthesis [n=3].
Description

Spacer 1

Spacer 2

Capsule (%)
Device (%)
Device ED (%)

10.7 (4.9)
2.2 (1.3)
87.1 (5.9)

7.6 (0.2)
1.2 (0.1)
91.2 (0.2)

Spacer (%)*
Spacer ED (%)*

12.2 (1.3)
74.8 (5.8)

9.0 (1.8)
82.2 (1.6)

FPF<5µm/ED (%)
89.4 (3.9)
86.5 (3.1)
FPF<1µm/ED (%)
12.2 (1.1)
13.0 (0.7)
MMAD (µm)
2.28 (0.18)
2.31 (0.11)
*p <0.05 significant difference between Spacer 1 and 2 (t-test).
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Table 7.3

Comparison of entire delivery system at 5 LPM and 8 LPM. Mean aerosol

characteristics with standard deviations (SD) shown in parenthesis [n=3].
Description

5 LPM

8 LPM

Capsule (%)
Device (%)
Device ED (%)

15.0 (2.3)
2.0 (0.2)
83.0 (2.1)

12.5 (3.3)
3.1 (0.9)
84.5 (2.6)

Spacer (%)
Spacer ED (%)

6.7 (0.3)
76.2 (1.8)

5.9 (1.0)
78.6 (2.7)

Y-Connector (%)
Tubing (%)
Cannula (%)
Cannula ED (%)

2.9 (0.6)
3.9 (0.7)
4.8 (0.7)
64.6 (1.1)

4.5 (1.2)
4.5 (1.3)
6.2 (3.1)
63.4 (3.1)

FPF<5µm/ED (%)*
84.4 (1.8)
92.4 (3.7)
FPF<1µm/ED (%)*
11.3 (0.3)
16.2 (0.7)
MMAD (µm)*
2.41 (0.05)
1.93 (0.09)
*p <0.05 significant difference between 5 LPM and 8 LPM (t-test).
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Chapter 8

Conclusions and Future Work

The objectives described in Chapter 1 have each been accomplished. A
summary of the tasks accomplished is as follows: (1.1) two prototype devices (CC1-3D
and CC90-3D) were designed around the 3D rod array technology and tested using in
vitro methods; (1.2) inlet hole position of the CC1-3D device developed in Task 1.1 was
investigated using high-speed photography and linked to device performance with in
vitro testing; (1.3) alternate materials were studied for the 3D rod array and the effect on
aerosolization performance was quantified; (2.1) a device using a critical orifice to
control flow rate with positive pressure applications was designed and optimized for
usage in high flow nasal cannula (HFNC) and low flow nasal cannula (LFNC) therapy;
(3.1-3.2) a high dose device, based on a fluidized bed design, that was capable of
delivering up to 100 mg of powder was designed to operate with both adult and pediatric
patients and the aerosolization performance was compared with the CC 90-3D device
developed in Task 1.1; (3.3) the mixing spheres that the fluidized bed initially included
were removed, leaving only the dose sphere as the main source of deaggregation, in
order to reduce device retention; (4.1) prototype devices were designed to deliver
loaded doses up to 50 mg and powered by a small volume of air provided by a syringe
or placebo MDI; (4.2) the devices from Task 4.1 were tested to discover the optimized
device and air source (syringe); (4.3) the device optimized in Task 4.2 was used to
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develop a delivery system to be used in LFNC delivery in steady state conditions.
Conclusions and possible future studies, identified based on the results of these
objectives, are summarized below in more detail.

8.1 Objective 1: Development of a High Efficiency Dry
Powder Inhaler
The poor performance of DPIs currently available on the market limit the
available medications and therapies that can be safely administered. Drugs requiring a
specific dose to be delivered, for effectiveness and prevention of side effects, are
difficult to use with standard DPIs because of large dose variabilities between patients.
This study has described new strategies for increasing the lung dose and decreasing
the dose variability in patients. The CC1 device was shown to work well for an adult
patient, while the CC90 device performed similar across a range of flow rates that
simulate use by children, adults, or patients with lung diseases causing less than ideal
inhalation conditions.
While the devices in this study have performed well, future modifications to the
designs could still be beneficial to both performance and manufacturability of the
devices. Integration of a capsule piercing mechanism is a concern because the location
of the optimal capsule piercings makes it difficult to pierce in a single motion. A simpler
piercing location needs to be tested before designing a mechanism. With the work
done in Objective 4, it was proven that a small air volume passing through the capsule
can produce a high ED and small MMAD. An alternative to a piercing mechanism that
pierces, then retracts back into the device, is to design the device to use hollow
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capillaries to pierce the capsule and stay in place to provide the inlet and outlet air.
Extrathoracic (mouth-throat or nasal) deposition studies also need to be performed to
test the efficacy of the devices with the AS formulation as well as with other
medications.

8.2 Objective 2: Development of an Inline DPI System using
3D Rod Array Technology
The effectiveness of DPIs in producing an aerosol capable of delivering
medication to the lungs using N2L delivery was shown in this study. With flow rates in
the range of 5-45 LPM investigated, small particle sizes and low losses were observed
which should correspond with low losses in the NMT region and high lung doses. The
active devices investigated should be especially helpful for delivering aerosols to
patients that lack the ability to produce a flow rate high enough to use passive devices,
as well as to patients on mechanical ventilation with HFNC therapy.
Future work to improve this technology includes modifying the design to reduce
device losses to below 20%, as well as adding an inhalation sensor and an activation
switch for detection and delivery during inhalation only. A challenge posed by capsulebased delivery in a positive pressure system is the need for a well sealed piercing
mechanism to prevent air leaks. The mechanism needs to be simple and easy to use in
order to prevent improper usage by the patient. Delivery using a NMT model and
realistic breathing profiles should also be investigated to confirm the efficacy of these
devices.
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8.3 Objective 3: High-Dose Dry Powder Inhaler Development
The classic deaggregation method of a fluidized bed (FB) was implemented in a
compact hand-held oral inhaler for the first time and optimized for the delivery of high
dose dry powder aerosols. Based on previous performance of new high efficiency
inhalers originally designed for lower doses, the optimized FB-DPI provided excellent
deaggregation of the aerosol but decreased ED under adult and pediatric inhalation
conditions (Behara et al. 2014a, Behara et al. 2014b). Removal of the mixing balls
improved emitted dose while maintaining excellent deaggregation, such that the
combination of the powder formulation with the mixing chamber and dose sphere is
likely most responsible for the high quality aerosol that was produced. Still, the
combination of the FB-DPI and EEG powders with or without the mixing balls achieved
MMADs and FPFs that are far superior to currently available products. Compared with
the newly proposed high dose Orbital inhaler, the strength of the FB-DPI is its improved
aerosolization (Young et al. 2013). However, the Orbital device is currently capable of
delivering 400 mg, which may be advantageous in some applications. Our approach is
to instead load 100 mg and be four times more efficient at targeted lung delivery, which
is to be determined in future studies. Analysis of the fluidized bed design indicated that
removal of the mixing balls and maintaining the newly designed dosing sphere and
chamber increased ED to 73.8% while maintaining excellent aerosolization
performance. As a result, it is concluded that the FB-DPI is highly effective but can be
simplified by maintaining only the newly designed dosing sphere and inhaler chamber.
Future studies will seek to optimize the simplified new design for high dose DPI delivery
to both adults and children. This simplified design will then need to be tested in a MT
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model for adults and children to show the efficacy of the devices in reducing losses with
large masses of powder.

8.4 Objective 4: Development of a low-volume capsulebased Dry Powder Inhaler and Nose-To-Lung Delivery
Platform
The results of this study show that a high quality aerosol can successfully be
generated using a low volume of air on the order of approximately 10 mL. While the
results do not meet all of the desired performance metrics for high efficiency EEG
aerosol delivery, this device provides a substantial advance. The device successfully
outperformed more complex devices (Tang et al. 2011, Pohlmann et al. 2013,
Hoppentocht et al. 2014b), while still being easy to load and operate. The LV devices
also compared well with the inline DPIs our group has developed, with improved ED
and FPF<5µm/ED values higher than obtained with current 3D rod array inline devices
while using 2 orders of magnitude less air (Behara et al. 2014c). Higher drug masses
on the order of 50 mg marginally decreased aerosol performance; however, it is
expected that improved performance can be obtained by optimizing the device for
operation with a known mass of powder for a specific application. Furthermore, we
expect that a quantitative analysis and design approach (Longest et al. 2009, Hindle et
al. 2013) implementing computational fluid dynamics (CFD) (Longest et al. 2013b) and
additional prototyping can be used to meet all of the high performance aerosol delivery
metrics that were initially set.

174

With the redesign of the straight-through (ST) device, great progress was shown
in delivery of an aerosol through a LFNC system using steady state conditions. While a
NMT model was not used to determine losses after the cannula exit, the high FPF
values and low MMAD obtained with this device should be able to avoid depositional
losses in the nasal passages and achieve a high lung dose. Future work with this
device will need to include the addition of at NMT model and realistic breathing profiles
to show that the delivery of the aerosol can be synced to the inhalation time of the
patient to prevent aerosol being delivered at the wrong time. The LV device was also
designed to accept a higher mass of powder in the capsule and this was tested with the
SS-0.89mm device previously. The redesigned ST 0.6mm_v2 device was not tested
with the larger mass, but considering the performance of the device was significantly
better with the 10 mg fill mass, the larger powder mass should also perform better. In
addition, the LFNC system developed in this study is designed to work with an adult
patient. Because of the flexibility of the LV device, it can also be adapted to deliver
aerosols to infants and children, but a new interface would have to be adapted to work
with the reduced flow rates and tidal volumes of these potential patients. With the
PennCentury DP-4 devices no longer available, there is a need for devices able to
deliver aerosols to test animals. The LV devices explored in this study could be a prime
candidate for use in testing environments because of its ease of use and high
performance with air volumes that would need to be used in these animals.
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8.4 Lessons Learned
There have been many takeaways from the research conducted in these studies.
Firstly, the coupling of device development and formulation development was found to
achieve optimal delivery conditions. Compared to devices/formulations on the market,
this is a major change, as current commercial devices are inefficient. While some
commercial devices have reasonable deaggregation capabilities, when paired with a
less dispersible powder formulation, they do not perform well. Likewise, if a highly
dispersible powder is used in a poor device, poor aerosolization results can be
expected.
If the powder formulation used is highly dispersible, as with the case of the EEG
powders studied in this research, device over complexity adds unnecessary
complications to design and usage. A simpler device design that focuses on the a
single deaggregation method together with ease-of-use may be advantageous. For
example, the original design of the high-dose oral inhaler attempted to use a fluidized
bed to disperse the power because it was expected that the small holes in the dosing
sphere would not create the needed amount of dispersion. When the mixing spheres
were removed, however, it was shown to be just as efficient in aerosolization, but
without the added complexity of the mixing balls contributing to the device retention.
In regard to the LV devices, small changes to the capillaries used in the devices
were shown to produce large changes in the efficiency of the devices. A 20% increase
in outlet capillary diameter was shown to increase the size on the order of 50% when
leaving the device. This speaks to the simplicity of the device, as the only variables
changed were the outlet diameter and capillary insertion length to move from a less
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efficient to a highly efficient device. Also, positive pressure devices as a whole have
been studied previously, but most have been dismissed as having poor efficiency. This
research shows that positive pressure devices can indeed be efficient when used in the
right circumstances and can even be highly adaptable delivery systems.

8.5 Contributions to Science
The phases of graduate student education shown in this work include training in
the research area, application of ideas, and innovation showing state-of-the-art
solutions to complex problems. The areas of study that are the focus of this research
include aerosol science, device development and design, and respiratory drug delivery.
During the training an application phases, the development of the 3D rod array system
as a means to disperse an aerosol was the primary focus. This includes the
development of both the CC1 and CC90 devices for oral delivery, as well as the inline 3D
rod array devices for EEG N2L delivery in both HFT and LFT. During this time, it was
shown that device design must be coupled with formulation design to truly optimize
delivery. The application phase also consisted of the high dose oral inhaler design
based on the technology of a fluidized bed, which had previously not been used in an
inhaler. This design provides an alternative to the load-dose-repeat cycle that is
required when using a capsule-based device that is unable to handle high doses of
powder. Innovation produced in this research includes the design of a simple, easily
adaptable, solution to aerosol delivery using a low air volume very efficiently, i.e., the
LV-DPI device. This device provides a new strategy for aerosol administration during
non-invasive ventilation, to children who are unable to use a DPI, and to infants in cases
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of respiratory distress. While not directly studied in this work, this innovative design will
also allow for use in test animals for pharmaceutical research.
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